Microorganisms and methods for producing glycolic acid from pentoses and hexoses
By expressing non-natural enzymes and rearranging central carbon metabolism, the problems of low glycolic acid yield and carbon loss in the prior art are solved, efficient and economical glycolic acid production is achieved, and the demand for biologically sourced glycolic acid is met.
Patent Information
- Application Number
- CN201980046988.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-07-13
- Filing Date
- 2019-07-12
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2039-07-12
AI Technical Summary
The prior art When extracting glycolic acid from plant biomass, the yield is limited by carbon loss and stoichiometric, and chemical synthesis methods in industrial scale production use harmful irritating compounds, resulting in an urgent need for biologically sourced glycolic acid.
By identifying and expressing three non-natural enzymes: D-arabinose-5-phosphate isomerase, fructose-6-phosphate aldolase and aldehyde dehydrogenase, the central carbon metabolism is rearranged, and glyceraldehyde-3-phosphate dehydrogenase is weakened. The activity of hydrogenase optimizes the assimilation pathway of pentose and hexose, and improves the maximum theoretical yield of glycolic acid.
Efficient production of glycolic acid from hexose and pentose has been achieved, which significantly improves yield, eliminates the stoichiometric requirements for E. coli metabolism, enables the maximum utilization of renewable carbon and the process is economical and feasible.
Smart Images

Figure BDA0002895837520000031 
Figure BDA0002895837520000041 
Figure BDA0002895837520000051
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of bioconversion of a carbon source into at least one target metabolite and in particular glycolic acid.
[0002] More particularly, the present invention relates to a microorganism whose central carbon metabolism has been altered so as to convert hexoses and pentoses from a carbon source, particularly plant biomass, into glycolic acid. The present invention also relates to a method for producing glycolic acid from hexoses and pentoses contained in plant biomass using such a microorganism. Background Art
[0003] Glycolic acid or glycolic acid, having the formula HO-CH2-C(=O)-OH, has many applications in different fields. In fact, by way of example, it can be used as a pH regulator or keratolytic agent in cosmetics and medicines, as a dye and tanning agent in the textile industry or even as a disinfectant in the agro-food industry. Glycolic acid can also be used to produce polymers, such as thermoplastic resins including poly(glycolic acid). Such polymers exhibit significant gas barrier properties and have the ability to hydrolyze in an aqueous environment in a stepwise and controllable manner, making these polymers good candidates for packaging materials or absorbable materials for use in the biomedical field.
[0004] Although glycolic acid can be obtained from sugar cane, beet or grape extracts, its industrial-scale production comes from chemical synthesis. Several of these synthetic methods use formaldehyde as a starting reagent, which is an irritant and carcinogenic compound, and any traces of this substance are excluded in preparations with market rights.
[0005] Therefore, bioderived glycolic acid is of interest in the pharmaceutical, cosmetic and textile fields. In polymeric form, poly(glycolic acid) and polymers containing poly(glycolic acid) could represent a new generation of packaging bioplastics and bioresorbable polymers [1]. This is why several research groups have been interested in producing glycolic acid via microbial routes in recent years.
[0006] Glycolic acid is produced naturally in small quantities by the reduction of glyoxylic acid in bacteria and molds (including yeast) [2]. Previous engineering projects were inspired by natural metabolism. The maximum theoretical yield that can be achieved via this natural pathway is 2 mol glycolic acid (GA) per mol hexose and 1.66 mol per mol pentose (or 0.84 g GA / g sugar).
[0007] Thus, a method for the bioproduction of glycolate based on the improvement of the natural metabolism of Escherichia coli has been the subject of international application WO2007 / 141316 [3]. This pathway is referred to below as the "glyoxylate bypass (SG) pathway". In the method described, reactions that consume glyoxylate and enzymes that metabolize glycolate have been deleted, while NADPH glyoxylate reductase that converts glyoxylate into glycolate has been overexpressed to increase the glycolate yield. The regulatory system of the glyoxylate cycle has also been modified to relieve inhibition and increase the carbon flux to glyoxylate. Since the work described in [3], other modifications have been made to improve the production of glycolate from (D)-glucose, which made it possible to achieve a maximum theoretical yield of 92.9% [4].
[0008] However, this synthetic pathway is not optimal from a stoichiometric point of view, with the theoretical yield limited by the carbon loss due to the decarboxylation of pyruvate to acetyl-CoA. In this context, synthetic pathway replacement and / or complementation of native metabolism for sugar assimilation and glycolate production are prospective strategies to overcome this limitation.
[0009] To this end, a semisynthetic pathway for the assimilation of pentoses has been described in the international application WO 2017 / 059236 [5]. This pathway involves phosphorylation at position 1 of the (D)-ribose or (L)-xylulose ring and is referred to hereinafter as the "ribose-1-P pathway". This synthetic pathway allows the assimilation of pentoses, more particularly (D)-xylose, the main pentose of hemicellulose. The yield of (D)-xylose is 0.44 g / g [6]. However, it should be noted that the pathway described in the international application WO 2017 / 059236 [5] requires, in order to be functional, the reduction or inactivation of xylulose enzyme activity and the overexpression of the following four enzymes: the epimerase that interconverts xylulose and ribulose, the (D)-ribulose-phosphate aldolase, the D-ribulokinase and the glycolaldehyde dehydrogenase.
[0010] Another synthetic pathway for glycolic acid production has been developed and is the subject of international application WO2016 / 079440 [7]. This synthetic pathway phosphorylates the pentose on the first carbon (C1) rather than on carbon 5 (C5) as is the case in the pentose phosphate pathway. The phosphorylation reaction is catalyzed by a heterologous ketohexose kinase from mammals, followed by a cleavage reaction by an aldolase, producing a C3 molecule (dihydroxyacetone-P) and a C2 molecule (glycolaldehyde). The latter is synthesized by an oxidation reaction catalyzed by glycolaldehyde dehydrogenase to produce glycolic acid or by a reduction reaction catalyzed by an endogenous reductase to produce ethylene glycol. This synthetic pathway, hereinafter referred to as the "xylulose-1-P pathway", involves three different enzymes, rather than five as in [5], and is able to achieve a theoretical yield of 1 mole per mole of pentose in glycolic acid and ethylene glycol.
[0011] It should be noted that the synthetic pathways independent of the glyoxylate pathway described in [5] and [7] do not have a decarboxylation step and the resulting CO2 loss, but both of them generate the C3 compound dihydroxyacetone phosphate (DHAP), which limits the maximum theoretical yield of glycolate.
[0012] Similarly, to enable the production of glycolic acid using DHAP, the synthetic pathways described in [5] and [7] were combined with the optimized natural pathway described in [3]. The combination of the pathways described in [7] and [3] resulted in a yield of 0.63 g glycolic acid per g sugar, but the maximum theoretical yield was still limited by CO2 losses, a consequence of using the optimized natural pathway [8].
[0013] In their communication to Nature Biotechnology [9], Dugar and Stephanopolous introduced the term “maximum energy yield (Y E )”. The yield is calculated based only on the energy balance between substrates and products, which is actually reflected by considering the redox states of substrates and products. Therefore, Y E By the ratio γ s / γ p Determine, where γ s and γ p is the degree of reduction of the substrate and product. For example, glucose γ s The reduction degree is equal to 24, and the product ethanol γ p The reduction degree of is equal to 12. Therefore, Y E is 2. On the other hand, the yield of the metabolic pathway (Y P ) depends on the pathway or metabolic network and is calculated based on the stoichiometry of the pathway under consideration. Thus, for the fermentation of glucose to ethanol, Y P is 2, and find Y E Yes P This equality was not found in all cases. For example, the conversion of glucose to acetate resulted in a yield of Y P is 2, but the maximum energy yield Y E is 3. Therefore, there is a potential material loss of 33%, which can be explained by the natural metabolic pathway. However, Liao et al. showed that it is possible to construct a feasible metabolic pathway that results in the production of 3 mol acetate per mol glucose
[10] . Based on the same principle, it can be calculated that from glucose (γ s =24) produces glycolic acid (γ p =6) would be 4, from pentose (γ p =20) would be 3.3. However, this yield is only achievable if the biological system is able to absorb carbon in the form of CO2.
[0014] Taking this hypothesis into account and in view of the growing interest in products from renewable carbon resources, the inventors have set themselves the goal of providing a microorganism and a process making it possible to produce glycolic acid from plant biomass, in particular from the hexoses and pentoses contained therein, in a simple and industrializable manner, with an increased yield compared to the processes of the prior art.
[0015] To this end, Table 1 below shows the theoretical yields (mol / mol) of prior art pathways for producing glycolic acid, depending on the carbon source used.
[0016] Table 1
[0017]
[0018] Summary of the invention
[0019] The present invention is able to solve the technical problems of the prior art process as defined above and achieve the purpose of the inventors.
[0020] To this end, the inventors' work has identified a method that can achieve Figure 1 The three enzymes presented in the non-natural way for synthesizing glycolic acid are:
[0021] i) D-arabinose-5-phosphate isomerase (KdsD), an enzyme in the lipopolysaccharide biosynthesis pathway that converts D-ribulose-5-phosphate to D-arabinose-5-phosphate
[11] ;
[0022] ii) fructose-6-phosphate aldolase (FSA), which catalyzes the cleavage of D-arabinose-5-phosphate to D-glyceraldehyde-3-phosphate and glycolaldehyde; it should be noted that this enzyme was originally identified as catalyzing the aldol cleavage of fructose-6-phosphate to dihydroxyacetone and glyceraldehyde-3-phosphate, but has been shown to have an aldolizing activity with an affinity for D-arabinose-5-phosphate that is 10 times higher than for fructose-6-phosphate
[12] and
[0023] iii) Aldehyde dehydrogenase (AldA), which oxidizes glycolaldehyde to glycolate
[13] .
[0024] It should be noted that the first substrate of this new pathway, D-ribulose-5-phosphate, is naturally obtained from pentoses via the pentose phosphate (PP) pathway.
[0025] Even if these three enzymes are naturally expressed in microorganisms such as E. coli, they do not allow glycolic acid synthesis because of overexpression of kdsD, fsa and aldA genes, and therefore overexpression of these enzymes is necessary for the production of glycolic acid. In other words, the synthetic pathway according to the present invention does not exist in the natural state of microorganisms such as E. coli. Therefore, it can be called a "non-natural pathway" or "anabolic pathway".
[0026] In addition, the activity of FSA on D-arabinose-5-phosphate produces glyceraldehyde 3P (C3), which is supported by oxidative glycolysis. As described in [8], this C3 molecule can produce glycolaldehyde, but with a loss of CO2 at the reaction catalyzed by pyruvate dehydrogenase. In order to circumvent this metabolic limitation, the inventors have rearranged the central carbon metabolism so that C3 is recovered in the PP pathway by weakening or even inactivating the gapA gene encoding glyceraldehyde-3-phosphate dehydrogenase, thereby optimizing carbon conservation. Due to this weakening / inactivation, glyceraldehyde-3-phosphate enters the PP pathway and participates in the synthesis of D-xylulose-5-phosphate, a precursor of D-ribulose-5-phosphate. Thus, the maximum theoretical yield is 2.5 mol glycolic acid per mol pentose.
[0027] Moreover, in order for the process to be economically feasible, it should convert the main lignocellulose sugars, i.e. pentoses such as D-xylose and hexoses such as D-glucose. The latter is naturally assimilated by the glycolytic pathway. Therefore, by inactivating / deleting the gapA gene, the carbon flow is redirected to the PP pathway, which converts D-glucose into glycolic acid with a theoretical maximum yield of 3 moles of glycolic acid per mole of D-glucose.
[0028] Table 2 below reproduces the theoretical yields of the prior art pathway and gives the theoretical yields (mol / mol) of the pathway according to the invention for the production of glycolic acid depending on the carbon source used.
[0029] Table 2
[0030]
[0031] Thus, the present invention enables glycolic acid synthesis from hexoses and pentoses by a single non-natural pathway that maximizes the utilization of renewable carbon. Finally, the method eliminates the stoichiometric requirements necessary for E. coli metabolism. Further, theoretical yield calculations of the non-natural pathways for pentose and hexose assimilation described in the present invention for the production of glycolic acid show that the yield is significantly improved compared to biosynthetic processes based on optimization of prior art natural and / or semi-synthetic pathways.
[0032] More particularly, the present invention relates to recombinant microorganisms that exhibit
[0033] i) increased conversion activity from D-ribulose-5-phosphate to D-arabinose-5-phosphate compared to a non-modified microorganism;
[0034] ii) increased aldehyde cleavage activity from D-arabinose-5-phosphate to D-glyceraldehyde-3-phosphate and glycolaldehyde compared to its non-modified microorganism;
[0035] iii) increased oxidation activity from glycolaldehyde to glycolic acid compared to its non-modified microorganism; and
[0036] iv) reduced oxidation activity from glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate compared to its non-modified microorganism,
[0037] The recombinant microorganism produces glycolic acid from pentose and hexose sugars.
[0038] "Microorganism" refers to any organism that exists in the form of a microscopic cell belonging to both the prokaryotic and eukaryotic domains. Thus, the term "microorganism" encompasses all species of prokaryotic microalgae, bacteria, archaea, and eubacteria, as well as eukaryotic microorganisms such as plant cells, eukaryotic microalgae, yeast, and fungi. The term also includes cell cultures of any species that can be cultured for glycolic acid production.
[0039] As examples of bacteria for use within the scope of the present invention, mention may be made of bacteria from the families Burkholderiaceae, Enterobacteriaceae, Brevibacteriaceae, Clostridiaceae, Bacillaceae, Moraxellaceae, Sphingomonadaceae, Lactobacillaceae, Streptomycetaceae, Streptococcaceae, Methylobacteriacae and Corynebacteriaceae. As more specific examples of bacteria used within the scope of the present invention, mention may be made of Brevibacterium flavum, Brevibacterium lactofermentum, Escherichia coli, Bacillus subtilis, Corynebacterium glutamicum, Corynebacterium efficientens, Zymomonas mobilis, Ralstonia eutropha, Clostridium acetobutylicum, Methylobacterium extorquens and Lactococcus lactis.
[0040] As examples of yeasts used within the scope of the present invention, mention may be made of yeasts from the families Saccharomycetaceae, Pichiaceae, Schizosaccharomycetaceae and Yarrowia. As more specific examples of yeasts used within the scope of the present invention, mention may be made of Saccharomyces cerevisiae, Schizosaccharomyces pombe, Candida albicans, Candida blankii, Candida rugosa, Kluyveromyces lactis, Kluyveromyces marxianus, Pichia jadinii, Scheffersomyces stipitis, Pichia pastoris and Yarrowia lipolytica.
[0041] As examples of fungi used within the scope of the present invention, mention may be made of fungi of the genera Penicillium, Aspergillus, Chrysosporium and Trichoderma. As more specific examples of fungi used within the scope of the present invention, mention may be made of Penicillium notatum, Penicillium chrysogenum, Aspergillus niger, Chrysosporium pannorum and Trichoderma reesei.
[0042] More particularly, the microorganism used within the scope of the present invention is a bacterium of the Escherichia coli type or a yeast of the Saccharomyces cerevisiae type.
[0043] "Recombinant microorganism" means a microorganism that is not found in nature and is genetically different from an equivalent in nature (such as previously defined). The terms "equivalent in nature", "non-modified microorganism", "natural microorganism" and "wild-type microorganism" are equivalent and used interchangeably. Recombinant microorganisms are modified by the introduction, deletion and / or modification of genetic elements.
[0044] The recombinant microorganism used in the present invention may be modified to regulate the expression level of an endogenous gene."Endogenous gene" means a gene present in a microorganism prior to any genetic modification of a wild-type microorganism.
[0045] Endogenous genes can be overexpressed by introducing other heterologous sequences or by replacing endogenous regulatory factors, or by introducing one or more other copies of genes in chromosomes or one or more plasmids. Endogenous genes also can be modified to regulate their expression and / or their activity. For example, mutations can be introduced into the encoding sequence to modify the gene product or heterologous sequences can be additionally introduced or replace endogenous regulatory factors. The regulation of endogenous genes can result in positive regulation and / or increase of endogenous gene product activity, or alternatively downregulation and / or reduction of endogenous gene product activity.
[0046] Another method of regulating the expression of an endogenous gene is to up-regulate or down-regulate the expression of an endogenous gene by exchanging its endogenous promoter as a wild-type promoter with a stronger or weaker promoter. These promoters can be homologous or heterologous.
[0047] Alternatively, the recombinant microorganism used in the present invention may also be modified to express foreign genes. The recombinant microorganism used in the present invention may be modified to express foreign genes, as long as these genes are introduced together with all elements that make them expressed in the microorganism. Those skilled in the art know different methods for modifying, transforming or transfecting microorganisms with foreign genes. As an example and not exhaustively, the method can be conjugation; electroporation; lipofection; microinjection; particle bombardment (or gene gun); biotransformation of plants using Agrobacterium tumefasciens; transformation by chemi-permeability; transformation by DEAE-dextran method or introduction through viruses, virions or viral particles.
[0048] "Foreign gene" means a gene that has been introduced into a microorganism by methods well known to those skilled in the art, and the gene is not naturally found in the microorganism. The foreign gene can be integrated into the chromosome of the microorganism or expressed extrachromosomally by means of a plasmid, vector, cosmid, phage or virus such as baculovirus. The foreign gene can be a homologous gene.
[0049] "Homologous gene" means a gene homologous to a gene encoding a reference protein and a protein homologous to the reference protein. "Protein homologous to a reference protein" means a protein having a similar function and / or a similar structure to the reference protein. Thus, when the reference protein is an enzyme, the protein homologous to the reference protein catalyzes the same enzymatic reaction.
[0050] By reference to databases such as Genbank or NCBI BioProject of amino acid or nucleotide sequences of known genes or proteins, those skilled in the art can determine homologous, i.e., equivalent genes or proteins in other organisms such as bacterial strains, yeasts, fungi, mammals or even plants. This routine work is advantageously performed by using consensus sequences identified by sequence alignment with genes or proteins derived from other organisms.
[0051] A gene A homologue may also be a gene encoding a variant of a protein encoded by gene A. Such homologues may be obtained by synthetic routes.
[0052] Typically, a protein (or gene) homologous to a reference protein (or reference gene) has at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% and / or at least 99% identity to the reference protein amino acid sequence (or the nucleotide sequence of the reference gene), respectively. The "percent identity" between two amino acid sequences (or between two nucleotide sequences) means, within the scope of the present invention, the percentage of identical amino acid residues (or nucleotides) between the compared sequences, which percentage is obtained by performing the best alignment (optimal alignment) between the two sequences. The skilled person is aware of different techniques that can obtain such a percentage of identity and involves homology algorithms or computer programs such as the BLAST program.
[0053] Recombination group microorganism according to the present invention has one or more enzymatic activities that increase compared with its non-modification microorganism and at least one enzymatic activity that reduces compared with its non-modification microorganism.In other words, the intracellular activity of some enzymes is to increase compared with its non-modification microorganism and the intracellular activity of at least one other enzyme is to reduce compared with its non-modification microorganism.
[0054] In the present invention, the term "activity" of an enzyme is used interchangeably with the term "function" and indicates a reaction catalyzed by an enzyme. Those skilled in the art know different techniques for measuring the enzymatic activity of a given enzyme. The experimental section below provides different enzymatic tests for measuring the activity of an enzyme included in the present invention.
[0055] In the context of the present invention, the term "increased activity" as applied to an enzyme indicates an increased catalytic activity specific for the enzyme and / or an increased amount or availability of the enzyme in the cell.
[0056] In the context of the present invention, an increased enzyme activity in a recombinant microorganism is understood to be an enzyme activity that is increased at least 2-fold, in particular at least 5-fold, in particular at least 10-fold and more particularly at least 20-fold relative to the enzyme activity of its non-modified microorganism.
[0057] The person skilled in the art is aware that different microbiological and molecular biological techniques can be used to obtain an increase in the activity of an enzyme in a given microorganism.
[0058] In fact, the increase in enzyme activity can a ) by increasing the copy number of genes encoding enzymes in microorganisms, (ii a ) by increasing the expression of the gene for the enzyme in the microorganism, for example, by modifying the promoter, regulatory region and / or ribosome binding site, (iii a ) by modifying the sequence of the gene encoding the enzyme so as to obtain a form that is more active or more resistant to inhibition and, optionally, (iv a ) by combining alternatives (i a )、(ii a ) and (iii a )
[0059] Regarding the above alternatives (i a ), the gene can be chromosomally encoded or extrachromosomally encoded. When the gene is located on the chromosome, several copies of the gene are introduced into the chromosome by recombination methods known to those skilled in the art (including gene replacement). When the gene is located outside the chromosome, it can be carried by a recombinant expression vector.
[0060] "Recombinant expression vector" means a nucleic acid suitable for expressing at least one enzyme encoded by the nucleotide sequence contained in the vector in a microorganism. In addition to the nucleotide sequence encoding the target enzyme, the expression vector according to the present invention includes one (or more) elements that allow the nucleotide sequence to be expressed, i.e., transcribed and translated.
[0061] The expression vector used in the present invention is advantageously selected from plasmids, cosmids, phages and viruses such as baculoviruses. In particular, the vector of the present invention is an autonomously replicating vector, including elements such as replication origins that allow it to be maintained and replicated in microorganisms. Further, the vector may include elements that allow it to be selected in microorganisms. These elements are also referred to as "selective markers". Such expression vectors are well known to those skilled in the art and are widely described in the literature.
[0062] The expression vector may further have one or more elements selected from a promoter, an enhancer, a 3'UTR ("untranslated region") signal, an IRES ("internal ribosome entry site") signal, a ribosome binding site (RBS), a transcription termination signal including a cleavage site and a polyadenylic acid signal ("polyadenylation signal"). The expression vector according to the invention may comprise 2, 3 or 4 of the elements listed above. A person skilled in the art will be able to select from this list the additional elements to be included in the expression vector according to the microorganism to be expressed.
[0063] "Selectable marker" means a marker selected from the selection markers used in prokaryotes or eukaryotes, such as bacterial genes for antibiotic resistance and metabolic genes for auxotrophic microorganisms, i.e., selection genes that ensure complementation of the respective genes deleted at the genome of the host microorganism. Thus, the expression vector according to the invention may contain bacterial genes for resistance to antibiotics such as amoxicillin, ampicillin, phleomycin, kanamycin, chloramphenicol, neomycin, hygromycin, geneticin (or G418), carboxin, nourseothricin or triclosan. As an illustrative example of a metabolic gene, the gene trp1 for a microorganism lacking phosphoribosylaminobenzoate isomerase, such as yeast trp1, may be mentioned. - or the gene URA3 for eukaryotic organisms lacking orotidine 5-phosphate decarboxylase, such as yeast ura3 - .
[0064] In the scope of the present invention, "promoter" means a constitutive or inducible promoter suitable for any microorganism, such as a previously defined microorganism, and a constitutive or inducible promoter specific to a group of specific microorganisms. The promoter used can be homologous or heterologous. Specifically, the constitutive promoter used within the scope of the present invention is particularly selected from promoter proD, promoter proC, promoter 35S, promoter 19S and promoter TEV ("tobacco etch virus"). The inducible promoter used within the scope of the present invention can be a promoter GAL1 induced by galactose, a promoter AOX1 induced by methanol, a promoter PA1lac0-1 induced by isopropyl β-D-1-thiogalactoside (IPTG), a pTac hybrid promoter induced by IPTG, a promoter MET15 induced by methionine depletion, or a promoter CUP1 induced by copper ions. In the vector used in the present invention, the promoter can be associated with one or more transcriptional regulatory sequences, i.e., enhancers.
[0065] Advantageously, the expression vector used in the present invention comprises a promoter that is operably connected together, a nucleotide sequence encoding the target enzyme and a transcription termination signal that comprises a cleavage site and / or a polyadenylic acid signal. "Being operably connected together" according to the present invention means an element that is connected together so that the function of one of the elements is changed by another element. By way of example, when its expression can be changed, the promoter is operably connected to the encoding sequence. The transcription, translation and ripe elements of the adjustable peptide that the carrier may include are known to those skilled in the art and those skilled in the art can select them according to the host microorganism to be expressed or cloned.
[0066] In addition, it is known to those skilled in the art that, as expression vectors, different plasmid types, their replication origins are different, and therefore their copy numbers are different in the cell. Typically, these plasmids exist in microorganisms with 10 to 15 copies, or about 30 to 50 copies, or even 100 copies at the most, depending on the plasmid properties: according to how much is replicated, the plasmid has a low copy number, the plasmid has a medium copy number, or the plasmid has a high copy number. The example of the plasmid used within the scope of the present invention can mention plasmids pSC101, RK2, pACYC, pRSF1010, pZ and pSK bluescript II.
[0067] Typically, the above alternative (ii a ) may include the use of a promoter that induces high expression levels of an endogenous gene. Depending on the nature and properties of the endogenous promoter, one skilled in the art will be able to determine the use of a homologous or heterologous, inducible or constitutive promoter to replace the endogenous promoter. Alternatively, alternative (ii) a ) may include reducing the activity or expression of specific or non-specific transcriptional repressors of endogenous genes.
[0068] In the scope of the present invention, the term "reduced activity" or "diminished activity" applied to an enzyme indicates a reduced catalytic activity specific for the enzyme and / or a reduced amount or availability of the enzyme in the cell.
[0069] Within the scope of the present invention, it is understood that a reduced enzyme activity in a recombinant microorganism is reduced to an enzyme activity that is at most 0.5-fold, particularly at most 0.1-fold, particularly at most 0.01-fold and more particularly at most 0.001-fold reduced relative to the enzyme activity of its non-modified microorganism.
[0070] Those skilled in the art are aware of the various microbiological and molecular biological techniques that can be used to reduce enzyme activity in a given microorganism.
[0071] In fact, the reduction of enzyme activity can d ) by reducing the expression of a gene encoding an enzyme in a microorganism, for example, by modifying a promoter, a regulatory region and / or a ribosome binding site, (ii) d ) by modifying the sequence of the gene encoding the enzyme so as to reduce the expression of the gene and / or reduce the expression of the enzyme activity, (iii) d ) by using an element that destabilizes the mRNA obtained after transcription of the gene and, optionally, (iv d ) by inactivating the gene, in particular by deleting the gene in whole or in part, by deleting the promoter preventing any expression of the gene in whole or in part and / or by inserting an external genetic element in the coding region or in the promoter region of the gene. It should be noted that in alternative (iv d) and in particular in the case of a complete deletion of the gene, may have no residual enzyme activity. In other words, in alternative (iv d ), the enzyme activity is silent.
[0072] The recombinant microorganism according to the present invention has an increased conversion activity from D-ribulose-5-phosphate to D-arabinose-5-phosphate compared to its non-modified microorganism. In other words, the intracellular activity of the enzyme that converts D-ribulose-5-phosphate into D-arabinose-5-phosphate in the recombinant microorganism is increased compared to its non-modified microorganism.
[0073] Enzyme that converts D-ribulose-5-phosphate to D-arabinose-5-phosphate i ) is in the form of D-arabinose-5-phosphate isomerase (EC 5.3.1.13). This enzyme is also known as "D-arabinose-5-phosphate aldose-ketose-isomerase", "arabinose phosphate isomerase", "D-arabinose-5-phosphate ketol-isomerase" and "arabinose phosphate isomerase". All of these nomenclatures refer to the same enzyme and are used interchangeably.
[0074] Therefore, the recombinant microorganism according to the present invention has an increased conversion activity from D-ribulose-5-phosphate to D-arabinose-5-phosphate catalyzed by an enzyme consisting of D-arabinose-5-phosphate isomerase that converts D-ribulose-5-phosphate into D-arabinose-5-phosphate compared to its non-modified microorganism.
[0075] Advantageously, the enzyme is encoded by the E. coli kdsD gene or by a homologue of this gene (E i ). Based on the definition of "homolog" provided previously, a homolog of the E. coli kdsD gene encoding a protein capable of converting D-ribulose-5-phosphate into D-arabinose-5-phosphate. As a specific example of the E. coli kdsD gene, mention may be made of the gene from strain K12 MG1655, which encodes the sequence between nucleotides 2829813 and 2830778 in the sequence NC_000913.3 accessed from the NCBI ("International Center for Biotechnology Information") website https: / / www.ncbi.nlm.nih.gov / and corresponds to the whole genome of strain K12 MG1655. On the NCBI website, the protein sequence of 321 amino acids encoded by this gene is referred to as sequence NP_417188.4 and corresponds to the sequence SEQ ID NO: 1 in the attached sequence listing.
[0076] All of the alternatives previously envisioned for increasing enzymatic activity can be used to increase the enzyme that converts D-ribulose-5-phosphate to D-arabinose-5-phosphate (E i) activity.
[0077] Typically, in the recombinant microorganism according to the invention, the increase in the activity of the conversion of D-ribulose-5-phosphate to D-arabinose-5-phosphate catalyzed by an enzyme consisting of D-arabinose-5-phosphate isomerase is obtained by increasing the copy number of the gene encoding the enzyme in the microorganism and / or by increasing the expression of the gene encoding the enzyme in the microorganism. In particular, the subject recombinant microorganism of the present invention exhibits overexpression of a gene encoding a D-arabinose-5-phosphate isomerase that converts D-ribulose-5-phosphate into D-arabinose-5-phosphate.
[0078] More particularly, the recombinant microorganism that is the subject of the present invention exhibits overexpression of the E. coli kdsD gene or a homologue thereof.
[0079] The recombinant microorganism according to the present invention exhibits an increased aldehyde cleavage activity from D-arabinose-5-phosphate to D-glyceraldehyde-3-phosphate and glycolaldehyde compared to its non-modified microorganism. In other words, the intracellular activity of the enzyme that catalyzes the cleavage of D-arabinose-5-phosphate to D-glyceraldehyde-3-phosphate and glycolaldehyde in the recombinant microorganism is increased compared to its non-modified microorganism.
[0080] Enzyme that catalyzes the cleavage of D-arabinose-5-phosphate into D-glyceraldehyde-3-phosphate and glycolaldehyde ii ) is in the form of fructose-6-phosphate aldolase (EC 4.1.2.-)
[14] .
[0081] Thus, the recombinant microorganism according to the present invention exhibits increased aldehyde cleavage activity from D-arabinose-5-phosphate to D-glyceraldehyde-3-phosphate and glycolaldehyde catalyzed by an enzyme consisting of fructose-6-phosphate aldolase that catalyzes the cleavage of D-arabinose-5-phosphate to D-glyceraldehyde-3-phosphate and glycolaldehyde compared to its non-modified microorganism.
[0082] Advantageously, the enzyme (E ii ) is encoded by the E. coli fsa gene or a homologue of this gene. Based on the definition of "homologue" provided previously, a homologue of the E. coli fsa gene encodes a protein capable of catalyzing the cleavage of D-arabinose-5-phosphate into D-glyceraldehyde-3-phosphate and glycolaldehyde. Specific examples of the E. coli fsa gene include:
[0083] - the gene fsaA from strain K12 MG1655, encoding a sequence comprised between nucleotides 863642 and 864304 in the sequence NC_000913.3 accessed from the NCBI website. The 220 amino acid protein sequence (FSAA) encoded by this gene is referred to on the NCBI website as the sequence NP_415346.4 and corresponds to the sequence SEQ ID NO: 2 in the attached sequence listing, and
[0084] - The gene fsaB from strain K12 MG1655, encoding a sequence included in the complementary strand between nucleotides 4139046 and 4139708 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the 220 amino acid protein sequence (FSAB) encoded by this gene is referred to as the sequence NP_418381.1 and corresponds to the sequence SEQ ID NO: 3 in the attached sequence listing.
[0085] As specific examples of E. coli fsa gene homologs, the genes encoding the fructose-6-phosphate aldolase variants FSAA L107Y / A129G and FSAAA129T / A165G disclosed by Szekrenyi et al., 2014
[15] may be mentioned.
[0086] All alternatives previously envisioned for increasing enzymatic activity can be used to increase the enzyme that catalyzes the cleavage of D-arabinose-5-phosphate to D-glyceraldehyde-3-phosphate and glycolaldehyde (E ii ) activity.
[0087] Typically, in the recombinant microorganism according to the invention, the increase in the activity of aldehyde cleavage from D-arabinose-5-phosphate to D-glyceraldehyde-3-phosphate and glycolaldehyde catalyzed by an enzyme consisting of fructose-6-phosphate aldolase is obtained by increasing the copy number of the gene encoding the enzyme in the microorganism and / or by increasing the expression of the gene encoding the enzyme in the microorganism. In particular, the subject recombinant microorganism of the present invention exhibits overexpression of a gene encoding a fructose-6-phosphate aldolase catalyzing the cleavage of D-arabinose-5-phosphate to D-glyceraldehyde-3-phosphate and glycolaldehyde.
[0088] More particularly, the recombinant microorganism that is the subject of the present invention exhibits overexpression of the E. coli fsa gene or a homologue thereof.
[0089] The recombinant microorganism according to the present invention exhibits an increased oxidation activity from glycolaldehyde to glycolic acid compared to its non-modified microorganism. In other words, the intracellular activity of the enzyme that oxidizes glycolaldehyde to glycolic acid in the recombinant microorganism is increased compared to its non-modified microorganism.
[0090] The enzyme that oxidizes glycolaldehyde to glycolic acid (E iii) is a glycolaldehyde dehydrogenase and specifically requires the presence of the cofactor NAD + A form of glycol-aldehyde dehydrogenase (EC 1.2.1.21).
[0091] Therefore, the recombinant microorganism according to the present invention exhibits increased oxidation activity from glycolaldehyde to glycolic acid catalyzed by an enzyme consisting of glycolaldehyde dehydrogenase that oxidizes glycolaldehyde to glycolic acid, compared to its non-modified microorganism.
[0092] Advantageously, the enzyme (E iii ) is encoded by the E. coli aldA gene or a homolog of this gene. Based on the definition of "homolog" provided previously, a homolog of the E. coli aldA gene encodes a gene that is involved in the production of an auxiliary factor, such as NAD + A protein capable of oxidizing glycolaldehyde to glycolic acid in the presence of hydroxyethyl ester. As a specific example of the Escherichia coli aldA gene, mention may be made of the gene from strain K12MG1655, which encodes a sequence between nucleotides 1488232 and 1489671 included in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the 479 amino acid protein sequence encoded by this gene is referred to as sequence NP_415933.1 and corresponds to the sequence SEQ ID NO: 4 in the attached sequence listing.
[0093] All of the alternatives previously envisioned for increasing enzymatic activity can be used to increase the enzyme that oxidizes glycolaldehyde to glycolic acid (E iii ) activity.
[0094] Typically, in the recombinant microorganism according to the invention, the increase in the oxidation activity from glycolaldehyde to glycolic acid catalyzed by an enzyme consisting of glycolaldehyde dehydrogenase is obtained by increasing the copy number of the gene encoding the enzyme in the microorganism and / or by increasing the expression of the gene encoding the enzyme in the microorganism. In particular, the subject recombinant microorganism of the present invention exhibits overexpression of a gene encoding a glycolaldehyde dehydrogenase that oxidizes glycolaldehyde to glycolic acid.
[0095] More particularly, the recombinant microorganism that is the subject of the present invention exhibits overexpression of the E. coli aldA gene or a homologue thereof.
[0096] In particular, the recombinant microorganism according to the present invention comprises:
[0097] at least one plasmid having the sequence of the E. coli KdsD gene or a homologue thereof, the sequence of the E. coli fsa gene or a homologue thereof and the sequence of the E. coli aldA gene or a homologue thereof, said sequences being optionally cloned as an operon,
[0098] - or at least two plasmids of the same nature, but with origins of replication of compatible or different nature, one having two sequences, optionally cloned as an operon, selected from the sequence of the E. coli kdsD gene or a homologue thereof, the sequence of the E. coli fsa gene or a homologue thereof and the sequence of the E. coli aldA gene or a homologue thereof, and the other plasmid being the third of these sequences. In this alternative, one plasmid has (fsa+aldA) and the other has kdsD; one plasmid has (fsa+kdsD) and the other has aldA or even one plasmid has (kdsD+aldA) and the other has fsa;
[0099] - or at least three identical or different plasmids, each having a different sequence selected from the sequence of the Escherichia coli kdsD gene or a homologue thereof, the sequence of the Escherichia coli fsa gene or a homologue thereof and the sequence of the Escherichia coli aldA gene or a homologue thereof.
[0100] All plasmids that have been previously described can be used as plasmids contained in the recombinant microorganisms that are the subject of the present invention.
[0101] More particularly, the recombinant microorganisms that are the subject of the present invention include:
[0102] a) a first plasmid comprising the sequence of the E. coli kdsD gene or a homologue thereof and the sequence of the E. coli fsa gene or a homologue thereof, said sequences being cloned as an operon and under the control of a first inducible or constitutive promoter, and
[0103] β) a second plasmid comprising the sequence of the E. coli aldA gene or a homologue thereof under the control of a second inducible or constitutive promoter,
[0104] The first and second promoters are the same or different.
[0105] The recombinant microorganism according to the present invention exhibits a reduced oxidation activity from glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate compared to its non-modified microorganism. In other words, the intracellular activity of oxidizing glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate in the recombinant microorganism is reduced compared to its non-modified microorganism.
[0106] The enzyme that oxidizes glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate (E iv ) is a glyceraldehyde-3-phosphate dehydrogenase and its cofactor is NAD + The enzyme is also known as "D-glyceraldehyde-3-phosphate:NAD + Oxidoreductase". Both nomenclatures refer to the same enzyme and are used interchangeably.
[0107] Advantageously, the enzyme (E iv ) is encoded by the E. coli gapA gene or by a homolog of this gene. Based on the definition of "homolog" provided previously, a homolog of the E. coli gapA gene encodes a homolog of the gapA gene in the presence of an auxiliary factor, such as NAD + A protein capable of oxidizing glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate in the presence of 1,3-bisphosphoglycerate. As a specific example of the gapA gene of Escherichia coli, mention may be made of the gene from strain K12 MG1655, which encodes a sequence comprised between nucleotides 1862771 and 1863766 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the protein sequence of 331 amino acids encoded by this gene is referred to as sequence NP_416293.1 and corresponds to the sequence SEQ ID NO: 4 in the attached sequence listing.
[0108] All alternatives previously envisioned to reduce enzymatic activity can be used to reduce the enzyme that oxidizes glycolaldehyde to glycolic acid (E iv ) activity.
[0109] Typically, in the recombinant microorganism according to the invention, the reduction of the oxidation activity from glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate catalyzed by an enzyme consisting of glyceraldehyde-3-phosphate dehydrogenase is obtained by reducing the expression of the gene encoding the enzyme and / or by inactivating the gene encoding the enzyme.
[0110] In a specific implementation, in the subject recombinant microorganism of the present invention, relative to the non-modified microorganism, the expression of the Escherichia coli gapA gene or its homologue is reduced but not inactivated. In this case, the reduction of gapA activity allows growth and the production of glycolic acid simultaneously. However, the glycolysis that keeps residual cannot reach maximum yield.
[0111] In alternative implementations, in the subject recombinant microorganism of the present invention, the expression of the E. coli gapA gene or its homologue is inactivated relative to the non-modified microorganism. In this case, the production of growth and glycolic acid is uncoupled. The gapA inactivation requires that the recombinant microorganism according to the present invention has a growth substrate, except pentoses and / or hexoses, which contains C2, C3 or C4 compounds such as acetate, pyruvate, malate or succinate or a substrate that enters after glyceraldehyde-3-phosphate (GAP).
[0112] Advantageously, the recombinant microorganism according to the invention is modified with respect to glucose transport, so that the phosphotransferase system (PTS) dependent on phosphoenolpyruvate (PEP) is inactivated, while the glucose transport activity and the conversion activity from glucose to glucose-6-phosphate encoded by Escherichia coli galP or Zymomonas mobilis glf or their homologues are increased compared to their non-modified microorganisms. This modification allows the assimilation of D-glucose and D-xylose [8, 16, 17].
[0113] It is reminded that in Escherichia coli, the phosphotransferase system (PTS), which is the most efficient system for glucose transport based on phosphoenolpyruvate (PEP). The activity of the PTS system has an impact on carbon flow distribution and plays a key role in carbon catabolism inhibition. The cytoplasmic PTS system is encoded by the operon ptsHIcrr. Specifically, the deletion of the ptsHIcrr operon in Escherichia coli is the most commonly used strategy to inactivate the PTS system.
[0114] PTS - The phenotype is characterized by very limited glucose transport and phosphorylation capacity. - strain, PEP is not required for glucose phosphorylation. Glucokinase catalyzes the ATP-dependent phosphorylation of glucose in the cytoplasm. Overexpression of galactose permease (GalP) for glucose transport and glucokinase (Glk) for phosphorylation restored the PTS phenotype. +
[18] Another strategy is to overexpress the glf gene encoding the glucose transporter (Glf) and the glucokinase of Zymomonas mobilis in Escherichia coli. Zm and glk Zm Gene
[19] .
[0115] Thus, in the recombinant microorganism according to the present invention, the glucose transport and phosphorylation activities from phosphoenolpyruvate by the phosphoenolpyruvate-dependent phosphotransferase system (PTS) are silenced compared to its non-modified microorganism.
[0116] By way of specific example, inactivation of the cytoplasmic PTS system encoded by the operon ptsHIcrr in E. coli results in the deletion of the gene:
[0117] - ptsH of the operon ptsHIcrr encoding the phosphate-carrying phosphohistidine protein Hpr of the PTS system. As a more specific example of the ptsH gene of Escherichia coli, mention may be made of the gene from strain K12 MG1655, which encodes a sequence on the complementary strand comprised between nucleotides 2533764 and 2534021 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the 85 amino acid protein sequence encoded by this gene is referred to as the sequence NP_416910.1 and corresponds to the sequence SEQ ID NO: 6 in the attached sequence listing.
[0118] - ptsI of the operon ptsHIcrr encoding enzyme I of the PTS system (EC 2.7.3.9). As a more specific example of a ptsl gene, mention may be made of the gene from strain K12 MG1655, which encodes a sequence on the complementary strand comprised between nucleotides 2534066 and 2535793 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the protein sequence of 575 amino acids encoded by this gene is referred to as sequence NP_416911.1 and corresponds to the sequence SEQ ID NO: 7 in the attached sequence listing.
[0119] - crr of the operon ptsHIcrr encoding the enzyme IIA of complex II of the PTS system (EC 2.7.1.69). As a more specific example of an E. coli crr gene, mention may be made of the gene from strain K12 MG1655, which encodes a sequence on the complementary strand comprised between nucleotides 2535834 and 2536343 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the protein sequence of 169 amino acids encoded by this gene is referred to as sequence NP_416912.1 and corresponds to the sequence SEQ ID NO: 8 in the attached sequence listing.
[0120] Advantageously, it is also desirable to delete the ptsG gene of the PTS system, which is not part of the operon ptsHIcrr, since PtsG is strongly involved in catabolism repression in E. coli. -The mutant is able to consume glucose, arabinose and xylose simultaneously, whereas the wild-type strain consumes glucose, then arabinose and finally xylose sequentially
[20] . The ptsG gene encodes the wild-type IIB / C hydrophobic domain of complex II of the PTS system. As a more specific example of the ptsG gene of Escherichia coli, mention may be made of the gene from strain K12 MG1655, which encodes a sequence on the complementary strand between nucleotides 1157869 and 1159302 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the protein sequence of 477 amino acids encoded by this gene is referred to as sequence NP_415619.1 and corresponds to the sequence SEQ ID NO: 9 in the attached sequence listing.
[0121] The E. coli galP gene encodes a galactose permease. Based on the definition of "homolog" provided previously, homologs of the E. coli galP gene encode galactose permease-type proteins. As a more specific example of an E. coli galP gene, mention may be made of the gene from strain K12 MG1655, which encodes a sequence between nucleotides 3088284 and 3089678 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the protein sequence of 464 amino acids encoded by this gene is referred to as the sequence NP_417418.1 and corresponds to the sequence SEQ ID NO: 10 in the attached sequence listing.
[0122] The mobilis Zymomonas glf gene encodes a glucose transporter. Based on the previously provided definition of "homologues", homologues of the mobilis Zymomonas glf gene encode glucose transporters. A more specific example of a mobilis Zymomonas glf gene may be mentioned, for example, a gene from the ATCC 31821 / ZM4 / CP4 strain encoding a protein of 473 amino acids, referred to as sequence P21906 in the UniProtKB website (http: / / www.uniprot.org / ) and corresponding to sequence SEQ ID NO: 11 in the attached sequence listing.
[0123] Advantageously, recombinant microorganisms according to the present invention show an increased conversion activity from glucose to glucose-6-phosphate compared with its non-modified microorganisms. In other words, the intracellular activity of the enzyme that converts glucose into glucose-6-phosphate in the recombinant microorganism increases compared with its non-modified microorganisms.
[0124] The enzyme that converts glucose to glucose-6-phosphate is in the form of glucokinase (EC 2.7.1.2).
[0125] Thus, the recombinant microorganism according to the present invention exhibits an increased conversion activity from glucose to glucose-6-phosphate catalyzed by an enzyme consisting of glucokinase that converts glucose into glucose-6-phosphate, compared to its non-modified microorganism.
[0126] Advantageously, the enzyme is encoded by the E. coli glK gene or by a homologue of this gene. Based on the definition of "homologue" provided previously, a homologue of the E. coli glK gene encodes a protein capable of converting glucose into glucose-6-phosphate. As a more specific example of an E. coli glK gene, mention may be made of the gene from strain K12 MG1655, which encodes a sequence comprised between nucleotides 2508461 and 2509426 in the sequence NC_000913.3 accessible from the NCBI website. On the NCBI website, the protein sequence of 321 amino acids encoded by this gene is referred to as sequence NP_416889.1 and corresponds to the sequence SEQ ID NO: 12 in the attached sequence listing.
[0127] All alternatives previously envisioned to increase enzymatic activity can be used to increase glucose transporter activity and conversion activity from glucose to glucose-6-phosphate.
[0128] Typically, in the recombinant microorganism according to the present invention, the increase of glucose transport catalyzed by the enzyme consisting of glucose transporter or galactose permease is obtained by increasing the copy number of the gene encoding the enzyme in the microorganism and / or by increasing the expression of the gene encoding the enzyme in the microorganism. In particular, the subject recombinant microorganism of the present invention shows a gene overexpressing the gene encoding the glucose transporter and / or overexpressing the gene encoding the galactose permease catalyzing the glucose transport. Moreover, in the recombinant microorganism according to the present invention, the increase of the conversion activity from glucose to glucose-6-phosphate by the enzyme consisting of the glucokinase that converts glucose into glucose-6-phosphate is obtained by increasing the copy number of the gene encoding the enzyme in the microorganism and / or by increasing the expression of the gene encoding the enzyme in the microorganism. In particular, the subject recombinant microorganism of the present invention shows a gene overexpressing the glucokinase that converts glucose into glucose-6-phosphate.
[0129] More particularly, the subject recombinant microorganism of the present invention exhibits overexpression of the E. coli aldA gene or the Zymomonas mobilis glf gene or one of their homologues and overexpression of the E. coli glK gene or its homologue. For this reason, in the recombinant microorganism according to the present invention, the genes listed above rely on a strong constitutive promoter such as the promoter proD.
[0130] Advantageously, in order to further optimize the production of glycolic acid via the non-natural synthetic pathway according to the invention, the subject recombinant microorganism of the invention may exhibit at least one of the following characteristics:
[0131] v) reduced oxidation activity from glycolate to glyoxylate compared to its non-modified microorganism;
[0132] vi) reduced repression of genes involved in regulating aerobic respiratory metabolism compared to its non-modified microorganism;
[0133] vii) reduced internalization of glycolate compared to its non-modified microorganism;
[0134] viii) reduced activity in the irreversible formation of methylglyoxal from dihydroxyacetone compared to a non-modified microorganism;
[0135] ix) reduced conversion activity from fructose-6-phosphate to fructose-1,6-bisphosphate compared to its non-modified microorganism;
[0136] x) reduced activity in producing D-ribose-1-phosphate from dihydroxyacetone phosphate and glycolaldehyde compared to a non-modified microorganism thereof; and
[0137] xi) The modified microorganism has an oxidation activity from D-glucose-6-phosphate to 6-phosphoglucono-1,5-lactone compared to its non-modified microorganism.
[0138] The recombinant microorganism according to the present invention exhibits reduced oxidation activity from glycolate to glyoxylate compared to its non-modified microorganism. In other words, the intracellular activity of the enzyme that oxidizes glycolate to glyoxylate in the recombinant microorganism is reduced compared to its non-modified microorganism.
[0139] The enzyme that oxidizes glycolate to glyoxylate (E v ) is based on glycolate dehydrogenase and its specific cofactor is NAD + The enzyme is also known as "glycolate oxidoreductase" and "glycolate oxidase". All of these nomenclatures refer to the same enzyme and are used interchangeably.
[0140] Therefore, the recombinant microorganism according to the present invention exhibits reduced oxidation activity from glycolate to glyoxylate catalyzed by an enzyme consisting of glycolate dehydrogenase that oxidizes glycolate to glyoxylate, compared to its non-modified microorganism.
[0141] Advantageously, the E. coli glycolate dehydrogenase activity is encoded by the glcDEF gene or a homologue of such a gene. Based on the definition of "homologue" provided previously, homologues of the E. coli glcD, glcE and glcF genes encode for the production of cofactors such as NAD. + Protein capable of oxidizing glycolate to glyoxylate when present.
[0142] As a more specific example of the E. coli glcD gene, there can be mentioned the gene from strain K12 MG1655, which encodes a sequence on the complementary strand between nucleotides 3126522 and 3128021 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the protein sequence of 499 amino acids encoded by this gene is referred to as sequence NP_417453.1 and corresponds to the sequence SEQ ID NO: 13 in the attached sequence listing.
[0143] As a more specific example of the E. coli glcE gene, mention may be made of the gene from strain K12 MG1655, which encodes a sequence on the complementary strand between nucleotides 3125470 and 3126522 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the 350 amino acid protein sequence encoded by this gene is referred to as the sequence NP_417418.1 and corresponds to the sequence SEQ ID NO: 14 in the attached sequence listing.
[0144] As a more specific example of the E. coli glcF gene, there can be mentioned the gene from strain K12 MG1655, which encodes a sequence on the complementary strand between nucleotides 3124236 and 3125459 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the 350 amino acid protein sequence encoded by this gene is referred to as sequence YP_026190.1 and corresponds to the sequence SEQ ID NO: 15 in the attached sequence listing.
[0145] All of the alternatives previously envisioned for reducing enzymatic activity can be used to reduce glycolate dehydrogenase activity.
[0146] Typically, in the recombinant microorganism according to the invention, the reduction of the oxidation activity from glycolate to glyoxylate catalyzed by an enzyme consisting of glycolate dehydrogenase is obtained by reducing the expression of the gene encoding this enzyme and / or by inactivating the gene encoding this enzyme.
[0147] More specifically, in the subject recombinant microorganism of the present invention, the expression of the E. coli glcD, glcE and glcF genes or their homologues is reduced relative to the non-modified microorganism. In a particular embodiment, the E. coli glcD, glcE and glcF genes or their homologues are deleted in the subject recombinant microorganism of the present invention so as to accumulate glycolic acid
[21] .
[0148] The recombinant microorganism according to the invention exhibits an increased aerobic respiration activity compared to its non-modified microorganism by reducing the inhibition of genes involved in regulating aerobic respiration metabolism. The inhibition does not involve enzymes, but involves transcriptional regulators.
[0149] Thus, the recombinant microorganism according to the invention exhibits, compared to its non-modified microorganism, a reduced repression of genes involved in the regulation of aerobic respiratory metabolism induced by transcriptional regulators capable of repressing genes involved in the regulation of aerobic respiratory metabolism.
[0150] Advantageously, the transcriptional regulator is encoded by the E. coli arcA gene or a homologue of this gene. Based on the definition of "homologue" provided previously, a homologue of the E. coli arcA gene encodes a protein capable of repressing genes involved in aerobic respiratory metabolism
[22] .
[0151] As a specific example of the E. coli arcA gene, there can be mentioned the gene from strain K12 MG1655, which encodes a sequence on the complementary strand between nucleotides 4639590 and 4640306 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the protein sequence of 238 amino acids encoded by this gene is referred to as the sequence NP_416911.1 and corresponds to the sequence SEQ ID NO: 16 in the attached sequence listing.
[0152] All of the alternatives previously envisioned for reducing enzymatic activity can be modified mutatis mutandis to reduce the activity of transcriptional regulators that repress genes involved in aerobic metabolism.
[0153] Typically, in the recombinant microorganism according to the invention, the reduced repression of genes involved in the regulation of aerobic respiratory metabolism induced by a transcriptional regulator is obtained by reducing the expression of the gene encoding the regulator and / or by inactivating the gene encoding the regulator.
[0154] More specifically, in the subject recombinant microorganism of the present invention, the expression of the E. coli arcA gene or its homologue is reduced relative to the non-modified microorganism. In a particular implementation, the E. coli arcA gene or its homologue is deleted in the subject recombinant microorganism of the present invention.
[0155] The recombinant microorganism according to the invention exhibits reduced internalization of glycolic acid compared to its non-modified counterpart. This internalization involves proteins that import glycolic acid [23, 24, 25].
[0156] Thus, the recombinant microorganism according to the invention exhibits reduced internalization of glycolic acid induced by at least one glycolic acid-importing protein compared to its non-modified microorganism.
[0157] Advantageously, the protein is encoded by the E. coli glcA, IIdP or yjcG gene or a homologue of such a gene.Based on the definition of "homologue" provided previously, a homologue of the E. coli glcA, IIdP or yjcG gene encodes a protein capable of internalizing glycolate.
[0158] As a specific example of the E. coli glcA gene, there can be mentioned the gene from strain K12 MG1655, which encodes a sequence between nucleotides 1157869 and 1159302 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the protein sequence of 477 amino acids encoded by this gene is referred to as sequence NP_415619.1 and corresponds to the sequence SEQ ID NO: 17 in the attached sequence listing.
[0159] As a specific example of an E. coli IIdP gene, there can be mentioned the gene from strain K12 MG1655, which encodes a sequence between nucleotides 3777399 and 3779054 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the protein sequence of 551 amino acids encoded by this gene is referred to as sequence NP_418060.1 and corresponds to the sequence SEQ ID NO: 18 in the attached sequence listing.
[0160] As a specific example of the E. coli yjcG gene, the gene from strain K12 MG1655 can be mentioned, which encodes a sequence between nucleotides 4283253 and 4284902 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the protein sequence of 549 amino acids encoded by this gene is referred to as sequence NP_418491.1 and corresponds to the sequence SEQ ID NO: 19 in the attached sequence listing.
[0161] All of the alternatives previously envisioned for reducing enzymatic activity can be used mutatis mutandis to reduce the activity of proteins that import glycolate.
[0162] Typically, in the recombinant microorganism of the present invention, the reduction in glycolate internalization induced by the introduction of one or more proteins of glycolate is obtained by reducing the expression of the gene encoding the protein(s) and / or by inactivating the gene(s) encoding the protein(s).
[0163] More particularly, in the theme recombinant microorganism of the present invention, the expression of Escherichia coli glcA, IIdP or yjcG gene or its homologue is reduced relative to non-modified microorganism. Alternatively, in the theme recombinant microorganism of the present invention, Escherichia coli glcA, IIdP or yjcG gene or its homologue is deleted relative to non-modified microorganism.
[0164] The recombinant microorganism according to the present invention exhibits a reduced activity of irreversibly forming methylglyoxal from dihydroxyacetone phosphate (DHAP) compared to its non-modified microorganism. In other words, the intracellular activity of the enzyme that irreversibly forms methylglyoxal (a cytotoxic compound) from DHAP in the recombinant microorganism is reduced compared to its non-modified microorganism.
[0165] Enzyme that irreversibly forms methylglyoxal from DHAP (E viii ) is in the form of methylglyoxal synthase (EC 4.2.3.3)
[26] .
[0166] Thus, the recombinant microorganism according to the present invention exhibits reduced activity in the irreversible formation of methylglyoxal from DHAP catalyzed by an enzyme consisting of methylglyoxal synthase which irreversibly forms methylglyoxal from DHAP, compared to its non-modified microorganism.
[0167] Advantageously, the enzyme (E viii ) is encoded by the E. coli mgsA gene or by a homologue of this gene. Based on the definition of "homologue" provided previously, a homologue of the E. coli mgsA gene encodes a protein capable of irreversibly forming methylglyoxal from DHAP. As a specific example of an E. coli mgsA gene, mention may be made of the gene from strain K12 MG1655, which encodes a sequence on the complementary strand between nucleotides 1026557 and 1027015 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the protein sequence of 152 amino acids encoded by this gene is referred to as sequence NP_415483.2 and corresponds to the sequence SEQ ID NO: 20 in the attached sequence listing.
[0168] All alternatives previously envisioned for reducing enzymatic activity can be used to reduce the enzyme that irreversibly forms methylglyoxal from DHAP (E viii ) activity.
[0169] Typically, in the recombinant microorganism according to the invention, the reduction of the activity catalyzing the irreversible formation of methylglyoxal from DHAP by an enzyme consisting of methylglyoxal synthase is obtained by reducing the expression of the gene encoding the enzyme and / or by inactivating the gene encoding the enzyme.
[0170] More specifically, in the subject recombinant microorganism of the present invention, the expression of the E. coli mgsA gene or its homolog is reduced relative to the non-modified microorganism. In a particular implementation, the E. coli mgsA gene or its homolog is deleted in the subject recombinant microorganism of the present invention.
[0171] The recombinant microorganism according to the present invention has a reduced conversion activity from fructose-6-phosphate to fructose-1,6-bisphosphate compared to its non-modified microorganism. In other words, the intracellular activity of the enzyme that converts fructose-6-phosphate into fructose-1,6-bisphosphate in the recombinant microorganism is reduced compared to its non-modified microorganism.
[0172] The enzyme that converts fructose-6-phosphate to fructose-1,6-bisphosphate (E iX ) is in the form of phosphofructokinase (EC 2.7.1.11).
[0173] Thus, the recombinant microorganism according to the present invention exhibits reduced conversion activity from fructose-6-phosphate to fructose-1,6-bisphosphate catalyzed by an enzyme consisting of phosphofructokinase that converts fructose-6-phosphate into fructose-1,6-bisphosphate, compared to its non-modified microorganism.
[0174] Advantageously, the enzyme (E ix ) is encoded by the Escherichia coli pfKA gene or a homologue of such a gene. Based on the definition of "homologue" provided previously, a homologue of the Escherichia coli pfKA gene encodes a protein capable of converting fructose-6-phosphate into fructose-1,6-bisphosphate. As a more specific example of Escherichia coli pfKA, mention may be made of the gene from strain K12 MG1655, which encodes a sequence on the complementary strand between nucleotides 4107552 and 4108514 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the protein sequence of 320 amino acids encoded by this gene is referred to as sequence NP_418351.1 and corresponds to the sequence SEQ ID NO: 21 in the attached sequence listing.
[0175] All of the alternatives previously envisioned for reducing enzymatic activity can be used to reduce the enzyme that converts fructose-6-phosphate to fructose-1,6-bisphosphate (E ix ) activity.
[0176] Typically, in the recombinant microorganism according to the invention, the reduction of the activity of the conversion of fructose-6-phosphate to fructose-1,6-bisphosphate catalyzed by an enzyme consisting of phosphofructokinase is obtained by reducing the expression of the gene encoding the enzyme and / or by inactivating the gene encoding the enzyme.
[0177] More specifically, in the subject recombinant microorganism of the present invention, the expression of the E. coli pfKA gene or its homolog is reduced relative to the non-modified microorganism. In a particular embodiment, the E. coli pfKA gene or its homolog is deleted in the subject recombinant microorganism of the present invention to avoid the ineffective cycle of fructose-1,6-bisphosphate
[27] .
[0178] The recombinant microorganism according to the present invention exhibits a reduced activity of producing D-ribose-1-phosphate from dihydroxyacetone phosphate and glycolaldehyde compared to its non-modified microorganism. In other words, in the recombinant microorganism, the intracellular activity of the enzyme producing D-ribose-1-phosphate from dihydroxyacetone phosphate and glycolaldehyde is reduced compared to its non-modified microorganism.
[0179] Enzyme that produces D-ribose-1-phosphate from dihydroxyacetone phosphate and glycolaldehyde x ) is in the form of L-fucose-phosphate aldolase (EC 4.1.2.17)
[28] .
[0180] Therefore, the recombinant microorganism according to the present invention exhibits reduced activity of producing D-ribose-1-phosphate from dihydroxyacetone phosphate and glycolaldehyde by an enzyme catalyzed by L-fucose-phosphate aldolase that produces D-ribose-1-phosphate from dihydroxyacetone phosphate and glycolaldehyde, compared to its non-modified microorganism.
[0181] Advantageously, the enzyme (E x ) is encoded by the E. coli fucA gene or a homologue of this gene. Based on the definition of "homologue" provided previously, a homologue of the E. coli fucA gene encodes a protein capable of producing D-ribose-1-phosphate from dihydroxyacetone phosphate and glycolaldehyde. As a more specific example of an E. coli fucA gene, mention may be made of the gene from strain K12 MG1655, which encodes a sequence on the complementary strand between nucleotides 2933041 and 2933688 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the protein sequence of 215 amino acids encoded by this gene is referred to as sequence NP_417280.1 and corresponds to the sequence SEQ ID NO: 22 in the attached sequence listing.
[0182] All alternatives previously envisioned for reducing enzymatic activity can be used to reduce the enzyme that catalyzes the reversible interconversion from D-ribose-1-phosphate to dihydroxyacetone phosphate and glycolaldehyde (E x ) activity.
[0183] Typically, in the recombinant microorganism according to the present invention, the reduction of the activity of producing D-ribose-1-phosphate from dihydroxyacetone phosphate and glycolaldehyde catalyzed by an enzyme consisting of L-fucose-phosphate aldolase is obtained by reducing the expression of the gene encoding the enzyme and / or by inactivating the gene encoding the enzyme.
[0184] More specifically, in the subject recombinant microorganism of the present invention, the expression of the E. coli fucA gene or its homologue is reduced relative to the non-modified microorganism. In a particular implementation, the E. coli fucA gene or its homologue is deleted in the subject recombinant microorganism of the present invention.
[0185] The recombinant microorganism according to the present invention exhibits a reduced or increased activity of producing 6-phospho-D-glucono-1,5-lactone from D-glucose-6-phosphate compared to its non-modified microorganism.
[0186] In a first embodiment, the recombinant microorganism according to the present invention exhibits reduced activity in producing 6-phospho-D-glucono-1,5-lactone from D-glucose-6-phosphate compared to its non-modified microorganism. In other words, the enzyme (E xi )'s intracellular activity was reduced compared to its non-modified microorganism.
[0187] Enzyme that produces 6-phospho-D-glucono-1,5-lactone from D-glucose-6-phosphate (E xi ) is dependent on NADP + form of glucose-6-phosphate dehydrogenase (EC 1.1.1.49)
[29] .
[0188] Thus, the recombinant microorganism according to the present invention exhibits reduced activity in producing 6-phospho-D-glucono-1,5-lactone from D-glucose-6-phosphate by an enzyme catalyzed by a cofactor-dependent glucose-6-phosphate dehydrogenase that produces 6-phospho-D-glucono-1,5-lactone from D-glucose-6-phosphate, compared to its non-modified microorganism.
[0189] Advantageously, the enzyme (E xi ) is encoded by the E. coli zwf gene or its homolog. Based on the definition of "homolog" provided previously, homologs of the E. coli zwf gene encode a cofactor, such as NADP + In the presence of, a protein capable of producing 6-phospho-D-glucono-1,5-lactone from D-glucose-6-phosphate. As a more specific example of the Escherichia coli zwf gene, mention may be made of the gene from strain K12 MG1655, which encodes a sequence on the complementary strand between nucleotides 1934839 and 1936314 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the protein sequence of 491 amino acids encoded by this gene is referred to as sequence NP_416366 and corresponds to the sequence SEQ ID NO: 23 in the attached sequence listing.
[0190] All of the alternatives previously envisioned for reducing enzymatic activity can be used to reduce the enzyme that produces 6-phospho-D-glucono-1,5-lactone from D-glucose-6-phosphate (E xi ) activity.
[0191] Typically, in the recombinant microorganism according to the invention, the reduction in the activity of an enzyme consisting of cofactor-dependent glucose-6-phosphate dehydrogenase catalyzing the production of 6-phospho-D-glucono-1,5-lactone from D-glucose-6-phosphate is obtained by reducing the expression of the gene encoding the enzyme and / or by inactivating the gene encoding the enzyme.
[0192] More particularly, in the subject recombinant microorganism of the present invention, the expression of the E. coli zwf gene or its homologue is reduced relative to the non-modified microorganism. In a particular implementation, the E. coli zwf gene or its homologue is deleted in the subject recombinant microorganism of the present invention.
[0193] In a second embodiment, the recombinant microorganism according to the present invention exhibits an increased activity of producing 6-phospho-D-glucono-1,5-lactone from D-glucose-6-phosphate compared to its non-modified microorganism. In other words, the enzyme (E xi )'s intracellular activity was increased compared to its non-modified microorganisms.
[0194] Thus, the recombinant microorganism according to the present invention exhibits increased activity of an enzyme catalyzing the production of 6-phospho-D-glucono-1,5-lactone from D-glucose-6-phosphate, which is composed of a cofactor-dependent glucose-6-phosphate dehydrogenase, compared to its non-modified microorganism.
[0195] All of the alternatives previously envisioned for reducing enzymatic activity can be used to increase the enzyme that produces 6-phospho-D-glucono-1,5-lactone from D-glucose-6-phosphate (E xi ) activity.
[0196] Typically, in the recombinant microorganism according to the invention, the increase in the activity of the enzyme consisting of a cofactor-dependent glucose-6-phosphate dehydrogenase catalyzing the production of 6-phospho-D-glucono-1,5-lactone from D-glucose-6-phosphate is obtained by increasing the copy number of the gene encoding the enzyme and / or by increasing the expression of the gene encoding the enzyme. In particular, the subject recombinant microorganism of the present invention exhibits overexpression of a gene encoding a cofactor-dependent glucose-6-phosphate dehydrogenase that produces 6-phospho-D-glucono-1,5-lactone from D-glucose-6-phosphate.
[0197] More particularly, the recombinant microorganism that is the subject of the present invention exhibits overexpression of the E. coli zwf gene or a homologue thereof.
[0198] In this second embodiment, the recombinant microorganism that is the subject of the present invention exhibits the following characteristics:
[0199] xi) increased oxidation activity of D-glucose-6-phosphate to 6-phosphoglucono-1,5-lactone compared to a non-modified microorganism thereof;
[0200] xii) reduced activity in forming 2-dehydroxy-3-deoxy-D-gluconate-6-phosphate from D-gluconate-6-phosphate compared to a non-modified microorganism thereof; and
[0201] xiii) reduced activity in forming glyceraldehyde-3-phosphate and pyruvate from 2-dehydroxy-3-deoxy-D-gluconate-6-phosphate as compared to its non-modified microorganism.
[0202] In this second embodiment, the recombinant microorganism according to the present invention exhibits a reduced activity of forming 2-dehydroxy-3-deoxy-D-gluconic acid-6-phosphate from D-gluconic acid-6-phosphate compared to its non-modified microorganism. In other words, the intracellular activity of the enzyme that forms 2-dehydroxy-3-deoxy-D-gluconic acid-6-phosphate from D-gluconic acid-6-phosphate in the recombinant microorganism is reduced compared to its non-modified microorganism.
[0203] Enzyme that produces 2-dehydroxy-3-deoxy-D-gluconate-6-phosphate from D-gluconate-6-phosphate (E xii ) is in the form of phosphogluconate dehydratase (EC 4.2.1.12)
[30] .
[0204] Therefore, the recombinant microorganism according to the present invention exhibits reduced activity in forming 2-dehydroxy-3-deoxy-D-gluconic acid-6-phosphate from D-gluconic acid-6-phosphate by an enzyme catalyzed by a phosphogluconate dehydratase that produces 2-dehydroxy-3-deoxy-D-gluconic acid-6-phosphate from D-gluconic acid-6-phosphate, compared to its non-modified microorganism.
[0205] Advantageously, the enzyme (E xii) is encoded by the E. coli edd gene or a homologue thereof. Based on the definition of "homologue" provided previously, a homologue of the E. coli edd gene encodes a protein capable of producing 2-dehydroxy-3-deoxy-D-gluconate-6-phosphate from D-gluconate-6-phosphate. As a more specific example of the E. coli edd gene, mention may be made of the gene from strain K12MG1655, which encodes a sequence on the complementary strand between nucleotides 1932794 and 1934604 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the protein sequence of 603 amino acids encoded by this gene is referred to as the sequence CAA45221 and corresponds to the sequence SEQ ID NO: 24 in the attached sequence listing.
[0206] Typically, in the recombinant microorganism according to the invention, the reduction of the oxidation activity from glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate catalyzed by an enzyme consisting of glyceraldehyde-3-phosphate dehydrogenase is obtained by reducing the expression of the gene encoding the enzyme and / or by inactivating the gene encoding the enzyme.
[0207] More particularly, in the recombinant microorganisms subject of the present invention, the expression of the E. coli edd gene or its homologues is reduced compared to non-modified microorganisms. In a particular embodiment, the E. coli edd gene or its homologues are deleted in the recombinant microorganisms subject of the present invention.
[0208] In this second embodiment, the recombinant microorganism according to the present invention exhibits a reduced activity of producing D-glyceraldehyde-3-phosphate and pyruvic acid from 2-dehydroxy-3-deoxy-D-gluconic acid-6-phosphate compared to its non-modified microorganism. In other words, the intracellular activity of the enzyme that produces D-glyceraldehyde-3-phosphate and pyruvic acid from 2-dehydroxy-3-deoxy-D-gluconic acid-6-phosphate in the recombinant microorganism is reduced compared to its non-modified microorganism.
[0209] Enzyme that produces D-glyceraldehyde-3-phosphate and pyruvate from 2-dehydroxy-3-deoxy-D-gluconate-6-phosphate (E xiii ) in the form of 2-dehydroxy-3-deoxy-phosphogluconate aldolase
[31] .
[0210] Therefore, the recombinant microorganism according to the present invention exhibits reduced activity of an enzyme consisting of 2-dehydroxy-3-deoxy-phosphogluconate aldolase that produces D-glyceraldehyde-3-phosphate and pyruvate from 2-dehydroxy-3-deoxy-D-gluconic acid-6-phosphate, catalyzing the production of D-glyceraldehyde-3-phosphate and pyruvate from 2-dehydroxy-3-deoxy-D-gluconic acid-6-phosphate, compared to its non-modified microorganism.
[0211] Advantageously, the enzyme (E xiii) is encoded by the E. coli eda gene or a homologue thereof. Based on the definition of "homologue" provided previously, a homologue of the E. coli edd gene encodes a protein capable of producing D-glyceraldehyde-3-phosphate and pyruvate from 2-dehydroxy-3-deoxy-D-gluconate-6-phosphate. As a more specific example of the E. coli eda gene, mention may be made of the gene from strain K12MG1655, which encodes a sequence on the complementary strand between nucleotides 1932115 and 1932756 in the sequence NC_000913.3 accessed from the NCBI website. On the NCBI website, the protein sequence of 213 amino acids encoded by this gene is referred to as sequence NP_416364.1 and corresponds to the sequence SEQ ID NO: 25 in the attached sequence listing.
[0212] Typically, in the recombinant microorganism according to the present invention, the reduction of the activity of producing D-glyceraldehyde-3-phosphate and pyruvate from 2-dehydroxy-3-deoxy-D-gluconic acid-6-phosphate catalyzed by an enzyme consisting of 2-dehydroxy-3-deoxy-phosphogluconate aldolase is obtained by reducing the expression of the gene encoding the enzyme and / or by inactivating the gene encoding the enzyme.
[0213] More particularly, in the subject recombinant microorganism of the present invention, the expression of the E. coli eda gene or its homologue is reduced compared to the non-modified microorganism. In a particular embodiment, the E. coli eda gene or its homologue is deleted in the subject recombinant microorganism of the present invention.
[0214] According to the present invention, a cyclic pathway for glycolic acid synthesis from the primary lignocellulosic monosaccharides with optimal carbon conservation is described in Figure 2 Indicated in.
[0215] The present invention also relates to the use of a recombinant microorganism as defined previously for producing glycolic acid from a culture medium comprising at least one pentose and / or at least one hexose as carbon source.
[0216] Therefore, the present invention relates to a method for producing glycolic acid comprising the steps of:
[0217] a) cultivating the recombinant microorganism as previously defined in a culture medium comprising at least one pentose and / or at least one hexose as carbon source; and
[0218] b) recovering glycolic acid from the microorganism and / or the culture medium.
[0219] The subject production method of the present invention uses steps and apparatus conventionally used in the field of biological fermentation.
[0220] Thus, in step (a) of the method according to the invention, the microorganism may be cultured in a culture medium according to the usual techniques for culturing that type of microorganism. The culture medium may be a commercial culture medium or an extemporaneously prepared culture medium.
[0221] Advantageously, the culture medium used in the method of the invention is in the form of a sterile liquid containing a carbon source, a nitrogen source, a phosphorus source, trace elements and optionally a sulphur source.
[0222] In the scope of the present invention, carbon source comprises at least one pentose and / or at least one hexose.As an example, this carbon source can comprise at least two different pentoses and at least one hexose, especially at least wood sugar, arabinose and glucose, and especially D-wood sugar, L-arabinose and D-glucose.These pentoses and hexose are usually from renewable carbon material such as plant biomass, and are especially lignocellulosic biomass.
[0223] The plant biomass is selected from the group consisting of agricultural products, such as so-called "energy" dedicated products, such as Miscanthus, switchgrass (Panicum virgatum) and very short rotational shrubs, for example poplar or willow; agricultural product residues such as cereal straw, corn stover and sugarcane cobs; forest products; forest product residues such as wood processing residues.
[0224] One of the main elements of plant biomass is lignocellulose, which corresponds to the main component of plant cell walls. Lignocellulose contains 75% carbohydrates and its hydrolysis releases fermentable sugars, mainly D-glucose, D-xylose and L-arabinose
[32] .
[0225] In the first embodiment of the step (a) according to the inventive method, the recombinant microorganism cultivated is a recombinant microorganism as previously defined and wherein the expression of the Escherichia coli gapA gene or its homologue is reduced relative to the non-modified microorganism, but is not inactivated. In this first embodiment, the carbon source used can only include an element selected from D-glucose, D-xylose, L-arabinose and mixtures thereof. "Mixture" means a mixture of D-glucose and D-xylose, a mixture of D-glucose and L-arabinose, a mixture of D-xylose and L-arabinose, and a mixture of D-glucose, D-xylose and L-arabinose.
[0226] In the second embodiment of step (a) according to the inventive method, the recombinant microorganism cultivated is a recombinant microorganism as previously defined and wherein the expression of the Escherichia coli gapA gene or its homologue is inactivated relative to a non-modified microorganism. In this second embodiment, in addition to D-xylose and / or L-arabinose and / or D-glucose, the carbon source used comprises one or more C2, C3 or C4 compounds selected from malic acid, pyruvic acid, succinic acid, acetic acid and mixtures thereof. In this second embodiment, the method for producing glycolic acid is carried out in two stages, with a first biomass production stage, followed by a production stage triggered when C2, C3 or C4 compounds are exhausted, promoting the bioconversion of hexose and pentose sugars into glycolic acid.
[0227] In the first and second embodiments of the process according to the present invention, the carbon source used may further include at least one other carbon element such as galactose, xylose, fructose, lactose, sucrose, maltose, syrup, starch and starch hydrolysate.
[0228] Examples of suitable nitrogen sources include ammonia, ammonium salts such as ammonium chloride, ammonium sulfate, ammonium acetate and ammonium phosphate, other nitrogen-containing compounds; peptone as tryptone; meat extract, yeast extract, corn steep liquor; casein hydrolysate; soy flour and soy flour hydrolysate.
[0229] The person skilled in the art is aware of different examples of sulfur sources, phosphorus sources and trace elements used during step (a) of the method according to the invention. They will be able to select the most suitable sources and trace elements according to the recombinant microorganisms cultivated and the culture conditions without creative effort.
[0230] The temperature during the cultivation in step (a) is usually between 15 and 45° C., and the pH during this cultivation is usually maintained at a value between 3.0 and 9.0. The pH can be adjusted by using, for example, inorganic or organic acids, alkaline solutions, urea or calcium carbonate.
[0231] It should be noted that, depending on the microorganism to be cultivated, the skilled person will be able to adapt the culture medium and culture conditions to their particular requirements, optionally by routine testing. Thus, during step (a), the recombinant microorganism is under conditions for producing glycolic acid from a carbon source as previously defined. Typically, the cultivation is carried out under aerobic conditions, i.e. in the presence of oxygen.
[0232] Advantageously, the recombinant microorganism is cultured as a suspension. A "suspension" of cells is generally understood to include all types of suspended or dispersed cell cultures. The term "as a suspension" is also used to distinguish cells that are not cultured in a liquid medium, such as cells that are cultured by adhesion to a culture dish. On the other hand, the term "suspension" includes both freely dispersed cells and aggregated cells, whether or not aggregation occurs spontaneously.
[0233] Alternatively, the recombinant microorganisms can be cultured attached to solid phases such as microbeads, beads, capillaries, hollow fibers, etc. These various elements are generally microorganism-compatible materials such as dextran, gelatin, glass, and cellulose.
[0234] Furthermore, the cultivation methods which can be used during step (a) of the method according to the invention include, but are not limited to, discontinuous cultivation, continuous cultivation or "fed-batch" cultivation.
[0235] A "continuous (cell) culture" is a cell culture characterized by a continuous supply of a nutrient liquid feed and a continuous liquid flow. Alternatively, a continuous culture may be a "perfusion culture", in which case the liquid flow contains culture medium that is substantially free of cells or has a cell concentration substantially lower than that in the bioreactor. In a perfusion culture, cells may be preserved, for example, by filtration, centrifugation or sedimentation.
[0236] A "fed-batch" culture is a discontinuous cell culture in which a substrate in concentrated solid or liquid form is added periodically or continuously during the assay. In discontinuous cultures, a "fed-batch" culture is initiated by inoculating cells into a culture medium, but, unlike discontinuous cultures, there is subsequent inflow of nutrients, such as via a concentrated nutrient feed. Unlike continuous cultures, in a "fed-batch" culture no liquid is systematically removed from the culture or cells.
[0237] Step (a) of the method according to the invention can be implemented in any container suitable for cell culture. As specific examples, conical flasks, bioreactors or biofermenters with different volumes can be mentioned. For further information on these different containers, reference is made to [5].
[0238] In the process according to the invention, steps (a) and (b) may occur one after the other, or simultaneously. Advantageously, during step (b) of the process according to the invention, glycolic acid is recovered in the culture medium.
[0239] Further characteristics and advantages of the present invention will become more apparent to a person skilled in the art upon reading the following examples given by way of illustration and non-limiting purpose, with reference to the accompanying drawings. Sequence Listing <110> INSA Toulouse French National Center for Scientific Research National Institute of Agricultural Research <120> Microorganisms and methods for producing glycolic acid from pentenes and hexoses <130> S64424 PCT SG-T <140> PCT / FR2019 / 051760 <141> 2019-07-12 <150> FR1856511 <151> 2018-07-13 <160> 43 <170> PatentIn Version 3.5 <210> 1 <211> 321 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(321) <223> Protein encoded by gene kdsD <400> 1 Met Ser Glu Ala Leu Leu Asn Ala Gly Arg Gln Thr Leu Met Leu Glu 1 5 10 15 Leu Gln Glu Ala Ser Arg Leu Pro Glu Arg Leu Gly Asp Asp Phe Val 20 25 30 Arg Ala Ala Asn Ile Ile Leu His Cys Glu Gly Lys Val Val Val Ser 35 40 45 Gly Ile Gly Lys Ser Gly His Ile Gly Lys Lys Ile Ala Ala Thr Leu 50 55 60 Ala Ser Thr Gly Thr Pro Ala Phe Phe Val His Pro Ala Glu Ala Leu 65 70 75 80 His Gly Asp Leu Gly Met Ile Glu Ser Arg Asp Val Met Leu Phe Ile 85 90 95 Ser Tyr Ser Gly Gly Ala Lys Glu Leu Asp Leu Ile Ile Pro Arg Leu 100 105 110 Glu Asp Lys Ser Ile Ala Leu Leu Ala Met Thr Gly Lys Pro Thr Ser 115 120 125 Pro Leu Gly Leu Ala Ala Lys Ala Val Leu Asp Ile Ser Val Glu Arg 130 135 140 Glu Ala Cys Pro Met His Leu Ala Pro Thr Ser Ser Thr Val Asn Thr 145 150 155 160 Leu Met Met Gly Asp Ala Leu Ala Met Ala Val Met Gln Ala Arg Gly 165 170 175 Phe Asn Glu Glu Asp Phe Ala Arg Ser His Pro Ala Gly Ala Leu Gly 180 185 190 Ala Arg Leu Leu Asn Lys Val His His Leu Met Arg Arg Asp Asp Ala 195 200 205 Ile Pro Gln Val Ala Leu Thr Ala Ser Val Met Asp Ala Met Leu Glu 210 215 220 Leu Ser Arg Thr Gly Leu Gly Leu Val Ala Val Cys Asp Ala Gln Gln 225 230 235 240 Gln Val Gln Gly Val Phe Thr Asp Gly Asp Leu Arg Arg Trp Leu Val 245 250 255 Gly Gly Gly Ala Leu Thr Thr Pro Val Asn Glu Ala Met Thr Val Gly 260 265 270 Gly Thr Thr Leu Gln Ser Gln Ser Arg Ala Ile Asp Ala Lys Glu Ile 275 280 285 Leu Met Lys Arg Lys Ile Thr Ala Ala Pro Val Val Asp Glu Asn Gly 290 295 300 Lys Leu Thr Gly Ala Ile Asn Leu Gln Asp Phe Tyr Gln Ala Gly Ile 305 310 315 320 Ile <210> 2 <211> 220 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(220) <223> Protein encoded by gene fsaA <400> 2 Met Glu Leu Tyr Leu Asp Thr Ser Asp Val Val Ala Val Lys Ala Leu 1 5 10 15 Ser Arg Ile Phe Pro Leu Ala Gly Val Thr Thr Asn Pro Ser Ile Ile 20 25 30 Ala Ala Gly Lys Lys Pro Leu Asp Val Val Leu Pro Gln Leu His Glu 35 40 45 Ala Met Gly Gly Gln Gly Arg Leu Phe Ala Gln Val Met Ala Thr Thr 50 55 60 Ala Glu Gly Met Val Asn Asp Ala Leu Lys Leu Arg Ser Ile Ile Ala 65 70 75 80 Asp Ile Val Val Lys Val Pro Val Thr Ala Glu Gly Leu Ala Ala Ile 85 90 95 Lys Met Leu Lys Ala Glu Gly Ile Pro Thr Leu Gly Thr Ala Val Tyr 100 105 110 Gly Ala Ala Gln Gly Leu Leu Ser Ala Leu Ala Gly Ala Glu Tyr Val 115 120 125 Ala Pro Tyr Val Asn Arg Ile Asp Ala Gln Gly Gly Ser Gly Ile Gln 130 135 140 Thr Val Thr Asp Leu His Gln Leu Leu Lys Met His Ala Pro Gln Ala 145 150 155 160 Lys Val Leu Ala Ala Ser Phe Lys Thr Pro Arg Gln Ala Leu Asp Cys 165 170 175 Leu Leu Ala Gly Cys Glu Ser Ile Thr Leu Pro Leu Asp Val Ala Gln 180 185 190 Gln Met Ile Ser Tyr Pro Ala Val Asp Ala Ala Val Ala Lys Phe Glu 195 200 205 Gln Asp Trp Gln Gly Ala Phe Gly Arg Thr Ser Ile 210 215 220 <210> 3 <211> 220 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(220) <223> Protein encoded by gene fsaB <400> 3 Met Glu Leu Tyr Leu Asp Thr Ala Asn Val Ala Glu Val Glu Arg Leu 1 5 10 15 Ala Arg Ile Phe Pro Ile Ala Gly Val Thr Thr Asn Pro Ser Ile Ile 20 25 30 Ala Ala Ser Lys Glu Ser Ile Trp Glu Val Leu Pro Arg Leu Gln Lys 35 40 45 Ala Ile Gly Asp Glu Gly Ile Leu Phe Ala Gln Thr Met Ser Arg Asp 50 55 60 Ala Gln Gly Met Val Glu Glu Ala Lys Arg Leu Arg Asp Ala Ile Pro 65 70 75 80 Gly Ile Val Val Lys Ile Pro Val Thr Ser Glu Gly Leu Ala Ala Ile 85 90 95 Lys Ile Leu Lys Lys Glu Gly Ile Thr Thr Leu Gly Thr Ala Val Tyr 100 105 110 Ser Ala Ala Gln Gly Leu Leu Ala Ala Leu Ala Gly Ala Lys Tyr Val 115 120 125 Ala Pro Tyr Val Asn Arg Val Asp Ala Gln Gly Gly Asp Gly Ile Arg 130 135 140 Thr Val Gln Glu Leu Gln Thr Leu Leu Glu Met His Ala Pro Glu Ser 145 150 155 160 Met Val Leu Ala Ala Ser Phe Lys Thr Pro Arg Gln Ala Leu Asp Cys 165 170 175 Leu Leu Ala Gly Cys Glu Ser Ile Thr Leu Pro Leu Asp Val Ala Gln 180 185 190 Gln Met Leu Asn Thr Pro Ala Val Glu Ser Ala Ile Glu Lys Phe Glu 195 200 205 His Asp Trp Asn Ala Ala Phe Gly Thr Thr His Leu 210 215 220 <210> 4 <211> 479 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(479) <223> Protein encoded by gene aldA <400> 4 Met Ser Val Pro Val Gln His Pro Met Tyr Ile Asp Gly Gln Phe Val 1 5 10 15 Thr Trp Arg Gly Asp Ala Trp Ile Asp Val Val Asn Pro Ala Thr Glu 20 25 30 Ala Val Ile Ser Arg Ile Pro Asp Gly Gln Ala Glu Asp Ala Arg Lys 35 40 45 Ala Ile Asp Ala Ala Glu Arg Ala Gln Pro Glu Trp Glu Ala Leu Pro 50 55 60 Ala Ile Glu Arg Ala Ser Trp Leu Arg Lys Ile Ser Ala Gly Ile Arg 65 70 75 80 Glu Arg Ala Ser Glu Ile Ser Ala Leu Ile Val Glu Glu Gly Gly Lys 85 90 95 Ile Gln Gln Leu Ala Glu Val Glu Val Ala Phe Thr Ala Asp Tyr Ile 100 105 110 Asp Tyr Met Ala Glu Trp Ala Arg Arg Tyr Glu Gly Glu Ile Ile Gln 115 120 125 Ser Asp Arg Pro Gly Glu Asn Ile Leu Leu Phe Lys Arg Ala Leu Gly 130 135 140 Val Thr Thr Gly Ile Leu Pro Trp Asn Phe Pro Phe Phe Leu Ile Ala 145 150 155 160 Arg Lys Met Ala Pro Ala Leu Leu Thr Gly Asn Thr Ile Val Ile Lys 165 170 175 Pro Ser Glu Phe Thr Pro Asn Asn Ala Ile Ala Phe Ala Lys Ile Val 180 185 190 Asp Glu Ile Gly Leu Pro Arg Gly Val Phe Asn Leu Val Leu Gly Arg 195 200 205 Gly Glu Thr Val Gly Gln Glu Leu Ala Gly Asn Pro Lys Val Ala Met 210 215 220 Val Ser Met Thr Gly Ser Val Ser Ala Gly Glu Lys Ile Met Ala Thr 225 230 235 240 Ala Ala Lys Asn Ile Thr Lys Val Cys Leu Glu Leu Gly Gly Lys Ala 245 250 255 Pro Ala Ile Val Met Asp Asp Ala Asp Leu Glu Leu Ala Val Lys Ala 260 265 270 Ile Val Asp Ser Arg Val Ile Asn Ser Gly Gln Val Cys Asn Cys Ala 275 280 285 Glu Arg Val Tyr Val Gln Lys Gly Ile Tyr Asp Gln Phe Val Asn Arg 290 295 300 Leu Gly Glu Ala Met Gln Ala Val Gln Phe Gly Asn Pro Ala Glu Arg 305 310 315 320 Asn Asp Ile Ala Met Gly Pro Leu Ile Asn Ala Ala Ala Leu Glu Arg 325 330 335 Val Glu Gln Lys Val Ala Arg Ala Val Glu Glu Gly Ala Arg Val Ala 340 345 350 Phe Gly Gly Lys Ala Val Glu Gly Lys Gly Tyr Tyr Tyr Pro Pro Thr 355 360 365 Leu Leu Leu Asp Val Arg Gln Glu Met Ser Ile Met His Glu Glu Thr 370 375 380 Phe Gly Pro Val Leu Pro Val Val Ala Phe Asp Thr Leu Glu Asp Ala 385 390 395 400 Ile Ser Met Ala Asn Asp Ser Asp Tyr Gly Leu Thr Ser Ser Ile Tyr 405 410 415 Thr Gln Asn Leu Asn Val Ala Met Lys Ala Ile Lys Gly Leu Lys Phe 420 425 430 Gly Glu Thr Tyr Ile Asn Arg Glu Asn Phe Glu Ala Met Gln Gly Phe 435 440 445 His Ala Gly Trp Arg Lys Ser Gly Ile Gly Gly Ala Asp Gly Lys His 450 455 460 Gly Leu His Glu Tyr Leu Gln Thr Gln Val Val Tyr Leu Gln Ser 465 470 475 <210> 5 <211> 331 <212> PRT <213> Escherichia coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(331) <223> Protein encoded by gene gapA <400> 5 Met Thr Ile Lys Val Gly Ile Asn Gly Phe Gly Arg Ile Gly Arg Ile 1 5 10 15 Val Phe Arg Ala Ala Gln Lys Arg Ser Asp Ile Glu Ile Val Ala Ile 20 25 30 Asn Asp Leu Leu Asp Ala Asp Tyr Met Ala Tyr Met Leu Lys Tyr Asp 35 40 45 Ser Thr His Gly Arg Phe Asp Gly Thr Val Glu Val Lys Asp Gly His 50 55 60 Leu Ile Val Asn Gly Lys Lys Ile Arg Val Thr Ala Glu Arg Asp Pro 65 70 75 80 Ala Asn Leu Lys Trp Asp Glu Val Gly Val Asp Val Val Ala Glu Ala 85 90 95 Thr Gly Leu Phe Leu Thr Asp Glu Thr Ala Arg Lys His Ile Thr Ala 100 105 110 Gly Ala Lys Lys Val Val Met Thr Gly Pro Ser Lys Asp Asn Thr Pro 115 120 125 Met Phe Val Lys Gly Ala Asn Phe Asp Lys Tyr Ala Gly Gln Asp Ile 130 135 140 Val Ser Asn Ala Ser Cys Thr Thr Asn Cys Leu Ala Pro Leu Ala Lys 145 150 155 160 Val Ile Asn Asp Asn Phe Gly Ile Ile Glu Gly Leu Met Thr Thr Val 165 170 175 His Ala Thr Thr Ala Thr Gln Lys Thr Val Asp Gly Pro Ser His Lys 180 185 190 Asp Trp Arg Gly Gly Arg Gly Ala Ser Gln Asn Ile Ile Pro Ser Ser 195 200 205 Thr Gly Ala Ala Lys Ala Val Gly Lys Val Leu Pro Glu Leu Asn Gly 210 215 220 Lys Leu Thr Gly Met Ala Phe Arg Val Pro Thr Pro Asn Val Ser Val 225 230 235 240 Val Asp Leu Thr Val Arg Leu Glu Lys Ala Ala Thr Tyr Glu Gln Ile 245 250 255 Lys Ala Ala Val Lys Ala Ala Ala Glu Gly Glu Met Lys Gly Val Leu 260 265 270 Gly Tyr Thr Glu Asp Asp Val Val Ser Thr Asp Phe Asn Gly Glu Val 275 280 285 Cys Thr Ser Val Phe Asp Ala Lys Ala Gly Ile Ala Leu Asn Asp Asn 290 295 300 Phe Val Lys Leu Val Ser Trp Tyr Asp Asn Glu Thr Gly Tyr Ser Asn 305 310 315 320 Lys Val Leu Asp Leu Ile Ala His Ile Ser Lys 325 330 <210> 6 <211> 85 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(85) <223> Protein encoded by gene ptsH <400> 6 Met Phe Gln Gln Glu Val Thr Ile Thr Ala Pro Asn Gly Leu His Thr 1 5 10 15 Arg Pro Ala Ala Gln Phe Val Lys Glu Ala Lys Gly Phe Thr Ser Glu 20 25 30 Ile Thr Val Thr Ser Asn Gly Lys Ser Ala Ser Ala Lys Ser Leu Phe 35 40 45 Lys Leu Gln Thr Leu Gly Leu Thr Gln Gly Thr Val Val Thr Ile Ser 50 55 60 Ala Glu Gly Glu Asp Glu Gln Lys Ala Val Glu His Leu Val Lys Leu 65 70 75 80 Met Ala Glu Leu Glu 85 <210> 7 <211> 575 <212> PRT <213> Escherichia coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(575) <223> Protein encoded by the gene ptsl <400> 7 Met Ile Ser Gly Ile Leu Ala Ser Pro Gly Ile Ala Phe Gly Lys Ala 1 5 10 15 Leu Leu Leu Lys Glu Asp Glu Ile Val Ile Asp Arg Lys Lys Ile Ser 20 25 30 Ala Asp Gln Val Asp Gln Glu Val Glu Arg Phe Leu Ser Gly Arg Ala 35 40 45 Lys Ala Ser Ala Gln Leu Glu Thr Ile Lys Thr Lys Ala Gly Glu Thr 50 55 60 Phe Gly Glu Glu Lys Glu Ala Ile Phe Glu Gly His Ile Met Leu Leu 65 70 75 80 Glu Asp Glu Glu Leu Glu Gln Glu Ile Ile Ala Leu Ile Lys Asp Lys 85 90 95 His Met Thr Ala Asp Ala Ala Ala His Glu Val Ile Glu Gly Gln Ala 100 105 110 Ser Ala Leu Glu Glu Leu Asp Asp Glu Tyr Leu Lys Glu Arg Ala Ala 115 120 125 Asp Val Arg Asp Ile Gly Lys Arg Leu Leu Arg Asn Ile Leu Gly Leu 130 135 140 Lys Ile Ile Asp Leu Ser Ala Ile Gln Asp Glu Val Ile Leu Val Ala 145 150 155 160 Ala Asp Leu Thr Pro Ser Glu Thr Ala Gln Leu Asn Leu Lys Lys Val 165 170 175 Leu Gly Phe Ile Thr Asp Ala Gly Gly Arg Thr Ser His Thr Ser Ile 180 185 190 Met Ala Arg Ser Leu Glu Leu Pro Ala Ile Val Gly Thr Gly Ser Val 195 200 205 Thr Ser Gln Val Lys Asn Asp Asp Tyr Leu Ile Leu Asp Ala Val Asn 210 215 220 Asn Gln Val Tyr Val Asn Pro Thr Asn Glu Val Ile Asp Lys Met Arg 225 230 235 240 Ala Val Gln Glu Gln Val Ala Ser Glu Lys Ala Glu Leu Ala Lys Leu 245 250 255 Lys Asp Leu Pro Ala Ile Thr Leu Asp Gly His Gln Val Glu Val Cys 260 265 270 Ala Asn Ile Gly Thr Val Arg Asp Val Glu Gly Ala Glu Arg Asn Gly 275 280 285 Ala Glu Gly Val Gly Leu Tyr Arg Thr Glu Phe Leu Phe Met Asp Arg 290 295 300 Asp Path Leu Pro Thr Glu Glu Glu Gln Phe Path Path Tyr Lys Path Val 305 310 315 320 Ala Glu Ala Cys Gly Ser Gln Ala Val Ile Val Arg Thr Met Asp Ile 325 330 335 Gly Gly Asp Lys Glu Leu Pro Tyr Met Asn Phe Pro Lys Glu Glu Asn 340 345 350 Pro Phe Leu Gly Trp Arg Ala Ile Arg Ile Ala Met Asp Arg Arg Glu 355 360 365 Ile Leu Arg Asp Gln Leu Arg Ala Ile Leu Arg Ala Ser Ala Phe Gly 370 375 380 Lys Leu Arg Ile Met Phe Pro Met Ile Ile Ser Val Glu Glu Val Arg 385 390 395 400 Ala Leu Arg Lys Glu Ile Glu Ile Tyr Lys Gln Glu Leu Arg Asp Glu 405 410 415 Gly Lys Ala Phe Asp Glu Ser Ile Glu Ile Gly Val Met Val Glu Thr 420 425 430 Pro Ala Ala Ala Thr Ile Ala Arg His Leu Ala Lys Glu Val Asp Phe 435 440 445 Phe Ser Ile Gly Thr Asn Asp Leu Thr Gln Tyr Thr Leu Ala Val Asp 450 455 460 Arg Gly Asn Asp Met Ile Ser His Leu Tyr Gln Pro Met Ser Pro Ser 465 470 475 480 Val Leu Asn Leu Ile Lys Gln Val Ile Asp Ala Ser His Ala Glu Gly 485 490 495 Lys Trp Thr Gly Met Cys Gly Glu Leu Ala Gly Asp Glu Arg Ala Thr 500 505 510 Leu Leu Leu Leu Gly Met Gly Leu Asp Glu Phe Ser Met Ser Ala Ile 515 520 525 Ser Ile Pro Arg Ile Lys Lys Ile Ile Arg Asn Thr Asn Phe Glu Asp 530 535 540 Ala Lys Val Leu Ala Glu Gln Ala Leu Ala Gln Pro Thr Thr Asp Glu 545 550 555 560 Leu Met Thr Leu Val Asn Lys Phe Ile Glu Glu Lys Thr Ile Cys 565 570 575 <210> 8 <211> 169 <212> PRT <213> Escherichia coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(169) <223> The protein encoded by the gene crr <400> 8 Met Gly Leu Phe Asp Lys Leu Lys Ser Leu Val Ser Asp Asp Lys Lys 1 5 10 15 Asp Thr Gly Thr Ile Glu Ile Ile Ala Pro Leu Ser Gly Glu Ile Val 20 25 30 Asn Ile Glu Asp Val Pro Asp Val Val Phe Ala Glu Lys Ile Val Gly 35 40 45 Asp Gly Ile Ala Ile Lys Pro Thr Gly Asn Lys Met Val Ala Pro Val 50 55 60 Asp Gly Thr Ile Gly Lys Ile Phe Glu Thr Asn His Ala Phe Ser Ile 65 70 75 80 Glu Ser Asp Ser Gly Val Glu Leu Phe Val His Phe Gly Ile Asp Thr 85 90 95 Val Glu Leu Lys Gly Glu Gly Phe Lys Arg Ile Ala Glu Glu Gly Gln 100 105 110 Arg Val Lys Val Gly Asp Thr Val Ile Glu Phe Asp Leu Pro Leu Leu 115 120 125 Glu Glu Lys Ala Lys Ser Thr Leu Thr Pro Val Val Ile Ser Asn Met 130 135 140 Asp Glu Ile Lys Glu Leu Ile Lys Leu Ser Gly Ser Val Thr Val Gly 145 150 155 160 Glu Thr Pro Val Ile Arg Ile Lys Lys 165 <210> 9 <211> 477 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(477) <223> Protein encoded by gene ptsG <400> 9 Met Phe Lys Asn Ala Phe Ala Asn Leu Gln Lys Val Gly Lys Ser Leu 1 5 10 15 Met Leu Pro Val Ser Val Leu Pro Ile Ala Gly Ile Leu Leu Gly Val 20 25 30 Gly Ser Ala Asn Phe Ser Trp Leu Pro Ala Val Val Ser His Val Met 35 40 45 Ala Glu Ala Gly Gly Ser Val Phe Ala Asn Met Pro Leu Ile Phe Ala 50 55 60 Ile Gly Val Ala Leu Gly Phe Thr Asn Asn Asp Gly Val Ser Ala Leu 65 70 75 80 Ala Ala Val Val Ala Tyr Gly Ile Met Val Lys Thr Met Ala Val Val 85 90 95 Ala Pro Leu Val Leu His Leu Pro Ala Glu Glu Ile Ala Ser Lys His 100 105 110 Leu Ala Asp Thr Gly Val Leu Gly Gly Ile Ile Ser Gly Ala Ile Ala 115 120 125 Ala Tyr Met Phe Asn Arg Phe Tyr Arg Ile Lys Leu Pro Glu Tyr Leu 130 135 140 Gly Phe Phe Ala Gly Lys Arg Phe Val Pro Ile Ile Ser Gly Leu Ala 145 150 155 160 Ala Ile Phe Thr Gly Val Val Leu Ser Phe Ile Trp Pro Pro Ile Gly 165 170 175 Ser Ala Ile Gln Thr Phe Ser Gln Trp Ala Ala Tyr Gln Asn Pro Val 180 185 190 Val Ala Phe Gly Ile Tyr Gly Phe Ile Glu Arg Cys Leu Val Pro Phe 195 200 205 Gly Leu His His Ile Trp Asn Val Pro Phe Gln Met Gln Ile Gly Glu 210 215 220 Tyr Thr Asn Ala Ala Gly Gln Val Phe His Gly Asp Ile Pro Arg Tyr 225 230 235 240 Met Ala Gly Asp Pro Thr Ala Gly Lys Leu Ser Gly Gly Phe Leu Phe 245 250 255 Lys Met Tyr Gly Leu Pro Ala Ala Ala Ile Ala Ile Trp His Ser Ala 260 265 270 Lys Pro Glu Asn Arg Ala Lys Val Gly Gly Ile Met Ile Ser Ala Ala 275 280 285 Leu Thr Ser Phe Leu Thr Gly Ile Thr Glu Pro Ile Glu Phe Ser Phe 290 295 300 Met Phe Val Ala Pro Ile Leu Tyr Ile Ile His Ala Ile Leu Ala Gly 305 310 315 320 Leu Ala Phe Pro Ile Cys Ile Leu Leu Gly Met Arg Asp Gly Thr Ser 325 330 335 Phe Ser His Gly Leu Ile Asp Phe Ile Val Leu Ser Gly Asn Ser Ser 340 345 350 Lys Leu Trp Leu Phe Pro Ile Val Gly Ile Gly Tyr Ala Ile Val Tyr 355 360 365 Tyr Thr Ile Phe Arg Val Leu Ile Lys Ala Leu Asp Leu Lys Thr Pro 370 375 380 Gly Arg Glu Asp Ala Thr Glu Asp Ala Lys Ala Thr Gly Thr Ser Glu 385 390 395 400 Met Ala Pro Ala Leu Val Ala Ala Phe Gly Gly Lys Glu Asn Ile Thr 405 410 415 Asn Leu Asp Ala Cys Ile Thr Arg Leu Arg Val Ser Val Ala Asp Val 420 425 430 Ser Lys Val Asp Gln Ala Gly Leu Lys Lys Leu Gly Ala Ala Gly Val 435 440 445 Val Val Ala Gly Ser Gly Val Gln Ala Ile Phe Gly Thr Lys Ser Asp 450 455 460 Asn Leu Lys Thr Glu Met Asp Glu Tyr Ile Arg Asn His 465 470 475 <210> 10 <211> 464 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(464) <223> Protein encoded by gene galP <400> 10 Met Pro Asp Ala Lys Lys Gln Gly Arg Ser Asn Lys Ala Met Thr Phe 1 5 10 15 Phe Val Cys Phe Leu Ala Ala Leu Ala Gly Leu Leu Phe Gly Leu Asp 20 25 30 Ile Gly Val Ile Ala Gly Ala Leu Pro Phe Ile Ala Asp Glu Phe Gln 35 40 45 Ile Thr Ser His Thr Gln Glu Trp Val Val Ser Ser Met Met Phe Gly 50 55 60 Ala Ala Val Gly Ala Val Gly Ser Gly Trp Leu Ser Phe Lys Leu Gly 65 70 75 80 Arg Lys Lys Ser Leu Met Ile Gly Ala Ile Leu Phe Val Ala Gly Ser 85 90 95 Leu Phe Ser Ala Ala Ala Pro Asn Val Glu Val Leu Ile Leu Ser Arg 100 105 110 Val Leu Leu Gly Leu Ala Val Gly Val Ala Ser Tyr Thr Ala Pro Leu 115 120 125 Tyr Leu Ser Glu Ile Ala Pro Glu Lys Ile Arg Gly Ser Met Ile Ser 130 135 140 Met Tyr Gln Leu Met Ile Thr Ile Gly Ile Leu Gly Ala Tyr Leu Ser 145 150 155 160 Asp Thr Ala Phe Ser Tyr Thr Gly Ala Trp Arg Trp Met Leu Gly Val 165 170 175 Ile Ile Ile Pro Ala Ile Leu Leu Leu Ile Gly Val Phe Phe Leu Pro 180 185 190 Asp Ser Pro Arg Trp Phe Ala Ala Lys Arg Arg Phe Val Asp Ala Glu 195 200 205 Arg Val Leu Leu Arg Leu Arg Asp Thr Ser Ala Glu Ala Lys Arg Glu 210 215 220 Leu Asp Glu Ile Arg Glu Ser Leu Gln Val Lys Gln Ser Gly Trp Ala 225 230 235 240 Leu Phe Lys Glu Asn Ser Asn Phe Arg Arg Ala Val Phe Leu Gly Val 245 250 255 Leu Leu Gln Val Met Gln Gln Phe Thr Gly Met Asn Val Ile Met Tyr 260 265 270 Tyr Ala Pro Lys Ile Phe Glu Leu Ala Gly Tyr Thr Asn Thr Thr Glu 275 280 285 Gln Met Trp Gly Thr Val Ile Val Gly Leu Thr Asn Val Leu Ala Thr 290 295 300 Phe Ile Ala Ile Gly Leu Val Asp Arg Trp Gly Arg Lys Pro Thr Leu 305 310 315 320 Thr Leu Gly Phe Leu Val Met Ala Ala Gly Met Gly Val Leu Gly Thr 325 330 335 Met Met His Ile Gly Ile His Ser Pro Ser Ala Gln Tyr Phe Ala Ile 340 345 350 Ala Met Leu Leu Met Phe Ile Val Gly Phe Ala Met Ser Ala Gly Pro 355 360 365 Leu Ile Trp Val Leu Cys Ser Glu Ile Gln Pro Leu Lys Gly Arg Asp 370 375 380 Phe Gly Ile Thr Cys Ser Thr Ala Thr Asn Trp Ile Ala Asn Met Ile 385 390 395 400 Val Gly Ala Thr Phe Leu Thr Met Leu Asn Thr Leu Gly Asn Ala Asn 405 410 415 Thr Phe Trp Val Tyr Ala Ala Leu Asn Val Leu Phe Ile Leu Leu Thr 420 425 430 Leu Trp Leu Val Pro Glu Thr Lys His Val Ser Leu Glu His Ile Glu 435 440 445 Arg Asn Leu Met Lys Gly Arg Lys Leu Arg Glu Ile Gly Ala His Asp 450 455 460 <210> 11 <211> 473 <212> PRT <213> Zymomonas mobilis strain ATCC 31821 / ZM4 / CP4 <220> <221> PEPTIDE <222> (1)..(473) <223> Protein encoded by the gene glf <400> 11 Met Ser Ser Glu Ser Ser Gln Gly Leu Val Thr Arg Leu Ala Leu Ile 1 5 10 15 Ala Ala Ile Gly Gly Leu Leu Phe Gly Tyr Asp Ser Ala Val Ile Ala 20 25 30 Ala Ile Gly Thr Pro Val Asp Ile His Phe Ile Ala Pro Arg His Leu 35 40 45 Ser Ala Thr Ala Ala Ala Ser Leu Ser Gly Met Val Val Val Ala Val 50 55 60 Leu Val Gly Cys Val Thr Gly Ser Leu Leu Ser Gly Trp Ile Gly Ile 65 70 75 80 Arg Phe Gly Arg Arg Gly Gly Leu Leu Met Ser Ser Ile Cys Phe Val 85 90 95 Ala Ala Gly Phe Gly Ala Ala Leu Thr Glu Lys Leu Phe Gly Thr Gly 100 105 110 Gly Ser Ala Leu Gln Ile Phe Cys Phe Phe Arg Phe Leu Ala Gly Leu 115 120 125 Gly Ile Gly Val Val Ser Thr Leu Thr Pro Thr Tyr Ile Ala Glu Ile 130 135 140 Ala Pro Pro Asp Lys Arg Gly Gln Met Val Ser Gly Gln Gln Met Ala 145 150 155 160 Ile Val Thr Gly Ala Leu Thr Gly Tyr Ile Phe Thr Trp Leu Leu Ala 165 170 175 His Phe Gly Ser Ile Asp Trp Val Asn Ala Ser Gly Trp Cys Trp Ser 180 185 190 Pro Ala Ser Glu Gly Leu Ile Gly Ile Ala Phe Leu Leu Leu Leu Leu 195 200 205 Thr Ala Pro Asp Thr Pro His Trp Leu Val Met Lys Gly Arg His Ser 210 215 220 Glu Ala Ser Lys Ile Leu Ala Arg Leu Glu Pro Gln Ala Asp Pro Asn 225 230 235 240 Leu Thr Ile Gln Lys Ile Lys Ala Gly Phe Asp Lys Ala Met Asp Lys 245 250 255 Ser Ser Ala Gly Leu Phe Ala Phe Gly Ile Thr Val Val Phe Ala Gly 260 265 270 Val Ser Val Ala Ala Phe Gln Gln Leu Val Gly Ile Asn Ala Val Leu 275 280 285 Tyr Tyr Ala Pro Gln Met Phe Gln Asn Leu Gly Phe Gly Ala Asp Thr 290 295 300 Ala Leu Leu Gln Thr Ile Ser Ile Gly Val Val Asn Phe Ile Phe Thr 305 310 315 320 Met Ile Ala Ser Arg Val Val Asp Arg Phe Gly Arg Lys Pro Leu Leu 325 330 335 Ile Trp Gly Ala Leu Gly Met Ala Ala Met Met Ala Val Leu Gly Cys 340 345 350 Cys Phe Trp Phe Lys Val Gly Gly Val Leu Pro Leu Ala Ser Val Leu 355 360 365 Leu Tyr Ile Ala Val Phe Gly Met Ser Trp Gly Pro Val Cys Trp Val 370 375 380 Val Leu Ser Glu Met Phe Pro Ser Ser Ile Lys Gly Ala Ala Met Pro 385 390 395 400 Ile Ala Val Thr Gly Gln Trp Leu Ala Asn Ile Leu Val Asn Phe Leu 405 410 415 Phe Lys Val Ala Asp Gly Ser Pro Ala Leu Asn Gln Thr Phe Asn His 420 425 430 Gly Phe Ser Tyr Leu Val Phe Ala Ala Leu Ser Ile Leu Gly Gly Leu 435 440 445 Ile Val Ala Arg Phe Val Pro Glu Thr Lys Gly Arg Ser Leu Asp Glu 450 455 460 Ile Glu Glu Met Trp Arg Ser Gln Lys 465 470 <210> 12 <211> 321 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(321) <223> Protein encoded by gene glK <400> 12 Met Thr Lys Tyr Ala Leu Val Gly Asp Val Gly Gly Thr Asn Ala Arg 1 5 10 15 Leu Ala Leu Cys Asp Ile Ala Ser Gly Glu Ile Ser Gln Ala Lys Thr 20 25 30 Tyr Ser Gly Leu Asp Tyr Pro Ser Leu Glu Ala Val Ile Arg Val Tyr 35 40 45 Leu Glu Glu His Lys Val Glu Val Lys Asp Gly Cys Ile Ala Ile Ala 50 55 60 Cys Pro Ile Thr Gly Asp Trp Val Ala Met Thr Asn His Thr Trp Ala 65 70 75 80 Phe Ser Ile Ala Glu Met Lys Lys Asn Leu Gly Phe Ser His Leu Glu 85 90 95 Ile Ile Asn Asp Phe Thr Ala Val Ser Met Ala Ile Pro Met Leu Lys 100 105 110 Lys Glu His Leu Ile Gln Phe Gly Gly Ala Glu Pro Val Glu Gly Lys 115 120 125 Pro Ile Ala Val Tyr Gly Ala Gly Thr Gly Leu Gly Val Ala His Leu 130 135 140 Val His Val Asp Lys Arg Trp Val Ser Leu Pro Gly Glu Gly Gly His 145 150 155 160 Val Asp Phe Ala Pro Asn Ser Glu Glu Glu Ala Ile Ile Leu Glu Ile 165 170 175 Leu Arg Ala Glu Ile Gly His Val Ser Ala Glu Arg Val Leu Ser Gly 180 185 190 Pro Gly Leu Val Asn Leu Tyr Arg Ala Ile Val Lys Ala Asp Asn Arg 195 200 205 Leu Pro Glu Asn Leu Lys Pro Lys Asp Ile Thr Glu Arg Ala Leu Ala 210 215 220 Asp Ser Cys Thr Asp Cys Arg Arg Ala Leu Ser Leu Phe Cys Val Ile 225 230 235 240 Met Gly Arg Phe Gly Gly Asn Leu Ala Leu Asn Leu Gly Thr Phe Gly 245 250 255 Gly Val Phe Ile Ala Gly Gly Ile Val Pro Arg Phe Leu Glu Phe Phe 260 265 270 Lys Ala Ser Gly Phe Arg Ala Ala Phe Glu Asp Lys Gly Arg Phe Lys 275 280 285 Glu Tyr Val His Asp Ile Pro Val Tyr Leu Ile Val His Asp Asn Pro 290 295 300 Gly Leu Leu Gly Ser Gly Ala His Leu Arg Gln Thr Leu Gly His Ile 305 310 315 320 Leu <210> 13 <211> 499 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(499) <223> Protein encoded by gene glcD <400> 13 Met Ser Ile Leu Tyr Glu Glu Arg Leu Asp Gly Ala Leu Pro Asp Val 1 5 10 15 Asp Arg Thr Ser Val Leu Met Ala Leu Arg Glu His Val Pro Gly Leu 20 25 30 Glu Ile Leu His Thr Asp Glu Glu Ile Ile Pro Tyr Glu Cys Asp Gly 35 40 45 Leu Ser Ala Tyr Arg Thr Arg Pro Leu Leu Val Val Leu Pro Lys Gln 50 55 60 Met Glu Gln Val Thr Ala Ile Leu Ala Val Cys His Arg Leu Arg Val 65 70 75 80 Pro Val Val Thr Arg Gly Ala Gly Thr Gly Leu Ser Gly Gly Ala Leu 85 90 95 Pro Leu Glu Lys Gly Val Leu Leu Val Met Ala Arg Phe Lys Glu Ile 100 105 110 Leu Asp Ile Asn Pro Val Gly Arg Arg Ala Arg Val Gln Pro Gly Val 115 120 125 Arg Asn Leu Ala Ile Ser Gln Ala Val Ala Pro His Asn Leu Tyr Tyr 130 135 140 Ala Pro Asp Pro Ser Ser Gln Ile Ala Cys Ser Ile Gly Gly Asn Val 145 150 155 160 Ala Glu Asn Ala Gly Gly Val His Cys Leu Lys Tyr Gly Leu Thr Val 165 170 175 His Asn Leu Leu Lys Ile Glu Val Gln Thr Leu Asp Gly Glu Ala Leu 180 185 190 Thr Leu Gly Ser Asp Ala Leu Asp Ser Pro Gly Phe Asp Leu Leu Ala 195 200 205 Leu Phe Thr Gly Ser Glu Gly Met Leu Gly Val Thr Thr Glu Val Thr 210 215 220 Val Lys Leu Leu Pro Lys Pro Pro Val Ala Arg Val Leu Leu Ala Ser 225 230 235 240 Phe Asp Ser Val Glu Lys Ala Gly Leu Ala Val Gly Asp Ile Ile Ala 245 250 255 Asn Gly Ile Ile Pro Gly Gly Leu Glu Met Met Asp Asn Leu Ser Ile 260 265 270 Arg Ala Ala Glu Asp Phe Ile His Ala Gly Tyr Pro Val Asp Ala Glu 275 280 285 Ala Ile Leu Leu Cys Glu Leu Asp Gly Val Glu Ser Asp Val Gln Glu 290 295 300 Asp Cys Glu Arg Val Asn Asp Ile Leu Leu Lys Ala Gly Ala Thr Asp 305 310 315 320 Val Arg Leu Ala Gln Asp Glu Ala Glu Arg Val Arg Phe Trp Ala Gly 325 330 335 Arg Lys Asn Ala Phe Pro Ala Val Gly Arg Ile Ser Pro Asp Tyr Tyr 340 345 350 Cys Met Asp Gly Thr Ile Pro Arg Arg Ala Leu Pro Gly Val Leu Glu 355 360 365 Gly Ile Ala Arg Leu Ser Gln Gln Tyr Asp Leu Arg Val Ala Asn Val 370 375 380 Phe His Ala Gly Asp Gly Asn Met His Pro Leu Ile Leu Phe Asp Ala 385 390 395 400 Asn Glu Pro Gly Glu Phe Ala Arg Ala Glu Glu Leu Gly Gly Lys Ile 405 410 415 Leu Glu Leu Cys Val Glu Val Gly Gly Ser Ile Ser Gly Glu His Gly 420 425 430 Ile Gly Arg Glu Lys Ile Asn Gln Met Cys Ala Gln Phe Asn Ser Asp 435 440 445 Glu Ile Thr Thr Phe His Ala Val Lys Ala Ala Phe Asp Pro Asp Gly 450 455 460 Leu Leu Asn Pro Gly Lys Asn Ile Pro Thr Leu His Arg Cys Ala Glu 465 470 475 480 Phe Gly Ala Met His Val His His Gly His Leu Pro Phe Pro Glu Leu 485 490 495 Glu Arg Phe <210> 14 <211> 350 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(350) <223> Protein encoded by the gene glcE <400> 14 Met Leu Arg Glu Cys Asp Tyr Ser Gln Ala Leu Leu Glu Gln Val Asn 1 5 10 15 Gln Ala Ile Ser Asp Lys Thr Pro Leu Val Ile Gln Gly Ser Asn Ser 20 25 30 Lys Ala Phe Leu Gly Arg Pro Val Thr Gly Gln Thr Leu Asp Val Arg 35 40 45 Cys His Arg Gly Ile Val Asn Tyr Asp Pro Thr Glu Leu Val Ile Thr 50 55 60 Ala Arg Val Gly Thr Pro Leu Val Thr Ile Glu Ala Ala Leu Glu Ser 65 70 75 80 Ala Gly Gln Met Leu Pro Cys Glu Pro Pro His Tyr Gly Glu Glu Ala 85 90 95 Thr Trp Gly Gly Met Val Ala Cys Gly Leu Ala Gly Pro Arg Arg Pro 100 105 110 Trp Ser Gly Ser Val Arg Asp Phe Val Leu Gly Thr Arg Ile Ile Thr 115 120 125 Gly Ala Gly Lys His Leu Arg Phe Gly Gly Glu Val Met Lys Asn Val 130 135 140 Ala Gly Tyr Asp Leu Ser Arg Leu Met Val Gly Ser Tyr Gly Cys Leu 145 150 155 160 Gly Val Leu Thr Glu Ile Ser Met Lys Val Leu Pro Arg Pro Arg Ala 165 170 175 Ser Leu Ser Leu Arg Arg Glu Ile Ser Leu Gln Glu Ala Met Ser Glu 180 185 190 Ile Ala Glu Trp Gln Leu Gln Pro Leu Pro Ile Ser Gly Leu Cys Tyr 195 200 205 Phe Asp Asn Ala Leu Trp Ile Arg Leu Glu Gly Gly Glu Gly Ser Val 210 215 220 Lys Ala Ala Arg Glu Leu Leu Gly Gly Glu Glu Val Ala Gly Gln Phe 225 230 235 240 Trp Gln Gln Leu Arg Glu Gln Gln Leu Pro Phe Phe Ser Leu Pro Gly 245 250 255 Thr Leu Trp Arg Ile Ser Leu Pro Ser Asp Ala Pro Met Met Asp Leu 260 265 270 Pro Gly Glu Gln Leu Ile Asp Trp Gly Gly Ala Leu Arg Trp Leu Lys 275 280 285 Ser Thr Ala Glu Asp Asn Gln Ile His Arg Ile Ala Arg Asn Ala Gly 290 295 300 Gly His Ala Thr Arg Phe Ser Ala Gly Asp Gly Gly Phe Ala Pro Leu 305 310 315 320 Ser Ala Pro Leu Phe Arg Tyr His Gln Gln Leu Lys Gln Gln Leu Asp 325 330 335 Pro Cys Gly Val Phe Asn Pro Gly Arg Met Tyr Ala Glu Leu 340 345 350 <210> 15 <211> 407 <212> PRT <213> Escherichia coli strain K12 MG1655 <220> <221> PEPTIDES <222> (1)..(407) <223> Protein encoded by the glcF gene <400> 15 Met Gln Thr Gln Leu Thr Glu Glu Met Arg Gln Asn Ala Arg Ala Leu 1 5 10 15 Glu Ala Asp Ser Ile Leu Arg Ala Cys Val His Cys Gly Phe Cys Thr 20 25 30 Ala Thr Cys Pro Thr Tyr Gln Leu Leu Gly Asp Glu Leu Asp Gly Pro 35 40 45 Arg Gly Arg Ile Tyr Leu Ile Lys Gln Val Leu Glu Gly Asn Glu Val 50 55 60 Thr Leu Lys Thr Gln Glu His Leu Asp Arg Cys Leu Thr Cys Arg Asn 65 70 75 80 Cys Glu Thr Thr Cys Pro Ser Gly Val Arg Tyr His Asn Leu Leu Asp 85 90 95 Ile Gly Arg Asp Ile Val Glu Gln Lys Val Lys Arg Pro Leu Pro Glu 100 105 110 Arg Ile Leu Arg Glu Gly Leu Arg Gln Val Val Pro Arg Pro Ala Val 115 120 125 Phe Arg Ala Leu Thr Gln Val Gly Leu Val Leu Arg Pro Phe Leu Pro 130 135 140 Glu Gln Val Arg Ala Lys Leu Pro Ala Glu Thr Val Lys Ala Lys Pro 145 150 155 160 Arg Pro Pro Leu Arg His Lys Arg Arg Val Leu Met Leu Glu Gly Cys 165 170 175 Ala Gln Pro Thr Leu Ser Pro Asn Thr Asn Ala Ala Thr Ala Arg Val 180 185 190 Leu Asp Arg Leu Gly Ile Ser Val Met Pro Ala Asn Glu Ala Gly Cys 195 200 205 Cys Gly Ala Val Asp Tyr His Leu Asn Ala Gln Glu Lys Gly Leu Ala 210 215 220 Arg Ala Arg Asn Asn Ile Asp Ala Trp Trp Pro Ala Ile Glu Ala Gly 225 230 235 240 Ala Glu Ala Ile Leu Gln Thr Ala Ser Gly Cys Gly Ala Phe Val Lys 245 250 255 Glu Tyr Gly Gln Met Leu Lys Asn Asp Ala Leu Tyr Ala Asp Lys Ala 260 265 270 Arg Gln Val Ser Glu Leu Ala Val Asp Leu Val Glu Leu Leu Arg Glu 275 280 285 Glu Pro Leu Glu Lys Leu Ala Ile Arg Gly Asp Lys Lys Leu Ala Phe 290 295 300 His Cys Pro Cys Thr Leu Gln His Ala Gln Lys Leu Asn Gly Glu Val 305 310 315 320 Glu Lys Val Leu Leu Arg Leu Gly Phe Thr Leu Thr Asp Val Pro Asp 325 330 335 Ser His Leu Cys Cys Gly Ser Ala Gly Thr Tyr Ala Leu Thr His Pro 340 345 350 Asp Leu Ala Arg Gln Leu Arg Asp Asn Lys Met Asn Ala Leu Glu Ser 355 360 365 Gly Lys Pro Glu Met Ile Val Thr Ala Asn Ile Gly Cys Gln Thr His 370 375 380 Leu Ala Ser Ala Gly Arg Thr Ser Val Arg His Trp Ile Glu Ile Val 385 390 395 400 Glu Gln Ala Leu Glu Lys Glu 405 <210> 16 <211> 238 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(238) <223> Protein encoded by gene arcA <400> 16 Met Gln Thr Pro His Ile Leu Ile Val Glu Asp Glu Leu Val Thr Arg 1 5 10 15 Asn Thr Leu Lys Ser Ile Phe Glu Ala Glu Gly Tyr Asp Val Phe Glu 20 25 30 Ala Thr Asp Gly Ala Glu Met His Gln Ile Leu Ser Glu Tyr Asp Ile 35 40 45 Asn Leu Val Ile Met Asp Ile Asn Leu Pro Gly Lys Asn Gly Leu Leu 50 55 60 Leu Ala Arg Glu Leu Arg Glu Gln Ala Asn Val Ala Leu Met Phe Leu 65 70 75 80 Thr Gly Arg Asp Asn Glu Val Asp Lys Ile Leu Gly Leu Glu Ile Gly 85 90 95 Ala Asp Asp Tyr Ile Thr Lys Pro Phe Asn Pro Arg Glu Leu Thr Ile 100 105 110 Arg Ala Arg Asn Leu Leu Ser Arg Thr Met Asn Leu Gly Thr Val Ser 115 120 125 Glu Glu Arg Arg Ser Val Glu Ser Tyr Lys Phe Asn Gly Trp Glu Leu 130 135 140 Asp Ile Asn Ser Arg Ser Leu Ile Gly Pro Asp Gly Glu Gln Tyr Lys 145 150 155 160 Leu Pro Arg Ser Glu Phe Arg Ala Met Leu His Phe Cys Glu Asn Pro 165 170 175 Gly Lys Ile Gln Ser Arg Ala Glu Leu Leu Lys Lys Met Thr Gly Arg 180 185 190 Glu Leu Lys Pro His Asp Arg Thr Val Asp Val Thr Ile Arg Arg Ile 195 200 205 Arg Lys His Phe Glu Ser Thr Pro Asp Thr Pro Glu Ile Ile Ala Thr 210 215 220 Ile His Gly Glu Gly Tyr Arg Phe Cys Gly Asp Leu Glu Asp 225 230 235 <210> 17 <211> 477 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(477) <223> Protein encoded by gene glcA <400> 17 Met Phe Lys Asn Ala Phe Ala Asn Leu Gln Lys Val Gly Lys Ser Leu 1 5 10 15 Met Leu Pro Val Ser Val Leu Pro Ile Ala Gly Ile Leu Leu Gly Val 20 25 30 Gly Ser Ala Asn Phe Ser Trp Leu Pro Ala Val Val Ser His Val Met 35 40 45 Ala Glu Ala Gly Gly Ser Val Phe Ala Asn Met Pro Leu Ile Phe Ala 50 55 60 Ile Gly Val Ala Leu Gly Phe Thr Asn Asn Asp Gly Val Ser Ala Leu 65 70 75 80 Ala Ala Val Val Ala Tyr Gly Ile Met Val Lys Thr Met Ala Val Val 85 90 95 Ala Pro Leu Val Leu His Leu Pro Ala Glu Glu Ile Ala Ser Lys His 100 105 110 Leu Ala Asp Thr Gly Val Leu Gly Gly Ile Ile Ser Gly Ala Ile Ala 115 120 125 Ala Tyr Met Phe Asn Arg Phe Tyr Arg Ile Lys Leu Pro Glu Tyr Leu 130 135 140 Gly Phe Phe Ala Gly Lys Arg Phe Val Pro Ile Ile Ser Gly Leu Ala 145 150 155 160 Ala Ile Phe Thr Gly Val Val Leu Ser Phe Ile Trp Pro Pro Ile Gly 165 170 175 Ser Ala Ile Gln Thr Phe Ser Gln Trp Ala Ala Tyr Gln Asn Pro Val 180 185 190 Val Ala Phe Gly Ile Tyr Gly Phe Ile Glu Arg Cys Leu Val Pro Phe 195 200 205 Gly Leu His His Ile Trp Asn Val Pro Phe Gln Met Gln Ile Gly Glu 210 215 220 Tyr Thr Asn Ala Ala Gly Gln Val Phe His Gly Asp Ile Pro Arg Tyr 225 230 235 240 Met Ala Gly Asp Pro Thr Ala Gly Lys Leu Ser Gly Gly Phe Leu Phe 245 250 255 Lys Met Tyr Gly Leu Pro Ala Ala Ala Ile Ala Ile Trp His Ser Ala 260 265 270 Lys Pro Glu Asn Arg Ala Lys Val Gly Gly Ile Met Ile Ser Ala Ala 275 280 285 Leu Thr Ser Phe Leu Thr Gly Ile Thr Glu Pro Ile Glu Phe Ser Phe 290 295 300 Met Phe Val Ala Pro Ile Leu Tyr Ile Ile His Ala Ile Leu Ala Gly 305 310 315 320 Leu Ala Phe Pro Ile Cys Ile Leu Leu Gly Met Arg Asp Gly Thr Ser 325 330 335 Phe Ser His Gly Leu Ile Asp Phe Ile Val Leu Ser Gly Asn Ser Ser 340 345 350 Lys Leu Trp Leu Phe Pro Ile Val Gly Ile Gly Tyr Ala Ile Val Tyr 355 360 365 Tyr Thr Ile Phe Arg Val Leu Ile Lys Ala Leu Asp Leu Lys Thr Pro 370 375 380 Gly Arg Glu Asp Ala Thr Glu Asp Ala Lys Ala Thr Gly Thr Ser Glu 385 390 395 400 Met Ala Pro Ala Leu Val Ala Ala Phe Gly Gly Lys Glu Asn Ile Thr 405 410 415 Asn Leu Asp Ala Cys Ile Thr Arg Leu Arg Val Ser Val Ala Asp Val 420 425 430 Ser Lys Val Asp Gln Ala Gly Leu Lys Lys Leu Gly Ala Ala Gly Val 435 440 445 Val Val Ala Gly Ser Gly Val Gln Ala Ile Phe Gly Thr Lys Ser Asp 450 455 460 Asn Leu Lys Thr Glu Met Asp Glu Tyr Ile Arg Asn His 465 470 475 <210> 18 <211> 551 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(551) <223> Protein encoded by gene lldP <400> 18 Met Asn Leu Trp Gln Gln Asn Tyr Asp Pro Ala Gly Asn Ile Trp Leu 1 5 10 15 Ser Ser Leu Ile Ala Ser Leu Pro Ile Leu Phe Phe Phe Phe Ala Leu 20 25 30 Ile Lys Leu Lys Leu Lys Gly Tyr Val Ala Ala Ser Trp Thr Val Ala 35 40 45 Ile Ala Leu Ala Val Ala Leu Leu Phe Tyr Lys Met Pro Val Ala Asn 50 55 60 Ala Leu Ala Ser Val Val Tyr Gly Phe Phe Tyr Gly Leu Trp Pro Ile 65 70 75 80 Ala Trp Ile Ile Ile Ala Ala Val Phe Val Tyr Lys Ile Ser Val Lys 85 90 95 Thr Gly Gln Phe Asp Ile Ile Arg Ser Ser Ile Leu Ser Ile Thr Pro 100 105 110 Asp Gln Arg Leu Gln Met Leu Ile Val Gly Phe Cys Phe Gly Ala Phe 115 120 125 Leu Glu Gly Ala Ala Gly Phe Gly Ala Pro Val Ala Ile Thr Ala Ala 130 135 140 Leu Leu Val Gly Leu Gly Phe Lys Pro Leu Tyr Ala Ala Gly Leu Cys 145 150 155 160 Leu Ile Val Asn Thr Ala Pro Val Ala Phe Gly Ala Met Gly Ile Pro 165 170 175 Ile Leu Val Ala Gly Gln Val Thr Gly Ile Asp Ser Phe Glu Ile Gly 180 185 190 Gln Met Val Gly Arg Gln Leu Pro Phe Met Thr Ile Ile Val Leu Phe 195 200 205 Trp Ile Met Ala Ile Met Asp Gly Trp Arg Gly Ile Lys Glu Thr Trp 210 215 220 Pro Ala Val Val Val Ala Gly Gly Ser Phe Ala Ile Ala Gln Tyr Leu 225 230 235 240 Ser Ser Asn Phe Ile Gly Pro Glu Leu Pro Asp Ile Ile Ser Ser Leu 245 250 255 Val Ser Leu Leu Cys Leu Thr Leu Phe Leu Lys Arg Trp Gln Pro Val 260 265 270 Arg Val Phe Arg Phe Gly Asp Leu Gly Ala Ser Gln Val Asp Met Thr 275 280 285 Leu Ala His Thr Gly Tyr Thr Ala Gly Gln Val Leu Arg Ala Trp Thr 290 295 300 Pro Phe Leu Phe Leu Thr Ala Thr Val Thr Leu Trp Ser Ile Pro Pro 305 310 315 320 Phe Lys Ala Leu Phe Ala Ser Gly Gly Ala Leu Tyr Glu Trp Val Ile 325 330 335 Asn Ile Pro Val Pro Tyr Leu Asp Lys Leu Val Ala Arg Met Pro Pro 340 345 350 Val Val Ser Glu Ala Thr Ala Tyr Ala Ala Val Phe Lys Phe Asp Trp 355 360 365 Phe Ser Ala Thr Gly Thr Ala Ile Leu Phe Ala Ala Leu Leu Ser Ile 370 375 380 Val Trp Leu Lys Met Lys Pro Ser Asp Ala Ile Ser Thr Phe Gly Ser 385 390 395 400 Thr Leu Lys Glu Leu Ala Leu Pro Ile Tyr Ser Ile Gly Met Val Leu 405 410 415 Ala Phe Ala Phe Ile Ser Asn Tyr Ser Gly Leu Ser Ser Thr Leu Ala 420 425 430 Leu Ala Leu Ala His Thr Gly His Ala Phe Thr Phe Phe Ser Pro Phe 435 440 445 Leu Gly Trp Leu Gly Val Phe Leu Thr Gly Ser Asp Thr Ser Ser Asn 450 455 460 Ala Leu Phe Ala Ala Leu Gln Ala Thr Ala Ala Gln Gln Ile Gly Val 465 470 475 480 Ser Asp Leu Leu Leu Val Ala Ala Asn Thr Thr Gly Gly Val Thr Gly 485 490 495 Lys Met Ile Ser Pro Gln Ser Ile Ala Ile Ala Cys Ala Ala Val Gly 500 505 510 Leu Val Gly Lys Glu Ser Asp Leu Phe Arg Phe Thr Val Lys His Ser 515 520 525 Leu Ile Phe Thr Cys Ile Val Gly Val Ile Thr Thr Leu Gln Ala Tyr 530 535 540 Val Leu Thr Trp Met Ile Pro 545 550 <210> 19 <211> 549 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(549) <223> Protein encoded by gene yjcG <400> 19 Met Lys Arg Val Leu Thr Ala Leu Ala Ala Thr Leu Pro Phe Ala Ala 1 5 10 15 Asn Ala Ala Asp Ala Ile Ser Gly Ala Val Glu Arg Gln Pro Thr Asn 20 25 30 Trp Gln Ala Ile Ile Met Phe Leu Ile Phe Val Val Phe Thr Leu Gly 35 40 45 Ile Thr Tyr Trp Ala Ser Lys Arg Val Arg Ser Arg Ser Asp Tyr Tyr 50 55 60 Thr Ala Gly Gly Asn Ile Thr Gly Phe Gln Asn Gly Leu Ala Ile Ala 65 70 75 80 Gly Asp Tyr Met Ser Ala Ala Ser Phe Leu Gly Ile Ser Ala Leu Val 85 90 95 Phe Thr Ser Gly Tyr Asp Gly Leu Ile Tyr Ser Leu Gly Phe Leu Val 100 105 110 Gly Trp Pro Ile Ile Leu Phe Leu Ile Ala Glu Arg Leu Arg Asn Leu 115 120 125 Gly Arg Tyr Thr Phe Ala Asp Val Ala Ser Tyr Arg Leu Lys Gln Gly 130 135 140 Pro Ile Arg Ile Leu Ser Ala Cys Gly Ser Leu Val Val Val Ala Leu 145 150 155 160 Tyr Leu Ile Ala Gln Met Val Gly Ala Gly Lys Leu Ile Glu Leu Leu 165 170 175 Phe Gly Leu Asn Tyr His Ile Ala Val Val Leu Val Gly Val Leu Met 180 185 190 Met Met Tyr Val Leu Phe Gly Gly Met Leu Ala Thr Thr Trp Val Gln 195 200 205 Ile Ile Lys Ala Val Leu Leu Leu Phe Gly Ala Ser Phe Met Ala Phe 210 215 220 Met Val Met Lys His Val Gly Phe Ser Phe Asn Asn Leu Phe Ser Glu 225 230 235 240 Ala Met Ala Val His Pro Lys Gly Val Asp Ile Met Lys Pro Gly Gly 245 250 255 Leu Val Lys Asp Pro Ile Ser Ala Leu Ser Leu Gly Leu Gly Leu Met 260 265 270 Phe Gly Thr Ala Gly Leu Pro His Ile Leu Met Arg Phe Phe Thr Val 275 280 285 Ser Asp Ala Arg Glu Ala Arg Lys Ser Val Phe Tyr Ala Thr Gly Phe 290 295 300 Met Gly Tyr Phe Tyr Ile Leu Thr Phe Ile Ile Gly Phe Gly Ala Ile 305 310 315 320 Met Leu Val Gly Ala Asn Pro Glu Tyr Lys Asp Ala Ala Gly His Leu 325 330 335 Ile Gly Gly Asn Asn Met Ala Ala Val His Leu Ala Asn Ala Val Gly 340 345 350 Gly Asn Leu Phe Leu Gly Phe Ile Ser Ala Val Ala Phe Ala Thr Ile 355 360 365 Leu Ala Val Val Ala Gly Leu Thr Leu Ala Gly Ala Ser Ala Val Ser 370 375 380 His Asp Leu Tyr Ala Asn Val Phe Lys Lys Gly Ala Thr Glu Arg Glu 385 390 395 400 Glu Leu Arg Val Ser Lys Ile Thr Val Leu Ile Leu Gly Val Ile Ala 405 410 415 Ile Ile Leu Gly Val Leu Phe Glu Asn Gln Asn Ile Ala Phe Met Val 420 425 430 Gly Leu Ala Phe Ala Ile Ala Ala Ser Cys Asn Phe Pro Ile Ile Leu 435 440 445 Leu Ser Met Tyr Trp Ser Lys Leu Thr Thr Arg Gly Ala Met Met Gly 450 455 460 Gly Trp Leu Gly Leu Ile Thr Ala Val Val Leu Met Ile Leu Gly Pro 465 470 475 480 Thr Ile Trp Val Gln Ile Leu Gly His Glu Lys Ala Ile Phe Pro Tyr 485 490 495 Glu Tyr Pro Ala Leu Phe Ser Ile Thr Val Ala Phe Leu Gly Ile Trp 500 505 510 Phe Phe Ser Ala Thr Asp Asn Ser Ala Glu Gly Ala Arg Glu Arg Glu 515 520 525 Leu Phe Arg Ala Gln Phe Ile Arg Ser Gln Thr Gly Phe Gly Val Glu 530 535 540 Gln Gly Arg Ala His 545 <210> 20 <211> 152 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(152) <223> Protein encoded by gene mgsA <400> 20 Met Glu Leu Thr Thr Arg Thr Leu Pro Ala Arg Lys His Ile Ala Leu 1 5 10 15 Val Ala His Asp His Cys Lys Gln Met Leu Met Ser Trp Val Glu Arg 20 25 30 His Gln Pro Leu Leu Glu Gln His Val Leu Tyr Ala Thr Gly Thr Thr 35 40 45 Gly Asn Leu Ile Ser Arg Ala Thr Gly Met Asn Val Asn Ala Met Leu 50 55 60 Ser Gly Pro Met Gly Gly Asp Gln Gln Val Gly Ala Leu Ile Ser Glu 65 70 75 80 Gly Lys Ile Asp Val Leu Ile Phe Phe Trp Asp Pro Leu Asn Ala Val 85 90 95 Pro His Asp Pro Asp Val Lys Ala Leu Leu Arg Leu Ala Thr Val Trp 100 105 110 Asn Ile Pro Val Ala Thr Asn Val Ala Thr Ala Asp Phe Ile Ile Gln 115 120 125 Ser Pro His Phe Asn Asp Ala Val Asp Ile Leu Ile Pro Asp Tyr Gln 130 135 140 Arg Tyr Leu Ala Asp Arg Leu Lys 145 150 <210> twenty one <211> 320 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(320) <223> Protein encoded by gene pfKA <400> twenty one Met Ile Lys Lys Ile Gly Val Leu Thr Ser Gly Gly Asp Ala Pro Gly 1 5 10 15 Met Asn Ala Ala Ile Arg Gly Val Val Arg Ser Ala Leu Thr Glu Gly 20 25 30 Leu Glu Val Met Gly Ile Tyr Asp Gly Tyr Leu Gly Leu Tyr Glu Asp 35 40 45 Arg Met Val Gln Leu Asp Arg Tyr Ser Val Ser Asp Met Ile Asn Arg 50 55 60 Gly Gly Thr Phe Leu Gly Ser Ala Arg Phe Pro Glu Phe Arg Asp Glu 65 70 75 80 Asn Ile Arg Ala Val Ala Ile Glu Asn Leu Lys Lys Arg Gly Ile Asp 85 90 95 Ala Leu Val Val Ile Gly Gly Asp Gly Ser Tyr Met Gly Ala Met Arg 100 105 110 Leu Thr Glu Met Gly Phe Pro Cys Ile Gly Leu Pro Gly Thr Ile Asp 115 120 125 Asn Asp Ile Lys Gly Thr Asp Tyr Thr Ile Gly Phe Phe Thr Ala Leu 130 135 140 Ser Thr Val Val Glu Ala Ile Asp Arg Leu Arg Asp Thr Ser Ser Ser 145 150 155 160 His Gln Arg Ile Ser Val Val Glu Val Met Gly Arg Tyr Cys Gly Asp 165 170 175 Leu Thr Leu Ala Ala Ala Ile Ala Gly Gly Cys Glu Phe Val Val Val 180 185 190 Pro Glu Val Glu Phe Ser Arg Glu Asp Leu Val Asn Glu Ile Lys Ala 195 200 205 Gly Ile Ala Lys Gly Lys Lys His Ala Ile Val Ala Ile Thr Glu His 210 215 220 Met Cys Asp Val Asp Glu Leu Ala His Phe Ile Glu Lys Glu Thr Gly 225 230 235 240 Arg Glu Thr Arg Ala Thr Val Leu Gly His Ile Gln Arg Gly Gly Ser 245 250 255 Pro Val Pro Tyr Asp Arg Ile Leu Ala Ser Arg Met Gly Ala Tyr Ala 260 265 270 Ile Asp Leu Leu Leu Ala Gly Tyr Gly Gly Arg Cys Val Gly Ile Gln 275 280 285 Asn Glu Gln Leu Val His His Asp Ile Ile Asp Ala Ile Glu Asn Met 290 295 300 Lys Arg Pro Phe Lys Gly Asp Trp Leu Asp Cys Ala Lys Lys Leu Tyr 305 310 315 320 <210> twenty two <211> 215 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(215) <223> Protein encoded by gene fucA <400> twenty two Met Glu Arg Asn Lys Leu Ala Arg Gln Ile Ile Asp Thr Cys Leu Glu 1 5 10 15 Met Thr Arg Leu Gly Leu Asn Gln Gly Thr Ala Gly Asn Val Ser Val 20 25 30 Arg Tyr Gln Asp Gly Met Leu Ile Thr Pro Thr Gly Ile Pro Tyr Glu 35 40 45 Lys Leu Thr Glu Ser His Ile Val Phe Ile Asp Gly Asn Gly Lys His 50 55 60 Glu Glu Gly Lys Leu Pro Ser Ser Glu Trp Arg Phe His Met Ala Ala 65 70 75 80 Tyr Gln Ser Arg Pro Asp Ala Asn Ala Val Val His Asn His Ala Val 85 90 95 His Cys Thr Ala Val Ser Ile Leu Asn Arg Ser Ile Pro Ala Ile His 100 105 110 Tyr Met Ile Ala Ala Ala Gly Gly Asn Ser Ile Pro Cys Ala Pro Tyr 115 120 125 Ala Thr Phe Gly Thr Arg Glu Leu Ser Glu His Val Ala Leu Ala Leu 130 135 140 Lys Asn Arg Lys Ala Thr Leu Leu Gln His His Gly Leu Ile Ala Cys 145 150 155 160 Glu Val Asn Leu Glu Lys Ala Leu Trp Leu Ala His Glu Val Glu Val 165 170 175 Leu Ala Gln Leu Tyr Leu Thr Thr Leu Ala Ile Thr Asp Pro Val Pro 180 185 190 Val Leu Ser Asp Glu Glu Ile Ala Val Val Leu Glu Lys Phe Lys Thr 195 200 205 Tyr Gly Leu Arg Ile Glu Glu 210 215 <210> twenty three <211> 491 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(491) <223> Protein encoded by gene zwf <400> twenty three Met Ala Val Thr Gln Thr Ala Gln Ala Cys Asp Leu Val Ile Phe Gly 1 5 10 15 Ala Lys Gly Asp Leu Ala Arg Arg Lys Leu Leu Pro Ser Leu Tyr Gln 20 25 30 Leu Glu Lys Ala Gly Gln Leu Asn Pro Asp Thr Arg Ile Ile Gly Val 35 40 45 Gly Arg Ala Asp Trp Asp Lys Ala Ala Tyr Thr Lys Val Val Arg Glu 50 55 60 Ala Leu Glu Thr Phe Met Lys Glu Thr Ile Asp Glu Gly Leu Trp Asp 65 70 75 80 Thr Leu Ser Ala Arg Leu Asp Phe Cys Asn Leu Asp Val Asn Asp Thr 85 90 95 Ala Ala Phe Ser Arg Leu Gly Ala Met Leu Asp Gln Lys Asn Arg Ile 100 105 110 Thr Ile Asn Tyr Phe Ala Met Pro Pro Ser Thr Phe Gly Ala Ile Cys 115 120 125 Lys Gly Leu Gly Glu Ala Lys Leu Asn Ala Lys Pro Ala Arg Val Val 130 135 140 Met Glu Lys Pro Leu Gly Thr Ser Leu Ala Thr Ser Gln Glu Ile Asn 145 150 155 160 Asp Gln Val Gly Glu Tyr Phe Glu Glu Cys Gln Val Tyr Arg Ile Asp 165 170 175 His Tyr Leu Gly Lys Glu Thr Val Leu Asn Leu Leu Ala Leu Arg Phe 180 185 190 Ala Asn Ser Leu Phe Val Asn Asn Trp Asp Asn Arg Thr Ile Asp His 195 200 205 Val Glu Ile Thr Val Ala Glu Glu Val Gly Ile Glu Gly Arg Trp Gly 210 215 220 Tyr Phe Asp Lys Ala Gly Gln Met Arg Asp Met Ile Gln Asn His Leu 225 230 235 240 Leu Gln Ile Leu Cys Met Ile Ala Met Ser Pro Pro Ser Asp Leu Ser 245 250 255 Ala Asp Ser Ile Arg Asp Glu Lys Val Lys Val Leu Lys Ser Leu Arg 260 265 270 Arg Ile Asp Arg Ser Asn Val Arg Glu Lys Thr Val Arg Gly Gln Tyr 275 280 285 Thr Ala Gly Phe Ala Gln Gly Lys Lys Val Pro Gly Tyr Leu Glu Glu 290 295 300 Glu Gly Ala Asn Lys Ser Ser Asn Thr Glu Thr Phe Val Ala Ile Arg 305 310 315 320 Val Asp Ile Asp Asn Trp Arg Trp Ala Gly Val Pro Phe Tyr Leu Arg 325 330 335 Thr Gly Lys Arg Leu Pro Thr Lys Cys Ser Glu Val Val Val Tyr Phe 340 345 350 Lys Thr Pro Glu Leu Asn Leu Phe Lys Glu Ser Trp Gln Asp Leu Pro 355 360 365 Gln Asn Lys Leu Thr Ile Arg Leu Gln Pro Asp Glu Gly Val Asp Ile 370 375 380 Gln Val Leu Asn Lys Val Pro Gly Leu Asp His Lys His Asn Leu Gln 385 390 395 400 Ile Thr Lys Leu Asp Leu Ser Tyr Ser Glu Thr Phe Asn Gln Thr His 405 410 415 Leu Ala Asp Ala Tyr Glu Arg Leu Leu Leu Glu Thr Met Arg Gly Ile 420 425 430 Gln Ala Leu Phe Val Arg Arg Asp Glu Val Glu Glu Ala Trp Lys Trp 435 440 445 Val Asp Ser Ile Thr Glu Ala Trp Ala Met Asp Asn Asp Ala Pro Lys 450 455 460 Pro Tyr Gln Ala Gly Thr Trp Gly Pro Val Ala Ser Val Ala Met Ile 465 470 475 480 Thr Arg Asp Gly Arg Ser Trp Asn Glu Phe Glu 485 490 <210> twenty four <211> 603 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(603) <223> Protein encoded by the gene edd <400> twenty four Met Asn Pro Gln Leu Leu Arg Val Thr Asn Arg Ile Ile Glu Arg Ser 1 5 10 15 Arg Glu Thr Arg Ser Ala Tyr Leu Ala Arg Ile Glu Gln Ala Lys Thr 20 25 30 Ser Thr Val His Arg Ser Gln Leu Ala Cys Gly Asn Leu Ala His Gly 35 40 45 Phe Ala Ala Cys Gln Pro Glu Asp Lys Ala Ser Leu Lys Ser Met Leu 50 55 60 Arg Asn Asn Ile Ala Ile Ile Thr Ser Tyr Asn Asp Met Leu Ser Ala 65 70 75 80 His Gln Pro Tyr Glu His Tyr Pro Glu Ile Ile Arg Lys Ala Leu His 85 90 95 Glu Ala Asn Ala Val Gly Gln Val Ala Gly Gly Val Pro Ala Met Cys 100 105 110 Asp Gly Val Thr Gln Gly Gln Asp Gly Met Glu Leu Ser Leu Leu Ser 115 120 125 Arg Glu Val Ile Ala Met Ser Ala Ala Val Gly Leu Ser His Asn Met 130 135 140 Phe Asp Gly Ala Leu Phe Leu Gly Val Cys Asp Lys Ile Val Pro Gly 145 150 155 160 Leu Thr Met Ala Ala Leu Ser Phe Gly His Leu Pro Ala Val Phe Val 165 170 175 Pro Ser Gly Pro Met Ala Ser Gly Leu Pro Asn Lys Glu Lys Val Arg 180 185 190 Ile Arg Gln Leu Tyr Ala Glu Gly Lys Val Asp Arg Met Ala Leu Leu 195 200 205 Glu Ser Glu Ala Ala Ser Tyr His Ala Pro Gly Thr Cys Thr Phe Tyr 210 215 220 Gly Thr Ala Asn Thr Asn Gln Met Val Val Glu Phe Met Gly Met Gln 225 230 235 240 Leu Pro Gly Ser Ser Phe Val His Pro Asp Ser Pro Leu Arg Asp Ala 245 250 255 Leu Thr Ala Ala Ala Ala Arg Gln Val Thr Arg Met Thr Gly Asn Gly 260 265 270 Asn Glu Trp Met Pro Ile Gly Lys Met Ile Asp Glu Lys Val Val Val 275 280 285 Asn Gly Ile Val Ala Leu Leu Ala Thr Gly Gly Ser Thr Asn His Thr 290 295 300 Met His Leu Val Ala Met Ala Arg Ala Ala Gly Ile Gln Ile Asn Trp 305 310 315 320 Asp Asp Phe Ser Asp Leu Ser Asp Val Val Pro Leu Met Ala Arg Leu 325 330 335 Tyr Pro Asn Gly Pro Ala Asp Ile Asn His Phe Gln Ala Ala Gly Gly 340 345 350 Val Pro Val Leu Val Arg Glu Leu Leu Lys Ala Gly Leu Leu His Glu 355 360 365 Asp Val Asn Thr Val Ala Gly Phe Gly Leu Ser Arg Tyr Thr Leu Glu 370 375 380 Pro Trp Leu Asn Asn Gly Glu Leu Asp Trp Arg Glu Gly Ala Glu Lys 385 390 395 400 Ser Leu Asp Ser Asn Val Ile Ala Ser Phe Glu Gln Pro Phe Ser His 405 410 415 His Gly Gly Thr Lys Val Leu Ser Gly Asn Leu Gly Arg Ala Val Met 420 425 430 Lys Thr Ser Ala Val Pro Val Glu Asn Gln Val Ile Glu Ala Pro Ala 435 440 445 Val Val Phe Glu Ser Gln His Asp Val Met Pro Ala Phe Glu Ala Gly 450 455 460 Leu Leu Asp Arg Asp Cys Val Val Val Val Arg His Gln Gly Pro Lys 465 470 475 480 Ala Asn Gly Met Pro Glu Leu His Lys Leu Met Pro Pro Leu Gly Val 485 490 495 Leu Leu Asp Arg Cys Phe Lys Ile Ala Leu Val Thr Asp Gly Arg Leu 500 505 510 Ser Gly Ala Ser Gly Lys Val Pro Ser Ala Ile His Val Thr Pro Glu 515 520 525 Ala Tyr Asp Gly Gly Leu Leu Ala Lys Val Arg Asp Gly Asp Ile Ile 530 535 540 Arg Val Asn Gly Gln Thr Gly Glu Leu Thr Leu Leu Val Asp Glu Ala 545 550 555 560 Glu Leu Ala Ala Arg Glu Pro His Ile Pro Asp Leu Ser Ala Ser Arg 565 570 575 Val Gly Thr Gly Arg Glu Leu Phe Ser Ala Leu Arg Glu Lys Leu Ser 580 585 590 Gly Ala Glu Gln Gly Ala Thr Cys Ile Thr Phe 595 600 <210> 25 <211> 213 <212> PRT <213> E. coli strain K12 MG1655 <220> <221> PEPTIDE <222> (1)..(213) <223> Protein encoded by gene eda <400> 25 Met Lys Asn Trp Lys Thr Ser Ala Glu Ser Ile Leu Thr Thr Gly Pro 1 5 10 15 Val Val Pro Val Ile Val Val Lys Lys Leu Glu His Ala Val Pro Met 20 25 30 Ala Lys Ala Leu Val Ala Gly Gly Val Arg Val Leu Glu Val Thr Leu 35 40 45 Arg Thr Glu Cys Ala Val Asp Ala Ile Arg Ala Ile Ala Lys Glu Val 50 55 60 Pro Glu Ala Ile Val Gly Ala Gly Thr Val Leu Asn Pro Gln Gln Leu 65 70 75 80 Ala Glu Val Thr Glu Ala Gly Ala Gln Phe Ala Ile Ser Pro Gly Leu 85 90 95 Thr Glu Pro Leu Leu Lys Ala Ala Thr Glu Gly Thr Ile Pro Leu Ile 100 105 110 Pro Gly Ile Ser Thr Val Ser Glu Leu Met Leu Gly Met Asp Tyr Gly 115 120 125 Leu Lys Glu Phe Lys Phe Phe Pro Ala Glu Ala Asn Gly Gly Val Lys 130 135 140 Ala Leu Gln Ala Ile Ala Gly Pro Phe Ser Gln Val Arg Phe Cys Pro 145 150 155 160 Thr Gly Gly Ile Ser Pro Ala Asn Tyr Arg Asp Tyr Leu Ala Leu Lys 165 170 175 Ser Val Leu Cys Ile Gly Gly Ser Trp Leu Val Pro Ala Asp Ala Leu 180 185 190 Glu Ala Gly Asp Tyr Asp Arg Ile Thr Lys Leu Ala Arg Glu Ala Val 195 200 205 Glu Gly Ala Lys Leu 210 <210> 26 <211> 39 <212> DNA <213> Artificial sequence <220> <223> Sense primer for gene xylA <400> 26 ctggtgccgc gcggcagcca tatgcaagcc tattttgac 39 <210> 27 <211> 42 <212> DNA <213> Artificial sequence <220> <223> Antisense primer of gene xylA <400> 27 gtcgacggag ctcgaattcg ttatttgtcg aacagataat gg 42 <210> 28 <211> 43 <212> DNA <213> Artificial sequence <220> <223> Sense primer for gene xylB <400> 28 ctggtgccgc gcggcagcca tatgtatatc gggatagatc ttg 43 <210> 29 <211> 38 <212> DNA <213> Artificial sequence <220> <223> Antisense primer of gene xylB <400> 29 gtcgacggag ctcgaattcg ttacgccatt aatggcag 38 <210> 30 <211> 46 <212> DNA <213> Artificial sequence <220> <223> Sense primer for gene araA <400> 30 ctggtgccgc gcggcagcca tatgacgatt tttgataatt atgaag 46 <210> 31 <211> 42 <212> DNA <213> Artificial sequence <220> <223> Antisense primer for gene araA <400> 31 gtcgacggag ctcgaattcg ttagcgacga aacccgtaat ac 42 <210> 32 <211> 38 <212> DNA <213> Artificial sequence <220> <223> Sense primer for gene araB <400> 32 ctggtgccgc gcggcagcca tatggcgatt gcaattgg 38 <210> 33 <211> 39 <212> DNA <213> Artificial sequence <220> <223> Antisense primer for gene araB <400> 33 gtcgacggag ctcgaattcg ttatagagtc gcaacggcc 39 <210> 34 <211> 41 <212> DNA <213> Artificial sequence <220> <223> Sense primer for gene araD <400> 34 ctggtgccgc gcggcagcca tatgttagaa gatctcaaac g 41 <210> 35 <211> 38 <212> DNA <213> Artificial sequence <220> <223> Antisense primer of gene araD <400> 35 gtcgacggag ctcgaattcg ttactgcccg taatatgc 38 <210> 36 <211> 41 <212> DNA <213> Artificial sequence <220> <223> Sense primer of gene rpe <400> 36 ctggtgccgc gcggcagcca tatgaaacag tatttgattg c 41 <210> 37 <211> 41 <212> DNA <213> Artificial sequence <220> <223> Antisense primers for gene rpe <400> 37 gtcgacggag ctcgaattcg ttattcatga cttacctttg c 41 <210> 38 <211> 37 <212> DNA <213> Artificial sequence <220> <223> Sense primer for gene kdsD <400> 38 gccgcgcggc agccatatat gtcgcacgta gagttac 37 <210> 39 <211> 38 <212> DNA <213> Artificial sequence <220> <223> Antisense primers for gene kdsD <400> 39 gtcgacggag ctcgaattcg ttacactacg cctgcacg 38 <210> 40 <211> 41 <212> DNA <213> Artificial sequence <220> <223> Sense primer for gene fsa <400> 40 gccgcgcggc agccatatat ggaactgtat ctggatactt c 41 <210> 41 <211> 38 <212> DNA <213> Artificial sequence <220> <223> Antisense primers for gene fsa <400> 41 gtcgacggag ctcgaattcg ttaaatcgac gttctgcc 38 <210> 42 <211> 40 <212> DNA <213> Artificial sequence <220> <223> Sense primer for gene aldA <400> 42 ctggtgccgc gcggcagcca tatgtcagta cccgttcaac 40 <210> 43 <211> 42 <212> DNA <213> Artificial sequence <220> <223> Antisense primer for gene aldA <400> 43 gtcgacggag ctcgaattcg ttaagactgt aaataaacca cc 42 BRIEF DESCRIPTION OF THE DRAWINGS
[0240] Figure 1Three key reactions for glycolate production isolated from the central carbon metabolism of Escherichia coli are shown.
[0241] Figure 2 Shown is a non-natural pathway for producing glycolic acid from D-glucose, D-xylose, and L-arabinose.
[0242] Figure 3 is a schematic representation of the enzymatic assays used to examine the activities of arabinose-5P isomerase (KdsD), fructose-6P aldolase (FSA) and aldehyde dehydrogenase (aldA). KdsD, FSA and aldA were purified, triose phosphate isomerase (Tpi) and glycerol-3P dehydrogenase (G3PDH) were ordered from Sigma.
[0243] FIG4 shows a system comprising seven purified enzymes (AraA, AraB, AraD, RPE, KdsD, FSA, AldA) that catalyze the conversion of L-arabinose to glycolic acid ( Figure 4A The glycolate production of this system was compared with that of a system without AraA in the presence of L-arabinose; the enzymatic reaction was based on the measurement of NADH at 340 nm ( Figure 4B ).
[0244] FIG5 shows a system including six purified enzymes (XylA, XylB, RPE, KdsD, FSA, AldA) capable of converting D-xylose into glycolic acid ( Figure 5A The glycolate production of this system was compared with that of a system without XylA in the presence of D-xylose; the enzymatic reaction was based on the measurement of NADH at 340 nm ( Figure 5B ).
[0245] FIG6 shows a system comprising seven purified enzymes (Hxk, Pgi, Tkt, RPE, KdsD, FSA, AldA) capable of converting D-glucose into glycolic acid ( Fig. 6A The glycolic acid produced by this system in the presence of D-glucose was compared to that produced by the system without Hxk; the enzymatic assay was based on the measurement of NADH at 340 nm ( Figure 6B ).
[0246] Figure 7Highlighted representation of the in vivo functionality of the non-native pathway according to the invention in E. coli MG1655 ΔtktA ΔtktB ΔglcD, bold: non-native pathway according to the invention, dashed line: deletion. Xu5P: xylulose-5-phosphate, Ru5P: ribulose-5-phosphate, R5P: ribose-5-phosphate, S7P: sedoheptulose-7-phosphate, F6P: fructose-6-phosphate, F16BP: fructose-1,6-bisphosphate, G6P: glucose-6-phosphate, DHAP: dihydroxyacetone phosphate, Glyald: glycolaldehyde, E4P: erythrose-4-phosphate, G3P: glyceraldehyde-3-phosphate.
[0247] Figure 8 It is shown that the E. coli strain MG1655ΔtktAΔtktBΔglcD expressing the kdsD-fsa-aldA-dependent non-native pathway according to the present invention produced glycolate from D-xylose or L-arabinose at 37°C for 100 h.
[0248] Fig. 9 It is shown that the E. coli WC3GΔgapAΔglcDΔarcAΔmgsAΔfucAΔpkfproD-galP strain expressing the kdsD-fsa-aldA-dependent non-native pathway according to the present invention produced glycolic acid from glucose, xylose and arabinose for 50 h at 37°C.
[0249] Detailed description of specific embodiments
[0250] I. In vitro feasibility verification
[0251] I.1. Materials and methods
[0252] A. Plasmid construction
[0253] In order to construct an in vitro system, the inventors have cloned the ORFs ("open reading frames") of xylose isomerase (XylA), xylulase (XylB), arabinose isomerase (AraA), ribulokinase (AraB), L-ribulose-5-phosphate 4-epimerase (AraD), ribulose-5-phosphate-3-epimerase (RPE), D-arabinose-5-phosphate isomerase (KdsD), fructose-6-phosphate aldolase (FSA corresponds to FSAA, such as previously defined) and aldehyde dehydrogenase (AldA) of E. coli K12 MG1655 with polyhistidine tags to facilitate purification. The oligonucleotides used to amplify the ORFs of the E. coli enzymes are listed in Table 3 below, with the sequences SEQ ID NO: referring to the attached sequence listing. The E. coli genomic DNA used as template was the DNA of strain K12 MG1655.
[0254] Plasmids for expressing C-terminal polyhistidine-tagged proteins XylA, XylB, AraA, AraB, AraD, AraB, Rpe, KdsD, FSA, AldA were prepared by HiFi using pET28a as a receiving vector. (NEB). pET28a had been linearized with restriction enzymes HindIII and BamHI (NEB) (Table 4). E. coli strain derived from DH5α For cloning and storage of different plasmids.
[0255] Table 3
[0256]
[0257]
[0258] Table 4: Plasmids used for in vitro feasibility testing
[0259]
[0260] B. Construction of strains
[0261] E. coli competent cells BL21 (DE3) were used to express the tagged proteins, since these cells express RNA polymerase T7 and are therefore compatible with the expression system T7 of the vector pET28a. The plasmid pET28a, previously checked by sequencing, was transformed in BL21 (DE3) according to the NEB protocol. The obtained strains were stored in 50% glycerol at -80°C (Table 5).
[0262] Table 5: E. coli strains used for in vitro feasibility testing
[0263]
[0264]
[0265] C. Expression and purification of polyhistidine-tagged proteins
[0266] All expressed proteins were soluble and produced from the expression vector pET28a transformed in the E. coli strain BL21 (DE3). Pre-cultivation was performed overnight at 37°C in LB ("Luria-Bertani") medium supplemented with the antibiotic kanamycin. At an OD 600 nm (OD 600 ) (37°C, 200 rpm), the preculture was used to inoculate a fresh culture of 200 ml LB-kanamycin. 600At between 0.6 and 0.8, the expression of the target protein was induced by adding final 1 mM IPTG. The protein was expressed overnight at 16°C. The cells were collected in 50 ml fractions and centrifuged at 4800 rpm for 15 min at 4°C. The cell pellets were stored at -20°C.
[0267] Purification of protein was carried out from the cell mass obtained during the production step. All steps were carried out under cold conditions to avoid protein degradation by protease. Resuspended cell mass in 1.5mL flushing buffer (50mM HEPES, pH 7.5; 0.3M NaCl), and then ultrasonicated on ice. The step of centrifuging 15min at 4°C with 13000rpm can separate cell debris from cytoplasmic liquid. The clarified lysate was deposited on the cobalt resin (Clontech) previously balanced with washing buffer of 600 μl. After contacting the resin for 20min at room temperature, centrifuged test tube (700rcf, 3min, 4°C). Remove supernatant, resin contacts 3mL washing buffer for 10min, so as to remove non-specific interactions. After centrifugation (700rcf, 3, min, 4°C) and removing supernatant, 3ml of 15mM imidazole solution contacts resin for 5min. Supernatant is separated from resin by centrifugation, replaced by 500μl of 200mM imidazole. Imidazole causes elution of proteins carrying polyhistidine tags. Buffers have been modified to promote protein stability at their optimal pH.
[0268] The method used to measure the concentration of protein in solution is based on the Bradford method. Protein sold by BioRad The reagent was diluted to 1 / 4, and the reaction mixture included 160 μl of reagent and 40 μl of diluted eluent (1 / 10 th and until 1 / 20 th ). Standards ranging from 12.5 to 100 μg / ml were prepared with BSA.
[0269] D. Enzymatic testing
[0270] All enzymes have been tested in 100 mM Tris, pH 7.5, 10 mM MgCl2 at 37°C. Cofactors and activators have been added if necessary.
[0271] Enzymes Saccharomyces cerevisiae hexokinase (Hxk), Escherichia coli transketolase (Tkt), Escherichia coli pyruvate kinase (PK), and Escherichia coli lactate dehydrogenase (LDH), triose-phosphate isomerase (Tpi), and glycerol-3-phosphate dehydrogenase (G3PDH) were ordered from Sigma. Escherichia coli phosphoglucose isomerase (Pgi) was from Megazyme.
[0272] All enzyme substrates were purchased from Sigma-Aldrich. Enzymatic assays were coupled to redox reactions using NADH as a cofactor. NADH absorbs UV light at 340 nm with a peak of 6220 M -1 .cm -1 The molar extinction coefficient of 2.5 was 2.17 W. Bio-Tek Epoch2 spectrophotometer was used for UV reaction monitoring.
[0273] Measurement of aldehyde dehydrogenase (AldA) activity : In 5mM glycolaldehyde, 3mM NAD + The activity was measured in the presence of 3 mM ATP. One molecule of glycolaldehyde was oxidized to glycolic acid, one molecule of NAD + The molecule is reduced to NADH.
[0274] Measurement of fructose-6P aldolase (FSA) activity : The enzyme FSA cleaves D-arabinose-5-phosphate into glycolaldehyde and glyceraldehyde-3-phosphate (GAP). The rate of glycolaldehyde appearance was measured in the presence of AldA and 2 mM NAD+. To monitor GAP appearance, TPI and G3PDH were added in the presence of 0.4 mM NADH.
[0275] Measurement of D-arabinose-5-phosphate isomerase (KdsD) activity : D-arabinose-5-phosphate isomerase catalyzes the interconversion of D-ribulose-5-phosphate to D-arabinose-5-phosphate. + The activity of KdsD on D-ribulose-5-phosphate was determined by adding excess FSA, aldA in the presence of .
[0276] In vitro conversion of D-xylose to glycolic acid The conversion of D-xylose to glycolate requires XylA, XylB, Rpe, KdsD, FSA, and aldA ( Figure 5A The conversion of D-xylose to glycolate was carried out in a 100 mM Tris HCl pH 7.5 solution containing 10 mM MgCl2, 0.5 mM MnCl2, 3 mM ATP, 2 mM NAD + , 1-10 μg of each enzyme and 5 mM D-xylose in the reaction mixture.
[0277] In vitro conversion of L-arabinose to glycolic acid : The conversion of L-arabinose to glycolate requires AraA, AraB, AraD, Rpe, KdsD, FSA, and aldA ( Figure 4A The conversion of L-arabinose to glycolate was carried out in 100 mM Tris HCl, pH 7.5, 10 mM MgCl2, 0.5 mM MnCl2, 3 mM ATP, 2 mM NAD + , 1-10 μg of each enzyme and 5 mM L-arabinose.
[0278] In vitro conversion of D-glucose to glycolic acid The conversion of D-glucose to glycolate requires the enzymes Hxk, Pgi, Tkt, Rpe, KdsD, FSA, and aldA ( Fig. 6A The feasibility was verified in 100 mM Tris HCl, pH 7.5, 10 mM MgCl2, 0.5 mM MnCl2, 1 mM TPP ("thiamine pyrophosphate"), 3 mM ATP, 2 mM NAD, 5 mM glyceraldehyde-3P, 1-10 μg of each enzyme and 5 mM D-glucose.
[0279] I.2. result
[0280] A. In vitro conversion of D-ribulose-5P to glycolic acid
[0281] Ribulose-5P is a common metabolite of the catabolism of arabinose, xylose and glucose in Escherichia coli. As the object of the present invention, the non-natural conversion pathway of D-ribulose-5P to glycolic acid is composed of the enzymes KdsD (D-arabinose 5P isomerase), FSA (fructose-6P aldolase) and AldA (glycol aldehyde dehydrogenase). The in vitro verification of feasibility includes the reconstruction of the pathway with purified enzymes in a suitable buffer. First, aldA has been characterized on glycolaldehyde, and then the activity of FSA on D-arabinose-5P is verified by coupling with aldA to check glycolaldehyde formation and by coupling with triose phosphate isomerase and glycerol-3P dehydrogenase to highlight glyceraldehyde-3P synthesis ( Figure 3 ). The FSA activity measurements obtained by these 2 methods were identical. Finally, the activity of KdsD on D-ribulose-5P was measured by coupling with excess enzymes FSA and aldA. This final enzymatic test enabled verification of KdsD functionality and reconstruction of the entire glycolate synthesis pathway. NADH and glycolate were produced in equimolar amounts. In order to verify evidence that NADH was indeed responsible for glycolate production, glycolate production was measured by HPLC.
[0282] The catalytic constants of these three enzymes are shown in Table 6. The polyhistidine-tagged proteins KdsD, FSA and aldA are active. The reaction mixture containing KdsD, FSA and AldA has been analyzed by HPLC in the presence of 5 mM D-ribulose-5P and 1.5 mM glycolic acid has been quantified. The measured glycolic acid production corresponds to the initial NAD + volume, indicating that the reaction has been completed.
[0283] Table 6: Polyhistidine-tagged arabinose-5P isomerase (KdsD), fructose-6P aldolase (FSA), aldehyde dehydrogenase (ADH) Catalytic constant of enzyme (AldA)
[0284]
[0285] B. Conversion of L-arabinose or D-xylose or D-glucose to glycolic acid
[0286] Enzymes that catalyze the conversion of L-arabinose, D-xylose, and D-glucose to glycolate have been purified (AraA, AraB, AraD, XylA, XylB, Rpe, KdsD, Fsa, AldA) or ordered (Tkt, Glk, Pgi) to demonstrate the feasibility of producing glycolate from these three substrates in vitro.
[0287] The conversion of L-arabinose to glycolate and glyceraldehyde 3P is catalyzed by AraA, araB, araD, Rpe, KdsD, FSA, and aldA ( Figure 4A The observation of NADH synthesis during the enzymatic assay in the presence of L-arabinose is indirect evidence for glycolic acid production (Table 7, Figure 4B ).
[0288] The conversion of L-arabinose to glycolic acid was demonstrated and thus this metabolic pathway is thermodynamically possible.
[0289] Table 7: Enzyme activity for the conversion of L-arabinose to glycolic acid measured at 340 nm at 37°C The enzyme activity unit (U) is defined as the conversion of one micromole of substrate per minute. The negative control is the absence of arabinose isomerase activity catalyzed by AraA.
[0290]
[0291] ii. Conversion of D-xylose to glycolic acid
[0292] The conversion of D-xylose to glycolate and glyceraldehyde 3P is catalyzed by XylA, XylB, Rpe, KdsD, FSA, and AldA ( Figure 5A When these enzymes were contacted with D-xylose, D-xylose was converted to glycolic acid in vitro, as evidenced by NADH production ( Figure 5B , Table 8).
[0293] Table 8: Enzyme activity for the conversion of D-xylose to glycolic acid measured at 37°C at 340 nm The enzyme activity unit (U) is defined as the conversion of one micromole of substrate per minute. The negative control is the absence of xylulose isomerase activity catalyzed by XylA.
[0294]
[0295] The conversion pathway of D-xylose to glycolic acid is functional and thermodynamically possible. iii. Conversion of D-glucose to glycolic acid
[0296] The conversion of D-glucose to glycolate has been demonstrated by contacting D-glucose and DL-glyceraldehyde-3P (GAP) with Hxk, Pgi, Tkt, Rpe, KdsD, FSA, and AldA ( Fig. 6A ). The negative control showed significant activity ( Figure 6B , Table 9). GAP is a relatively unstable molecule and thus spontaneously dephosphorylates to glyceraldehyde. Baldoma et al. (1987) have demonstrated that E. coli AldA is active towards glycolaldehyde, lactaldehyde, methylglyoxal and L-glyceraldehyde
[13] . Therefore, NADH synthesis in the negative control is not related to the synthesis of glycolic acid, but is related to the synthesis of glyceric acid from glyceraldehyde oxidation. This secondary activity is not relevant in vivo, especially since L-glyceraldehyde is not formed in E. coli.
[0297] Table 9: Enzyme activity for the conversion of D-glucose to glycolic acid measured at 340 nm at 37°C A unit of enzyme activity is defined as the conversion of one micromole of substrate per minute. The negative control had no hexokinase (Hxk) activity.
[0298]
[0299] From these results, the conversion pathway of D-glucose to glycolate is functional in vitro and thus thermodynamically favorable.
[0300] In E. coli, the carbohydrates L-arabinose, D-xylose, and D-glucose are naturally assimilated and converted to D-ribulose-5P, and the non-natural conversion of D-ribulose-5P to glycolate produced by overexpressed KdsD, FSA, and aldA has been demonstrated. The implementation of the non-natural pathway KdsD-FSA-aldA is thermodynamically favorable, and the complete assimilation and conversion pathway of reconstructed pentoses and hexoses enables glycolate to be synthesized in vitro.
[0301] However, in vitro demonstrations are, by definition, isolated from the natural metabolism of E. coli and these results do not take into account reactions involving intermediates, the efficiency of substrate transport across the membrane and excretion of glycolate, the availability of cofactors, etc. Complementary in vivo feasibility demonstrations were performed to consolidate these preliminary results.
[0302] II. In vivo feasibility verification
[0303] II.1. Materials and methods
[0304] A. Plasmid construction
[0305] i. Selection of vector
[0306] The vector series pZ (Expressys) has the advantage of being tunable: the replication origin, resistance markers and vector promoter can be easily changed by restriction / ligation.
[0307] Vectors pZA23, pZA33, pZE23 and pZS23 have the promoter PAllacO-1, which is a promoter derived from the promoter of the lactose operon including the operon o. PAllacO-1 is under the control of the repressor lacI: in its active form, the repressor lacI is connected to the operon o and inhibits transcription, when complexed with IPTG, it changes conformation and is no longer able to bind site o, whereby transcription can be carried out. The promoter PAllacO-1 is IPTG inducible. Even though E. coli replicates naturally with a copy of the lacI gene in its genome upstream of the operon lac, most IPTG-inducible bacterial expression vectors carry the lacI gene in order to ensure complete inhibition of transcription of genes dependent thereon. The vector pZ is characterized by having the characteristics of a lightweight structure of the lacI gene, providing it with a small size (2358 to 3764 bp).
[0308] The vector pZA33 was modified by replacing the promoter PA1lac0-1 with the constitutive promoter proD and the inducible promoter Ptac, generating vectors pZA36 and pZA38, respectively. The promoter PA1lac0-1 of pZS23 was modified with the promoter proD, generating vector pZS27.
[0309] ii. Cloning method: HiFi Assembly
[0310] Use HiFi (NEB) method to construct the vector used in the context. This method is able to assemble several fragments. It has been validated for fragments of different sizes (15-80 bp) with variable overlapping regions. The fragments can be assembled in a single step, and it is a simple and flexible common method.
[0311] The commercial mixture provided by New England Biolabs contains different enzymes: (a) an exonuclease, which generates 3' single-stranded ends, facilitating the assembly of fragments of common sequence complementarity; (b) a polymerase, which fills in empty spaces behind already assembled fragments; and (c) a ligase, which joins the fragments together.
[0312] The genes kdsD, fsa and aldA of the glycolic acid production pathway according to the present invention have been amplified by PCR from genomic DNA extracted from Escherichia coli K12 MG1655 and purified by HiFi Insertion was into vector pZ, which had been previously linearized by PCR with primers hybridizing on both sides of the MCS. Prior to use, all plasmids were checked by sequencing.
[0313] iii. Expression vector for overexpression of kdsD, fsa, aldA
[0314] The vectors used to overexpress kdsD, fsa and aldA are shown in Table 10 below.
[0315] Table 10
[0316]
[0317] B. Construction of strains
[0318] i. Gene deletion
[0319] Deletion by transduction using bacteriophage P1vir Preparation of lysate P1vir and transduction procedures were performed as described previously with minor modifications
[34] .
[0320] Therefore, strain KEIO (donor strain) carrying a single deletion and a kanamycin antibiotic-resistance cassette was infected with P1vir and high titer lysate λ was obtained
[35] . The donor strain (KEIO) was cultured overnight in LB at 37°C. The next day, 5 ml of LB containing 0.2% glucose and 5 mM CaCl2 was inoculated with 200 μl of the donor strain and cultured at 37°C for 30 min. Then, 100 μl of the P1vir lysate (~5×10 8 phage / ml) were added to each donor culture medium and incubated again at 37°C for 2 to 3 hours until the medium was clear and the cells were completely lysed. The lysate was filtered through a 25 mm sterile syringe filter with a 0.2 μm support membrane (Pall) and stored at 4°C.
[0321] The bacterial strain to be deleted (receiving strain) is infected with Plvir containing the donor gene deletion box with kanamycin resistance. For this reason, the receiving strain is cultivated at 37°C in 5ml LB medium. The cells are centrifuged at 1500g for 10min and resuspended in 1.5ml of 10mM MgSO4 and 5mM CaCl2. The lysate (0.1ml) from the donor strain is added to the cell suspension and incubated for 30min. Then, 0.1ml of 1M sodium citrate is added to the cell and Plvir mixture. Then, 1mL LB is added to the homogenous suspension, and then incubated for 1h at 37°C, 200rpm.
[0322] The cell suspension was plated on solid LB with appropriate antibiotics and colonies were screened by PCR for highlighting successful transduction events.
[0323] To remove the antibiotic cassette, cells were transformed with the plasmid pCP20 carrying the FLP recombinase. Each step has been checked by PCR. When the strain deleted after removal of the cassette is sensitive to kanamycin, it can be used again as a receiving strain to add new deletions from new phage lysates.
[0324] ii. Preparation of Competent Bacteria and Transformation
[0325] Competent non-commercial strains were prepared according to the protocol of Chung et al., 1989 with slight modifications
[36] . Pre-culture was performed overnight in LB to generate an OD of 0.1 on the next day. 600 Inoculate fresh LB culture. When OD 600 Reach 0.3-0.5 (the bacterial competence can be up to 1 OD 600 ), will be equal to OD 600 The amount of cell culture was sampled and centrifuged (8000 rpm, 2 min). The supernatant was removed and the pellet was placed in 300 μl TSS buffer (2.5% (wt / vol) PEG 3350, 1M MgCl2, 5% (vol / vol) DMSO). The mixture was incubated on ice for 10 min. Then, the plasmid can be added to the competent cells. After further ice incubation for 30 minutes, heat shock was performed at 42°C for 90 seconds. The transformed cells were placed on ice for 10 min. 400 μl LB was added and incubated at 200 rpm for 1 h at a suitable temperature (the temperature should not exceed 30°C when the plasmid with a thermosensitive origin of replication is transformed). The bacterial culture was centrifuged at 8000 rpm for 2.5 min. 600 μl of supernatant was removed and the remaining volume was inoculated on a solid LB plate with appropriate antibiotics.
[0326] iii. Strains for glycolic acid production
[0327] The E. coli strains used in this study are listed in Table 11 below.
[0328] Table 11
[0329]
[0330] C. Culture medium and culture conditions
[0331] i. Composition of the culture medium
[0332] Cell culture is on LB medium, for molecular biology (cloning, deletion, transformation) step.This rich medium is made up of 10g / L tryptone, 5g / L yeast extract and 5g / L NaCl.Add 15g / L agar to obtain solid medium.LB with or without agar is sterilized by autoclaving 20min at 110 ℃ before use.
[0333] Cultivation for glycolic acid production was performed in mineral medium M9 (Table 12) containing a carbon source (glucose, xylose or arabinose) at a concentration of 10 g / L or 20 g / L and trace amounts of LB to reduce the latent phase (2 g / L tryptone, 1 g / L yeast extract and 1 g / L NaCl).
[0334] Table 12: Composition of medium M9
[0335]
[0336] About bacterial strain MG1655ΔtktAΔtktBΔglcD, culture medium M9 with trace LB is supplemented with 500μM L-phenylalanine, 250μM L-tyrosine, 200μM L-tryptophan, 6μM p-aminobenzoate, 6μM p-hydroxybenzoate and 280μM shikimic acid.For the bacterial strain that has removed glyceraldehyde-3-phosphate dehydrogenase activity, culture medium is supplemented with 0.4g / L malic acid, is adjusted to pH 7 with KOH in advance.At pH 7, by adding 20g / L 3-(N-morpholinyl) propane sulfonic acid (MOPS) buffer culture medium, and then by 0.2μm membrane filtration to obtain sterile culture medium.If necessary, appropriate antibiotic (100μg / mL ampicillin, 50μg / mL kanamycin, 25μg / mL chloramphenicol) is added to culture medium.For the bacterial strain containing IPTG inducible carrier, 0.1mM IPTG final concentration is used.All products are ordered from Sigma. The cultures were placed in a stirrer (Infors) at 200 rpm and maintained at 37°C for the duration of the experiment. The culture growth was measured by measuring the optical density (OD) at 600 nm using a spectrophotometer (Biochrom Libra S11). 600 ) for monitoring.
[0337] ii. Fermentation method in 250 mL baffled conical flask
[0338] Strains containing constitutive promoters
[0339] Solution 1
[0340] The strains were taken from a glycerol stock stored at -80°C and grown overnight at 37°C in 10 mL LB. The pre-culture was centrifuged at 4 000 rpm for 5 min and resuspended in 20 ml of M9 medium with 1% xylose or arabinose in a 100 mL conical flask the next day. The adaptation phase of 24 h duration allowed the strains to adapt to the use of pentoses. The cells were then centrifuged (4000 rpm, 5 min) and then taken out under final culture conditions: 50 mL of medium (M9 with 1% xylose or arabinose) with the same composition as used during the adaptation phase was used at an initial OD of 0.5. 600 . 250 mL baffled flasks were used for optimal oxygenation. The cultures were stirred at 200 rpm at 37°C.
[0341] Solution 2
[0342] Strain GA23 was taken from a glycerol stock stored at -80°C in 10 mL of LB containing the following antibiotics: tetracycline (10 μg / mL), kanamycin (50 μg / ml) and chloramphenicol (25 μg / ml). The preculture was incubated overnight at 37°C, 200 rpm.
[0343] The process was divided into two phases: a growth phase dedicated to biomass production and a production phase dedicated to glycolic acid production. The growth phase was carried out in a 250 ml conical flask at an OD of 0.2. 600 The pre-culture inoculation contains 1.5g / L xylose, 5g / L succinic acid, 73mg / L L-methionine, 73mg / L L-tryptophan and 1g / L casamino acid in the 50ml culture medium M9 of pH 7 to realize.At 37 ℃, 200rpm cultivate 24h after, by cell centrifugation, washing and recovery in 250ml conical flask contains 10g / L lignocellulose sugar (glucose, xylose or arabinose), 73mg / L L-methionine, 73mg / L L-tryptophan and 1g / L casamino acid in the 50mL M9 of pH 7.The culture medium for production does not have succinic acid and does not allow growth, and carbon source (glucose, xylose or arabinose) is used to produce glycolic acid.The production stage continues 48h at 37 ℃, 200rpm, and regularly takes out sample to measure pH, optical density and tracks sugar consumption and GA production by HPLC.
[0344] Strains containing inducible promoters
[0345] An LB preculture of the strain containing the vector with an inducible promoter was grown in 30 ml of M9 with 1% glucose at an initial OD of 0.1. 600 When OD 600When it reaches 0.6, 0.1 mM IPTG is added to induce gene expression under the control of IPTG inducible promoter (plac or ptac). After 24 h, the cells are centrifuged, washed with sterile water to remove traces of glucose, and they are resuspended in 20 ml of the medium selected for the adaptation phase (M9 with 1% xylose or arabinose, 0.1 mM IPTG). The rest of the culture protocol is the same as that for strains with constitutive promoters. iii.2L Fermentation methods in the bioreactor of Startorius Stedim Biotechnology
[0346] The culture of previously described bacterial strain GA23 was carried out in a 2L bioreactor. Pre-culture was carried out in LB added with kanamycin, chloramphenicol and tetracycline, at 37°C, 200rpm culture. The first 3mL pre-culture was spent the night, and it was used for the second 15mL pre-culture 24h of inoculation culture. It was used to inoculate the third and last pre-culture 8h in a 150mL conical flask. In the exponential phase, this last pre-culture was inoculated with an OD of 0.3 in a fermenter culture. M9 substratum (table 12) contains 1g / L xylose or glucose, and LB (10%) and 0.4g / L malic acid. Stir (300-1500rpm) culture at 37°C, and the exhaust dissolved oxygen was kept higher than 20% of the air flow rate. pH was maintained at 7 with KOH alkaline solution. Cultivated 40h in batch mode.
[0347] D. Measurement of extracellular metabolite concentrations
[0348] Sugar consumption and glycolic acid production were monitored by sampling samples regularly under sterile conditions, centrifuging at 13000 rpm for 5 min in a laboratory centrifuge (Eppendorf 5415D), filtering through a 0.2 μm filter and storing at -20 ° C. The measurement of extracellular metabolites was performed by high performance liquid chromatography (HPLC) using an Ultimate 3000 chromatograph (Dionex, Sunnyvale, USA). The HPLC system was equipped with a cation exchange column (Aminex, HPX87H-300x 7,8mm, 9μm, BioRad), an automatic injector (WPS-3000RS, Dionex), an IR detector (RID 10A, Shimadzu) and a UV detector (SPD-20A, Shimadzu). The mobile phase was a 1.25 mM sulfuric acid solution at a flow rate of 0.5 mL / min. The sample was kept at 4 ° C and 20 μl of injection was performed in the column at 35 ° C.
[0349] II.2. Results obtained with baffled conical flasks
[0350] The inventors have shown that overexpression of three non-native pathway enzymes according to the invention, namely arabinose-5-phosphate isomerase (KdsD), fructose-6-phosphate aldolase (FSA) and aldehyde dehydrogenase (AldA) in Escherichia coli, is necessary and sufficient for the synthesis of glycolic acid from lignocellulosic monosaccharides.
[0351] A. Use pentose sugars as carbon source
[0352] To this end, a strain of Escherichia coli K12MG1655 lacking the genes tktA, tktB encoding transketolase has been constructed to highlight the functionality of the pathway according to the invention. Transketolase is the main enzyme of the pentose phosphate pathway. In their absence, growth on pentoses is impossible, and the intermediate pentose phosphates (D-ribose-5-phosphate and D-xylulose-5-phosphate) accumulate and cannot be converted into glyceraldehyde-3-phosphate for growth
[38] . This strain requires a non-natural pathway according to the invention to grow from pentoses. In fact, only the coupled activity of KdsD and FSA can produce glyceraldehyde-3-phosphate involved in glycolysis for the production of precursors necessary for growth
[39] . Therefore, functional screening by growth testing is considered, in which growth will be an indicator of the efficiency of the pathway synthesized in vivo ( Figure 7 ).
[0353] The three genes have been cloned as an operon and expressed in the strain of E. coli MG1655ΔtktAΔtktBΔglcD. For this purpose, a two-vector expression system was used, which has been accepted by the strain without generating deleterious modifications for the expression of the synthetic pathway according to the invention. Thus, the expression system of the synthetic pathway according to the invention comprises the co-expression of a medium copy number vector carrying kdsD-fsa and a low copy number vector carrying aldA.
[0354] A dual expression system was investigated, one vector with an IPTG-inducible promoter (pZA36 kdsD fsa and pZS23 aldA, expression system n° 9) and another vector with a constitutive promoter (pZA37 kdsD fsa and pZS28 aldA, expression system n° 23).
[0355] Cultivation of strain MG1655ΔtktAΔtktBΔglcD expressing systems 9 (Screen 09) and 23 (Screen 23) was performed at 37°C and showed significant growth, indicating that the overexpressed kdsD and fsa genes were functional. HPLC analysis of the exometabolome of bacterial cultures on L-arabinose and D-xylose has confirmed the presence of glycolic acid with both expression systems. This result indicates the feasibility of synthesizing glycolic acid from pentoses via an in vivo synthetic pathway ( Figure 8). Table 13 below shows the glycolic acid yields from xylose and arabinose of strains Screen09 and Screen23.
[0356] Table 13
[0357]
[0358] B. Use pentose and hexose sugars as carbon sources
[0359] The E. coli WC3GΔgapAΔglcDΔarcAΔmgsAΔfucAΔpkfproD-galP (GA00) strain designed to produce glycolic acid from hexoses and pentoses with optimal carbon conservation was transformed with expression systems 9 and 23 to generate strains GA09 and GA23, respectively.
[0360] Bacterial cultivation was carried out on D-glucose, L-arabinose and D-xylose in Erlenmeyer flasks at 37° C. for 46 h. Overexpression of kdsD, fsa and aldA genes is essential for glycolate production.
[0361] Using the previously defined scheme 1
[0362] Strain GA00 with constitutive expression system n°23 has been shown to produce glycolic acid from D-glucose (0.29 g / L), D-xylose (0.41 g / L) and L-arabinose (0.07 g / L). Strain GA09 with inducible expression system n°9 produced no significant amount of glycolic acid on D-glucose (0.1 g / L), D-xylose (0.05 g / L) and L-arabinose (0.03 g / L). Fig. 9 ). An expression system comprising a constitutive promoter is advantageous. The yield of glycolic acid in strain GA23 was 0.09 g / g (0.21 mol / mol) from glucose, 0.18 g / g (0.36 mol / mol) from xylose and 0.16 g / g (0.32 mol / mol) from arabinose.
[0363] Using the previously defined scheme 2
[0364] The yields of glycolic acid in strain GA23 were 0.096 g / g (0.19 mol / mol) from glucose, 0.3 g / g (0.60 mol / mol) from xylose, and 0.34 g / g (0.68 mol / mol) from arabinose.
[0365] References
[0366] [1] et al,2014,《The industrial potential of bio-based glycolicacidand polyglycolic acid》,Appita Journal,vol.67,pages 1-2.
[0367] [2]Kunze et al,2006,《A central role for the peroxisomal membraneinglyoxylate cycle function》,Biochimica et Biophysica Acta-MolecularCellResearch,vol.1763,pages 1441-1452.
[0368] [3]International application WO 2007 / 141316filed on behalf ofMetabolicExplorer,published on 13December 2007.
[0369] [4]Deng,et al,2018,《Balancing the carbon flux distributions betweentheTCA cycle and glyoxylate shunt to produce glycolate at high yield andtiter inEscherichia coli》,Metabolic Engineering,vol.46,pages 28–34.
[0370] [5]International application WO 2017 / 09236filed on behalf ofMassachusettsInstitute of Technology,published on 6April 2017.
[0371] [6]Pereira et al,2016,《Efficient utilization of pentoses forbioproduction ofthe renewable two-carbon compounds ethylene glycol andglycolate》,MetabolicEngineering,vol.34,pages 80-87.
[0372] [7]International application WO 2016 / 079440field on behalf of INRA,INSAand CNRS,published on 26may 2016.
[0373] [8]Alkim et al,2016,《The synthetic xylulose-1 phosphate pathwayincreasesproduction of glycolic acid from xylose-rich sugar mixtures》,Biotechnology forBiofuels,9.doi:10.1186 / s13068-016-0610-2.
[0374] [9]Dugar and Stephanopoulos,2011,《Relative potential ofbiosyntheticpathways for biofuels and bio-based products》,Nat Biotechnol,vol.29,pages1074-1078.
[0375]
[10] Bogorad et al,2013,《Synthetic non-oxidative glycolysisenablescomplete carbon conservation》,Nature,vol.502,pages 693-697.
[0376]
[11] Meredith and Woodard,2006,《Characterization of Escherichia coliD-arabinose 5-phosphate isomerase encoded by kpsF:implications for group2capsule biosynthesis》,Biochemical Journal.doi:10.1042 / BJ20051828.
[0377]
[12] Garrabou et al,2009,《Asymmetric self-and cross-aldol reactionsofglycolaldehyde catalysed by d-fructose-6-phosphate aldolase》,AngewandteChemie-International Edition,vol.48,pages 5521-5525.
[0378]
[13] Baldomàand Aguilar,1987,《Involvement of lactaldehydedehydrogenasein several metabolic pathways of Escherichia coli K12》,TheJournal ofbiological chemistry,vol.262,pages 13991-13996.
[0379]
[14] Schürmann and Sprenger,2001,《Fructose-6-phosphate aldolase isanovel class I aldolase from Escherichia coli and is related to a novel groupofbacterial transaldolases》,Journal of Biological Chemistry,vol.276,pages11055–11061.
[0380]
[15] Szekrenyi et al,2014,《Engineering the donor selectivity of D-fructose-6-phosphate aldolase for biocatalytic asymmetric cross-aldoladditions ofglycolaldehyde》,Chemistry–A European Journal,vol.20,pages 12572-12583.
[0381]
[16] Ward et al,1999,《Expression of prokaryotic membranetransportproteins in Escherichia coli》,Biochemical Society Transactions,vol.27,pages893-899.
[0382]
[17] Lu et al,2012,《Combinatorial modulation of galP and glkgeneexpression for improved alternative glucose utilization》,AppliedMicrobiologyand Biotechnology,vol.93,pages 2455-2462.
[0383]
[18] Hernández-Montalvo et al,2003,《Expression of galP and glk inaEscherichia coli PTS mutant restores glucose transport and increasesglycolyticflux to fermentation products》,Biotechnology and Bioengineering,vol.83,pages687-694.
[0384]
[19] Snoep et al,1994,《Reconstitution of glucose uptakeandphosphorylation in a glucose-negative mutant of Escherichia coli byusingZymomonas mobilis genes encoding the glucose facilitator proteinandglucokinase》,J.Bacteriol.,vol.176,pages 2133-2135.
[0385]
[20] García et al,2001,《Characterization of sugar mixtures utilizationby anEscherichia coli mutant devoid of the phosphotransferase system》,AppliedMicrobiology and Biotechnology,vol.57,pages 186-191.
[0386]
[21] Lord,1972,《Glycolate oxidoreductase in Escherichia coli》,BBA-Bioenergetics,vol.267,pages 227-237.
[0387]
[22] Alexeeva et al,2003,《Requirement of ArcA for redox regulationinEscherichia coli under microaerobic but not anaerobic or aerobicconditions》,JBacteriol.,vol.185,pages 204-209.
[0388]
[23] Pellicer et al,1999,《A mutational study of the ArcA-Pbindingsequences in the aldA promoter of Escherichia coli》,Molecular andGeneralGenetics,vol.261,pages 170-176.
[0389]
[24] Liu and De Wulf,2004,《Probing the ArcA-P Modulon ofEscherichiacoli by Whole Genome Transcriptional Analysis and SequenceRecognitionProfiling》,Journal of Biological Chemistry,vol.279,pages 12588-12597.
[0390]
[25] Cho et al,2006,《Transcriptional regulation of the fad regulongenes ofEscherichia coli by ArcA》,Microbiology,vol.152,pages 2207-2219.
[0391]
[26] Saadat and Harrison,1998,《Identification of catalytic bases inthe activesite of Escherichia coli methylglyoxal synthase:Cloning,expression,andfunctional characterization of conserved aspartic acid residues》,Biochemistry,vol.37,pages 10074-10086.
[0392]
[27] Atkinson and Walton,1965,《Kinetics of regulatoryenzymesEscherichia coli phosphofructokinase》,The Journal of BiologicalChemistry,vol.240,pages 757-764.
[0393]
[28] Ghalambor and Heath,1962,《The metabolism of L-Fucose》,TheJournalof Biological Chemistry,vol.237,pages 2427-2433.
[0394]
[29] Banerjee and Fraenkel,1972,《Glucose-6-phosphate dehydrogenasefromEscherichia coli and from“high level”mutant》,J.bacteriol.,vol.110,pages155-160.
[0395]
[30] Gardner and Fridovich,1991,《Superoxide sensitivity of theEscherichiacoli aconitase》,Journal of Biological Chemistry,vol.266,pages19328-19333.
[0396]
[31] Fong et al,2000,《Directed evolution of D-2-keto-3-deoxy-6-phosphogluconate aldolase to new variants for the efficient synthesis of D-and L-sugars》,Chemistry and Biology,vol.7,pages 873-883.
[0397]
[32] et al,2007,《Enzymatic conversion of lignocelluloseintofermentable sugars:Challenges and opportunities》,Biofuels,BioproductsandBiorefining,vol.1,pages 119-134.
[0398]
[33] Dykxhoorn et al,1996,《A set of compatible tac promoterexpressionvectors》,Gene,vol.177,pages 133–136.
[0399]
[34] Bremer et al,1984,《λplacMu:A transposable derivativeofbacteriophage lambda for creating lacZ protein fusions in a single step》,Journalof Bacteriology,vol.158,pages 1084-1093.
[0400]
[35] Baba et al,2006,《Construction of Escherichia coli K-12 in-frame,single-gene knockout mutants:The Keio collection》,Molecular Systems Biology,2.doi:10.1038 / msb4100050.
[0401]
[36] Chung et al,1989,《One-step preparation of competent Escherichiacoli:transformation and storage of bacterial cells in the same solution》,Proceedings ofthe National Academy of Sciences,vol.86,pages 2172-2175.
[0402]
[37] Ganter et Pliickthun,1990,《Glycine to alanine substitutions inhelicesof glyceraldehyde-3-phosphate dehydrogenase:effects on stability》,Biochemistry,vol.29,pages 9395-2402.
[0403]
[38] Teleman et al,1999,《Identification and quantitation ofphosphorusmetabolites in yeast neutral pH extracts by nuclear magneticresonancespectroscopy》,Analytical Biochemistry,vol.272,pages 71-79.
[0404]
[39] Zhao and Winkler,1994,《An Escherichia coli K-12 tktA tktBmutantdeficient in transketolase activity requires pyridoxine(vitamin B6)aswell as thearomatic amino acids and vitamins for growth》,J.Bacteriol.,vol.176,pages6134-6138
Claims
1. A recombinant microorganism exhibiting: i) increased conversion activity of D-ribulose-5-phosphate into D-arabinose-5-phosphate catalyzed by an enzyme consisting of D-arabinose-5-phosphate isomerase that converts D-ribulose-5-phosphate into D-arabinose-5-phosphate, as compared to a non-modified microorganism thereof, which is obtained in the recombinant microorganism by increasing the copy number of the gene encoding the D-arabinose-5-phosphate isomerase and / or by increasing the expression of the gene encoding the D-arabinose-5-phosphate isomerase in order to obtain a form that is more active or more resistant to inhibition; ii) increased aldehyde cleavage activity from D-arabinose-5-phosphate to D-glyceraldehyde-3-phosphate and glycolaldehyde catalyzed by an enzyme consisting of fructose-6-phosphate aldolase catalyzing the cleavage of D-arabinose-5-phosphate to D-glyceraldehyde-3-phosphate and glycolaldehyde, as compared to a non-modified microorganism thereof, which is obtained in the recombinant microorganism by increasing the copy number of the gene encoding the fructose-6-phosphate aldolase and / or by increasing the expression of the gene encoding the fructose-6-phosphate aldolase so as to obtain a form that is more active or more resistant to inhibition; iii) increased oxidation activity from glycolaldehyde to glycolic acid catalyzed by an enzyme consisting of a glycolaldehyde dehydrogenase that oxidizes glycolaldehyde to glycolic acid, obtained in the recombinant microorganism by increasing the copy number of the gene encoding the glycolaldehyde dehydrogenase and / or by increasing the expression of the gene encoding the glycolaldehyde dehydrogenase so as to obtain a form that is more active or more resistant to inhibition, compared to its non-modified microorganism; and iv) reduced glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate oxidation activity catalyzed by an enzyme consisting of glyceraldehyde-3-phosphate dehydrogenase which oxidizes glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate, as compared to a non-modified microorganism thereof, which is obtained in the recombinant microorganism by reducing the expression of a gene encoding said glyceraldehyde-3-phosphate dehydrogenase and / or by inactivating a gene encoding said glyceraldehyde-3-phosphate dehydrogenase, The recombinant microorganism produces glycolic acid from pentoses and hexoses, The microorganism is Escherichia coli.
2. The recombinant microorganism according to claim 1, characterized in that The microorganism exhibits overexpression of the E. coli kdsD gene.
3. The recombinant microorganism according to claim 1, characterized in that The microorganism exhibits overexpression of the E. coli fsa gene.
4. The recombinant microorganism according to claim 1, characterized in that The microorganism exhibits overexpression of the E. coli aldA gene.
5. The recombinant microorganism according to any one of claims 1 to 4, characterized in that The microorganisms include: a) a first plasmid in which the sequence of the E. coli kdsD gene and the sequence of the E. coli fsa gene are located, said sequences being cloned as an operon and under the control of a first inducible or constitutive promoter, β) a second plasmid, in which the sequence of the E. coli aldA gene under the control of a second inducible or constitutive promoter is located, The first and second promoters are the same or different.
6. The recombinant microorganism according to any one of claims 1 to 4, characterized in that The expression of the gapA gene of E. coli was reduced relative to that of the non-modified microorganism, but was not inactivated.
7. The recombinant microorganism according to any one of claims 1 to 4, characterized in that The expression of the E. coli gapA gene is inactivated relative to the non-modified microorganism.
8. The recombinant microorganism according to any one of claims 1 to 4, characterized in that The phosphotransferase system (PTS) that is dependent on phosphoenolpyruvate (PEP) and encoded by the operon ptsHIcrr is inactive. The glucose transport activity encoded by E. coli galP or Zymomonas mobilis glf is increased compared to its non-modified microorganism, which is obtained in the recombinant microorganism by increasing the copy number of the gene of E. coli galP or Zymomonas mobilis glf and / or by increasing the expression of the gene of E. coli galP or Zymomonas mobilis glf so as to obtain a form that is more active or more resistant to inhibition, and The conversion activity from glucose to glucose-6-phosphate catalyzed by an enzyme consisting of glucokinase that converts glucose into glucose-6-phosphate is increased compared to its non-modified microorganism, which is obtained in the recombinant microorganism by increasing the copy number of the E. coli glK gene encoding the glucokinase and / or by increasing the expression of the E. coli glK gene encoding the glucokinase in order to obtain a form that is more active or more resistant to inhibition.
9. The recombinant microorganism according to any one of claims 1 to 4, characterized in that The microorganism exhibits at least one of the following characteristics: v) reduced activity of the oxidation of glycolate to glyoxylate catalyzed by an enzyme consisting of glycolate dehydrogenase which oxidizes glycolate to glyoxylate, obtained in said recombinant microorganism by reducing the expression of the glcDEF gene encoding said glycolate dehydrogenase and / or by inactivating the glcDEF gene encoding said glycolate dehydrogenase; vi) reduced repression of genes involved in the regulation of aerobic respiratory metabolism induced by the transcriptional regulator arcA capable of repressing genes involved in the regulation of aerobic respiratory metabolism, as compared to its non-modified microorganism, which is obtained in the recombinant microorganism by reducing the expression of the gene encoding the transcriptional regulator arcA and / or by inactivating the gene encoding the transcriptional regulator arcA; vii) reduced glycolate internalization induced by at least one glycolate-importing protein compared to a non-modified microorganism thereof, which is obtained in the recombinant microorganism by reducing the expression of one or more of the E. coli glcA, IIdP or yjcG genes encoding the at least one glycolate-importing protein and / or by inactivating the E. coli glcA, IIdP or yjcG genes encoding the at least one glycolate-importing protein; viii) reduced activity of irreversibly forming methylglyoxal from dihydroxyacetone phosphate (DHAP) catalyzed by an enzyme consisting of methylglyoxal synthase which irreversibly forms methylglyoxal from dihydroxyacetone phosphate (DHAP) compared to a non-modified microorganism thereof, which is obtained in the recombinant microorganism by reducing the expression of the Escherichia coli mgsA gene encoding the methylglyoxal synthase and / or by inactivating the Escherichia coli mgsA gene encoding the methylglyoxal synthase; ix) reduced conversion activity of fructose-6-phosphate into fructose-1,6-bisphosphate catalyzed by an enzyme consisting of a phosphofructokinase which converts fructose-6-phosphate into fructose-1,6-bisphosphate, as compared to a non-modified microorganism thereof, which is obtained in the recombinant microorganism by reducing the expression of the Escherichia coli pfKA gene encoding the phosphofructokinase and / or by inactivating the Escherichia coli pfKA gene encoding the phosphofructokinase; and x) reduced activity of producing D-ribose-1-phosphate from dihydroxyacetone phosphate and glycoaldehyde catalyzed by an enzyme consisting of L-fucose-phosphate aldolase that produces D-ribose-1-phosphate from dihydroxyacetone phosphate and glycoaldehyde, as compared to a non-modified microorganism thereof, which is obtained in the recombinant microorganism by reducing the expression of the Escherichia coli fucA gene encoding the L-fucose-phosphate aldolase and / or by inactivating the Escherichia coli fucA gene encoding the L-fucose-phosphate aldolase.
10. The recombinant microorganism according to claim 9, characterized in that The activity of producing 6-phospho-D-glucono-1,5-lactone from D-glucose-6-phosphate catalyzed by an enzyme composed of a cofactor-dependent glucose-6-phosphate dehydrogenase that produces 6-phospho-D-glucono-1,5-lactone from D-glucose-6-phosphate is reduced compared to its non-modified microorganism, which is obtained in the recombinant microorganism by reducing the expression of the Escherichia coli zwf gene encoding the cofactor-dependent glucose-6-phosphate dehydrogenase and / or by inactivating the Escherichia coli zwf gene encoding the cofactor-dependent glucose-6-phosphate dehydrogenase.
11. The recombinant microorganism according to claim 9, characterized in that The recombinant microorganism exhibits the following characteristics: xi) increased oxidation activity from D-glucose-6-phosphate to 6-phospho-D-glucono-1,5-lactone catalyzed by an enzyme consisting of a cofactor-dependent glucose-6-phosphate dehydrogenase producing 6-phospho-D-glucono-1,5-lactone from D-glucose-6-phosphate, as compared to a non-modified microorganism thereof, which is obtained in said recombinant microorganism by increasing the copy number of the E. coli zwf gene encoding said cofactor-dependent glucose-6-phosphate dehydrogenase and / or by increasing the expression of the E. coli zwf gene encoding said cofactor-dependent glucose-6-phosphate dehydrogenase in order to obtain a form that is more active or more resistant to inhibition; xii) reduced activity in forming 2-dehydroxy-3-deoxy-D-gluconic acid-6-phosphate from D-gluconic acid-6-phosphate catalyzed by an enzyme consisting of a phosphogluconate dehydratase that produces 2-dehydroxy-3-deoxy-D-gluconic acid-6-phosphate from D-gluconic acid-6-phosphate, as compared to a non-modified microorganism thereof, which is obtained in the recombinant microorganism by reducing the expression of an E. coli edd gene encoding the phosphogluconate dehydratase and / or by inactivating the E. coli edd gene encoding the phosphogluconate dehydratase; and xiii) reduced activity of forming D-glyceraldehyde-3-phosphate and pyruvate from 2-dehydroxy-3-deoxy-gluconic acid-6-phosphate catalyzed by an enzyme consisting of 2-dehydroxy-3-deoxy-phosphogluconate aldolase that produces D-glyceraldehyde-3-phosphate and pyruvate from 2-dehydroxy-3-deoxy-gluconic acid-6-phosphate, as compared to a non-modified microorganism thereof, which is obtained in the recombinant microorganism by reducing the expression of the Escherichia coli eda gene encoding the 2-dehydroxy-3-deoxy-phosphogluconate aldolase and / or by inactivating the Escherichia coli eda gene encoding the 2-dehydroxy-3-deoxy-phosphogluconate aldolase.
12. A method for producing glycolic acid comprising the steps of: a) cultivating the recombinant microorganism as defined in any of the preceding claims in a culture medium comprising at least one pentose and / or at least one hexose as carbon source; and b) recovering glycolic acid from the microorganism and / or the culture medium.
13. The method of claim 12, characterized in that The cultured recombinant microorganism is a recombinant microorganism in which the expression of the Escherichia coli gapA gene is reduced but not inactivated relative to a non-modified microorganism; and is characterized in that the carbon source used therein comprises only one element selected from the group consisting of D-glucose, D-xylose, L-arabinose and a mixture thereof.
14. The method of claim 12, characterized in that The cultured recombinant microorganism is a recombinant microorganism in which the expression of the Escherichia coli gapA gene is inactivated relative to a non-modified microorganism; and is characterized in that, in addition to D-xylose and / or L-arabinose and / or D-glucose, the carbon source includes one or more C2, C3 and C4 compounds selected from malic acid, pyruvic acid, succinic acid, acetic acid and mixtures thereof.
Citation Information
Patent Citations
Ceramic and glass correction inks
WO2007014131A2
Glycolic acid production by fermentation from renewable resources
WO2007141316A2
Process for producing at least one metabolite of interest by conversion of a pentose in a microorganism
WO2016079440A1
Microbial production of renewable glycolate
WO2017059236A1
Process for producing at least one metabolite of interest by conversion of a pentose in a microorganism
CN107429269A
